

Eva Lucille Feldman, M.D., Ph.D., F.A.A.N., F.A.N.A.
Russell N. DeJong Professor of Neurology
University of Michigan
Department of Neurology
5017 BSRB, 109 Zina Pitcher
Ann Arbor, Michigan 48109-2200
734-763-7274
efeldman@umich.edu

Education and Training

Education

Undergraduate: Earlham College, B.A., Biology and Chemistry,
Richmond, Indiana, May 1973
Graduate: University of Notre Dame, M.S., Zoology,
South Bend, Indiana, May 1975
The University of Michigan, Ph.D., Neuroscience,
Ann Arbor, Michigan, May 1979
Medical: The University of Michigan, M.D.
Ann Arbor, Michigan, May 1983

Postgraduate Training

July 1983 - June 1984 Intern, Department of Medicine, William Beaumont Hospital,
Royal Oak, Michigan
July 1984 - June 1987 Resident in Neurology, The Johns Hopkins Hospital,
Baltimore, Maryland
July 1986 - June 1987 Chief Resident, Department of Neurology,
The Johns Hopkins Hospital, Baltimore, Maryland
July 1987 - June 1988 Neuromuscular Fellow, Departments of Neurology and
Physical Medicine & Rehabilitation, The University of
Michigan, Ann Arbor, Michigan

Certification and Licensure

Board Certification: Diplomate, National Board of Medical Examiners, 1984
Diplomate, American Board of Psychiatry and Neurology,
1988
Diplomate, American Board of Electrodiagnostic Medicine,
1989

Medical Licensure: Michigan #051632, 1988

Academic, Administrative, and Clinical Appointments

July 1987 - June 1988	Instructor, Department of Neurology, The University of Michigan, Ann Arbor, Michigan
July 1988 - June 1994	Assistant Professor, Department of Neurology, The University of Michigan, Ann Arbor, Michigan
July 1988 - Present	Faculty Member, Neuroscience Program, The University of Michigan
July 1988 - Present	Faculty Member, Michigan Diabetes Research and Training Center
July 1992 - Present	Faculty Member, The University of Michigan Cancer Center
July 1994 - August 2000	Associate Professor, Department of Neurology, The University of Michigan, Ann Arbor, Michigan
August 1998 - Present	Faculty Member, Cellular and Molecular Biology Program
January 2000 - Present	Director, Program for Neurology Research and Discovery
May 2000 – June 2010	Director, Juvenile Diabetes Research Foundation Center for the Study of Complications in Diabetes
September 2000 - Present	Professor, Department of Neurology The University of Michigan, Ann Arbor, Michigan
May 2001 - Present	Director of Research, ALS Center of Excellence at Michigan Medicine
October 2004 - Present	Russell N. DeJong Professor of Neurology
March 2005 - Present	Director, Neuropathy Center, The University of Michigan
January 2008 – June 2017	Director, A. Alfred Taubman Medical Research Institute

Grants

a) Present and Active Grants:

Funding Sponsor: CDC R01 TS000289
Period: 09/30/2018 – 09/29/2021
Direct/Total Costs for Award: \$958,794/\$1,482,859
Title: Metabolomic Signatures Linking ALS to Persistent Organic Pollutant Exposures
Principle Investigator: Eva L. Feldman

Funding Sponsor: NIH R21 NS102924
Period: 09/01/2018 – 08/31/2020
Direct/Total Costs for Award: \$275,000/\$429,000
Title: Linking Nerve Bioenergetics with Metabolomics: New Insights into Diabetic Neuropathy
Principle Investigator: Eva L. Feldman

Funding Sponsor: NIH U01 AG057562
Period: 08/15/2018 – 07/31/2021
Direct/Total Costs for Award: \$2,001,151/\$3,120,695
Title: Neural Stem Cell Transplantation: A Novel Cellular Therapy for Alzheimer's Disease
Principle Investigator: Eva L. Feldman

Funding Sponsor: NIH R01 DK115687
Period: 07/01/2018 – 05/31/2023
Direct Costs for Award: \$651,421
Title: The Effect of High Intensity Interval Training and Surgical Weight Loss on Distal Symmetric Polyneuropathy Outcomes
Principle Investigator: Brian Callaghan
Co-Investigator: Eva L. Feldman

Funding Sponsor: NIH R21 NS102960
Period: 04/01/2018 – 03/31/2020
Direct/Total Costs for Award: \$250,000/\$387,500
Title: The Role of NK Cells in ALS
Principle Investigator: Eva L. Feldman

Funding Sponsor: NIH T32 NS07222
Period: 07/01/17 - 06/30/22
Direct/Total Costs for Award: \$1,832,694/\$1,964,821
Title: Training in Basic and Clinical Neurosciences
Principal Investigator: Eva L. Feldman

Funding Sponsor: NIH/NIEHS K23

Period: 06/01/2017 – 05/31/2022
Direct/Total Costs for Award: \$1,013,855/\$1,094,963
Title: Impact of Geospatial Factors and Environmental Pollutants on Amyotrophic Lateral Sclerosis in the State of Michigan
Principal Investigator: Stephen A. Goutman
Sponsor: Eva L. Feldman

Funding Sponsor: NIH R01 NS099280
Period: 09/01/2016-05/31/2021
Direct/Total Costs for Award: \$1,739,209/\$2,646,144
Title: Hexanucleotide Repeat Translation in ALS and Frontotemporal Dementia
Principle Investigator: Peter Todd
Co Investigator: Eva L. Feldman

Funding Sponsor: NIH Mouse Metabolic Phenotyping Centers Consortium (U2C)
Period: 08/02/2016 – 06/30/21
Direct/Total Costs for Award: \$4,080,000/\$6,324,000
Title: Michigan Mouse Metabolic Phenotyping Center
Principal Investigator: Malcolm Low
Co Investigator: Eva L. Feldman

Funding Sponsor: NIH R24 DK082841
Period: 08/01/16 – 07/31/2021
Direct/Total Costs for Award: \$989,401/\$1,533,572
Title: Integrated Systems Biology Approach to Diabetic Microvascular Complications
Principal Investigator: Eva L. Feldman

Funding Sponsor: NIH R01 DK107956
Period: 03/01/16 – 02/28/21
Direct/Total Costs for Award: \$2,119,690/\$3,258,926
Title: Targeting Inflammation and Salsalate as a Novel Therapy for Diabetic Neuropathy
Principal Investigators: Eva L. Feldman and Rodica Pop-Busui

Funding Sponsor: Prime: NIH/NIDDK R01 DK108173
Direct: Wake Forest University
Period: 09/30/15 – 09/29/20
Direct/Total Costs for Award: \$14,041/\$21,766
Title: SEARCH for Diabetes in Youth Cohort Study
Site Principal Investigator: Eva L. Feldman

Funding Sponsor: NNF14SA0006 Novo Nordisk Foundation
Period: 05/01/15 – 04/30/21
Direct/Total Costs for Award: \$705,127/\$1,093,618
Title: The International Diabetic Neuropathy Consortium (IDNC)
Principal Investigator: Eva L. Feldman

Period: 10/01/99 - Present (\$3,500,000)
Title: Program for Neurology Research and Discovery
Principal Investigator: Eva L. Feldman
Funding Sponsor: Research Endowment

b) Previous Grants (from oldest to most recent)

Funding Sponsor: NIH (CIDA) NS01381
Period: 09/01/89 - 08/31/94 (\$354,240 Annual Direct Costs)
Title: The Role of Insulin-Like Growth Factors in the PNS
Principal Investigator: Eva L. Feldman

Funding Sponsor: NIH (FIRST) NS32843
Period: 04/01/94 - 03/31/99 (\$349,980 Annual Direct Costs)
Title: Role of IGFs in Human Neuroblastoma Growth
Principal Investigator: Eva L. Feldman

Funding Sponsor: Juvenile Diabetes Foundation International
Period: 09/01/94 - 08/31/96 (\$81,927 Annual Direct Costs)
Title: Insulin-Like Growth Factor-I is a Neural Osmoprotectant
Principal Investigator: Eva L. Feldman

Funding Sponsor: American Diabetes Association
Period: 07/01/95 - 06/30/97 (\$94,513 Annual Direct Costs)
Title: Hyperglycemia and Programmed Cell Death in Neurons
Principal Investigator: Eva L. Feldman

Funding Sponsor: NIH (NRSA)
Period: 09/01/95 - 08/31/97 (\$52,300 Annual Direct Costs)
Title: The Role of c-Src in Matrix-Induced Neurite Growth
Principal Investigator: Phillip S. Leventhal
Sponsor: Eva L. Feldman

Funding Sponsor: Muscular Dystrophy Association
Period: 07/01/96 - 06/30/98 (\$100,610 Annual Direct Costs)
Title: IGF-I Prevents Oxidative Injury in Motor Neurons
Principal Investigator: Eva L. Feldman

Funding Sponsor: Juvenile Diabetes Foundation International
Period: 09/01/96 - 08/31/98 (\$67,809 Annual Direct Costs)
Title: Insulin-Like Growth Factor-I is a Neural Osmoprotectant
Principal Investigator: Eva L. Feldman

Funding Sponsor: NIH (CSDA) K08 NS01928

Period: 12/01/96 - 11/30/01 (\$410,000 Annual Direct Costs)
Title: The Role of Oligodendrocyte-Myelin Glycoprotein in the PNS
Principal Investigator: Daniel D. Mikol
Sponsor: Eva L. Feldman

Funding Sponsor: NIH (CSDA) K08 NS01938
Period: 12/01/96 - 11/30/01 (\$410,000 Annual Direct Costs)
Title: IGF-I Protects Neurons From Glucose-Induced Cell Death
Principal Investigator: James W. Russell
Sponsor: Eva L. Feldman

Funding Sponsor: American Diabetes Association
Period: 07/01/97 - 06/30/00 (\$148,208 Annual Direct Costs)
Title: Hyperglycemia Disrupts Axonal Pathfinding
Principal Investigator: Eva L. Feldman

Funding Sponsor: NIH T32 NS07222
Period: 07/01/97 - 06/30/02 (\$1,239,582 Annual Direct Costs)
Title: Training in Basic and Clinical Neurosciences
Principal Investigator: Sid Gilman
Co-Investigator: Eva L. Feldman

Funding Sponsor: NIH 5 P60 DK20572
Period: 12/01/97 - 11/30/98 (\$6,328,820 Annual Direct Costs)
Title: Michigan Diabetes Research and Training Center
Principal Investigator: Douglas A. Greene
Co-Investigator: Eva L. Feldman

Funding Sponsor: University of Michigan Cancer Research Committee
Period: 01/01/98 - 12/31/98 (\$10,000 Annual Direct Costs)
Title: IGF-I Enhanced Neuroblastoma Invasiveness
Principal Investigator: Eva L. Feldman

Funding Sponsor: University of Michigan
Period: 01/01/98 - 12/31/99 (\$30,000 Annual Direct Costs)
Title: Adenoviral Neurotrophic Gene Transfer to Spinal Cord: Therapy and Mechanisms
Principal Investigator: Nicholas Boulis
Sponsor: Eva L. Feldman

Funding Sponsor: Warner-Lambert Company
Period: 01/01/98 - 08/31/01 (\$653,000 Annual Direct Costs)
Title: A 24-Month, Double-Blind, Randomized, Placebo-Controlled, Fixed-Dose, Parallel-Group, Multicenter Study of Zenarestat (CI-1014) in the Treatment of Diabetic Neuropathy (Protocol 1014-01)
Principal Investigator: Eva L. Feldman

Funding Sponsor: NIH RO1 NS36778
Period: 06/01/98 - 02/29/04 (\$553,444 Annual Direct Costs)
Title: IGFs Mediate Motility in Human Neuroblastoma Cells
Principal Investigator: Eva L. Feldman
Funding Sponsor: University of Michigan Biomedical Research Council
Period: 07/01/98 - 6/30/99 (\$15,000 Annual Direct Costs)
Title: Mechanisms Underlying Loss of Proprioception
Principal Investigator: Eva L. Feldman
Co-Investigator: Kelli Sullivan

Funding Sponsor: Juvenile Diabetes Foundation International
Period: 09/01/98 - 08/31/00 (\$136,822 Annual Direct Costs)
Title: Insulin-Like Growth Factor-I Prevents Glucose Mediated Injury
Principal Investigator: Eva L. Feldman

Funding Sponsor: NIH RO1 NS38849
Period: 09/30/98 - 08/31/01 (\$303,448 Annual Direct Costs)
Title: Glucotoxicity Mediates Apoptosis in Diabetic Neuropathy
Principal Investigator: Eva L. Feldman

Funding Sponsor: ALS Association
Period: 02/01/99 - 07/31/02 (\$53,870 Annual Direct Costs)
Title: FDA Approved Compound Screens for ALS
Principal Investigator: Eva L. Feldman

Funding Sponsor: ALS Association
Period: 02/01/99 - 01/31/02 (\$149,582 Annual Direct Costs)
Title: Adenoviral Gene Therapy of Amyotrophic Lateral Sclerosis
Principal Investigator: Eva L. Feldman

Funding Sponsor: University of Michigan Biomedical Research Council
Period: 07/01/99 - 12/31/99 (\$24,600 Annual Direct Costs)
Title: Automated Image Analysis of *In Vivo* and *In Vitro* Disease Models
Principal Investigator: Eva L. Feldman

Funding Sponsor: ASTA Medica AG N001128
Period: 09/01/99 - 05/30/04 (\$396,000 Annual Direct Costs)
Title: Assessment Efficacy and Safety of Thioctic Acid in Oral Treatment of Diabetic Polyneuropathy (Stage 1 and 2a)
Principal Investigator: Eva L. Feldman

Funding Sponsor: Juvenile Diabetes Research Foundation

Period: 01/01/00 - 12/31/07 (\$110,500 Annual Direct Costs)

Title: Oxidative Injury and Diabetic Complications: The Antioxidant Response as a Therapeutic Target in Diabetic Neuropathy

Principal Investigator: Eva L. Feldman

Funding Sponsor: Juvenile Diabetes Research Foundation

Period: 01/01/00 - 12/31/09 (\$1,000,000 Annual Direct Costs)

Title: Juvenile Diabetes Research Foundation Center for the Study of Complications in Diabetes: Oxidative Injury and Diabetic Complications

Principal Investigator: Eva L. Feldman

Funding Sponsor: University of Michigan Center for Gene Therapy

Period: 01/01/00 - 06/30/02 (\$50,000 Annual Direct Costs)

Title: Adeno-Associated and Advanced Generation Adenoviral Gene Therapy of Amyotrophic Lateral Sclerosis

Principal Investigator: Nicholas Boulis

Co-Investigator: Eva L. Feldman

Funding Sponsor: NIH T32 DK07245

Period: 07/01/00 - 06/30/05 (\$777,204 Annual Direct Costs)

Title: Training Program in Endocrinology and Metabolism

Principal Investigator: William Herman

Co-Principal Investigator: Eva L. Feldman

Funding Sponsor: Michigan Diabetes Research and Training Center

Period: 12/01/00 - 11/30/01 (\$76,646 Annual Direct Costs)

Title: Postgenomic Approaches to the Study of Diabetic Complications

Principal Investigator: Eva L. Feldman

Funding Sponsor: University of Michigan Bioinformatics Program

Period: 06/01/01 - 05/31/02 (\$74,667 Annual Direct Costs)

Title: The Center for the Study of Complications in Diabetes Bioinformatics Program

Principal Investigator: Eva L. Feldman

Funding Sponsor: NIH (NRSA) NS43023

Period: 09/01/01 - 08/31/04 (\$81,693 Annual Direct Costs)

Title: The Role of JNK in Neuronal Apoptosis

Principal Investigator: Gina Gehrke

Sponsor: Eva L. Feldman

Funding Sponsor: NIH U01 DK60994

Period: 09/01/01 - 11/30/06 (\$1,036,000 Annual Direct Costs)

Title: Mouse Models of Diabetic Nephropathy and Neuropathy

Principal Investigator: Frank Brosius

Co-Investigator: Eva L. Feldman
Funding Sponsor: NIH 3 P60 DK20572-24S2
Period: 12/01/01 - 11/30/02 (\$50,000 Annual Direct Costs)
Title: Postgenomic Approaches to the Study of Diabetic Complications
Principal Investigator: Eva L. Feldman

Funding Sponsor: NIH RO1 NS42759
Period: 12/01/01 - 11/30/07 (\$150,000 Annual Direct Costs)
Title: A Trial of Insulin-Like Growth Factor-I (IGF-I) in the Treatment of Patients With ALS
Principal Investigator: Eric J. Sorenson
Co-Investigator: Eva L. Feldman

Funding Sponsor: Pfizer Incorporated (Protocol 1014-051)
Period: 02/21/02 - 08/31/02 (\$7,125 Annual Direct Costs)
Title: A Retrospective Study for the Collection of DNA From Patients Previously Enrolled in Study 1014-001
Principal Investigator: Eva L. Feldman

Funding Sponsor: ALS Association
Period: 02/01/02 - 03/31/03 (\$52,911 Annual Direct Costs)
Title: Gene Therapy in Amyotrophic Lateral Sclerosis
Principal Investigator: Eva L. Feldman

Funding Sponsor: NIH RO1 NS38849
Period: 04/01/02 - 03/31/07 (\$570,000 Annual Direct Costs)
Title: Glucotoxicity Mediates Apoptosis in Diabetic Neuropathy
Principal Investigator: Eva L. Feldman

Funding Sponsor: NIH (NRSA) NS43865
Period: 04/01/02 – 09/19/03 (\$21,834 Annual Direct Costs)
Title: Remote Viral Gene Delivery in a Mouse Model of ALS
Principal Investigator: Bret Mobley
Sponsor: Eva L. Feldman

Funding Sponsor: NIH NS40458
Period: 07/01/02 - 06/30/06 (\$1,084,942 Annual Direct Costs)
Title: Impaired Glucose Tolerance Causes Neuropathy
Principal Investigator: J. Robinson Singleton
Co-Principal Investigator: Eva L. Feldman

Funding Sponsor: NIH DK063340
Period: 09/30/02 - 07/31/04 (\$450,000 Annual Direct Costs)
Title: Postgenomic Approaches to Diabetic Complications

Principal Investigator: Michael Uhler
Co-Investigator: Eva L. Feldman

Funding Sponsor: NIH KO8 EB003996
Period: 08/01/04 – 07/31/09 (\$162,522 Annual Direct Costs)
Title: Fibrous Templates for Directed Nerve Regeneration
Principal Investigator: Joseph Corey
Sponsor: Eva L. Feldman

Funding Sponsor: NIH N01-DK-6-2204 (George Washington University)
Period: 01/01/05 – 08/31/08 (\$25,622 Annual Direct Costs)
Title: Neuropathy Assessment in the EDIC Study
Principal Investigator: Eva L. Feldman

Funding Sponsor: NIH N01-DK-6-2204 (George Washington University)
Period: 01/01/05 – 08/31/07 (\$51,244 Annual Direct Costs)
Title: Neuropathy Assessment in the EDIC Study
Principal Investigator: Eva L. Feldman

Funding Sponsor: American Diabetes Association
Period: 01/01/05 – 12/31/07 (\$86,957 Annual Direct Costs)
Title: AGE Formation and RAGE Activation Underlie Metabolic Memory in Diabetic Neuropathy
Principal Investigator: Eva L. Feldman

Funding Sponsor: Takeda Pharmaceuticals North America
Period: 09/12/05 – 12/31/07 (\$139,600 Annual Direct Costs)
Title: Takeda 01-04-TL-128-003 Diabetic Peripheral Neuropathy Study
Principal Investigator: Eva L. Feldman

Funding Sponsor: NIH 5 U54 DA021519-03
Period: 09/25/05 – 12/31/10 (\$2,531,601 Annual Direct Costs)
Title: National Center for Integrative Biomedical Informatics
Principal Investigator: Brian Athey
Co-Investigator: Eva L. Feldman

Funding Sponsor: Mitsubishi Pharma America
Period: 01/01/06 – 12/01/07 (\$84,328 Annual Direct Costs)
Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Finding Study to Evaluate the Efficacy and Safety of 20 mg, 40 mg, and 80 mg of MCC-257 in Patients with Mild to Moderate Diabetic Polyneuropathy
Principal Investigator: Eva L. Feldman

Funding Sponsor: Juvenile Diabetes Research Foundation
Period: 02/01/06 – 01/31/07 (\$77,072 Annual Direct Costs)

Title: Drug Screening for Diabetic Neuropathy
Principal Investigator: Eva L. Feldman

Funding Sponsor: Juvenile Diabetes Research Foundation
Period: 02/01/06 - 7/31/08 (\$96,014 Annual Direct Costs)
Title: Drug Screening for Diabetic Neuropathy
Principal Investigator: Eva L. Feldman

Funding Sponsor: Amyotrophic Lateral Sclerosis Association
Period: 07/01/06 – 06/30/08 (\$47,000 Annual Direct Costs)
Title: Preclinical Pilot Assessment of Intraparenchymal AAV-IGF-I (CERE-130) Therapy
Principal Investigator: Eva L. Feldman

Funding Sponsor: NIH U01 DK076160
Period: 09/01/06 – 08/31/11 (\$139,339 Annual Direct Costs)
Title: Mitochondrial SOD as a Target for Diabetic Neuropathy
Principal Investigator: Eva L. Feldman

Funding Sponsor: Covance Clinical & Periapproval Services:
Takeda Pharmaceuticals North America
Period: 05/17/07 – 12/31/07 (\$174,050 Annual Direct Costs)
Title: Takeda 01-04-TL-128-003 Diabetic Peripheral Neuropathy Study
Principal Investigator: Eva L. Feldman

Funding Sponsor: Muscular Dystrophy Association
Period: 07/01/07 - 06/30/10 (\$122,727 Annual Direct Costs)
Title: Characterization and Rescue of a Murine Model of Myotubular Myopathy
Principal Investigator: James Dowling
Sponsor: Eva L. Feldman

Funding Sponsor: Juvenile Diabetes Research Foundation
Period: 09/01/07 - 8/31/08 (\$88,440 Annual Direct Costs)
Title: Preclinical Testing of DRG Protective Drugs in a Mouse Model of Diabetic Neuropathy
Principal Investigator: Eva L. Feldman

Funding Sponsor: NIH 2 P01 AG020591-06A1
Period: 01/01/08 – 04/30/13 (\$1,033,068 Annual Direct Costs)
Title: Reactive Oxygen Species: Stress and Damage in Old Muscle
Principal Investigator: Susan Herzog
Co-Investigator: Eva L. Feldman
Funding Sponsor: Avanir Pharmaceuticals
Period: 01/01/08 - 12/01/08 (\$84,328 Annual Direct Costs)

Title: A phase II, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Finding Study to Moderate Diabetic Polyneuropathy
Principal Investigator: Eva L. Feldman

Funding Sponsor: Juvenile Diabetes Research Foundation
Period: 06/01/08 - 05/31/11 (\$196,003 Annual Direct Costs)
Title: Diffusion Tensor Imaging of Sural Nerves in Diabetic Peripheral Neuropathy
Principal Investigator: Rodica Pop-Busui
Co-Investigator: Eva L. Feldman
Funding Sponsor: American Diabetes Association
Period: 07/01/08 – 06/30/11 (\$86,957 Annual Direct Costs)
Title: An Informatics Approach to Human Sural Nerve Biomarkers of Diabetic Neuropathy
Principal Investigator: Eva L. Feldman

Funding Sponsor: University of Michigan Medical School
Period: 07/01/08 – 06/30/09 (\$100,000 Annual Direct Costs)
Title: Stem Cell Research Grant
Principal Investigator: Eva L. Feldman

Funding Sponsor: NIH AMDCC (Animal Models of Diabetes and Complications Consortium) U24 DK076169
Period: 08/01/08 – 07/31/09 (\$100,000 Annual Direct Costs)
Title: Murine-Human Transcriptomic Comparisons in Diabetic Nephropathy and Neuropathy
Principal Investigator: Frank Brosius
Co-Investigator: Eva L. Feldman

Funding Sponsor: NIH 1 R24 DK082841-01
Period: 09/30/08 – 09/29/09 (\$300,000 Annual Direct Costs)
Title: Integrated Systems Biology Approach to Diabetic Microvascular Complications
Principal Investigator: Eva L. Feldman

Funding Sponsor: K08 AR054835
Period: 12/01/08 – 11/30/13 (\$119,000 Annual Direct Costs)
Title: Myotubularin and the Pathogenesis of Myotubular Myopathy
Principal Investigator: James Dowling
Sponsor: Eva L. Feldman

Funding Sponsor: NIH 1RC 1NS068182
Period: 09/30/09 – 08/31/11 (\$170,649 Annual Direct Costs)
Title: Biomarkers in Diabetic Neuropathy
Principal Investigator: Eva L. Feldman
Funding Sponsor: NIH/NIDDK R24 082841
Period: 04/01/10 – 03/31/16 (\$709,310 Annual Direct Costs)

Title: Integrated Systems Biology Approach to Diabetic Microvascular Complications
Principal Investigators: Frank Brosius and Eva L. Feldman

Funding Sponsor: NIH/DHHS R01 HL102334
Period: 05/01/10 – 04/30/15 (\$212,498 Annual Direct Costs)
Title: Cardiac Autonomic Neuropathy and Myocardial Dysfunction in Type 1 Diabetes
Principal Investigator: Rodica Pop-Busui
Co-Investigator: Eva L. Feldman

Funding Sponsor: Prime: Wake Forest University (WFUHS 30225)
Direct: NIH NIDDK (CDC Contract #200-2010-35171)
Period: 09/30/10 – 09/29/15 (\$28,883 Annual Direct Costs)
Title: Surveillance, Natural History, Quality of Care and Outcomes of Diabetes Mellitus with Onset in Childhood and Adolescence (SEARCH)
Site Principal Investigator: Eva L. Feldman

Funding Sponsor: United States-Israel Binational Science Foundation
Period: 10/01/10 – 09/30/14 (\$15,000 Annual Direct Costs)
Title: Human Pluripotent Stem Cells for Modeling and Studying the Pathophysiology of ALS
Principal Investigator: Eva L. Feldman

Funding Sponsor: Juvenile Diabetes Research Foundation
Period: 03/01/11 – 02/28/14 (\$43,240 Annual Direct Costs)
Title: Cross-Tissue Transcriptomics Predicts Diabetic Complications
Principal Investigator: Junguk Hur
Sponsor: Eva L. Feldman

Funding Sponsor: American Diabetes Association
Period: 07/01/11 – 06/30/14 (\$119,938 Annual Direct Costs)
Title: The Impact of the Metabolic Syndrome on the Incidence of Neuropathy in Obese Subjects
Principal Investigator: Brian Callaghan
Sponsor: Eva L. Feldman

Funding Sponsor: Type 1 Diabetes Impact Award (DP3) NIH 1DP3 DK094292
Period: 09/01/11 – 06/30/16 (\$798,771 Annual Direct Costs)
Title: Tissue-Specific Metabolic Reprogramming in Diabetic Complications
Principal Investigators: Frank Brosius and Eva L. Feldman

Funding Sponsor: NIH NIDDK 1 R03 DK094499
Period: 09/15/11 – 08/31/12 (\$50,000 Annual Direct Costs)
Title: Targeting Inflammation Using Salsalate in Type 1 Diabetic Neuropathy (TINSAL-T1DN)
Principal Investigator: Eva L. Feldman

Funding Sponsor: Juvenile Diabetes Research Foundation
Period: 11/01/11 – 10/31/14 (\$48,124 Annual Direct Costs)
Title: Studying the Link Between Type-1 Diabetes and Cardiac Arrhythmias
Principal Investigator: Catherine Stables
Sponsor: Eva L. Feldman

Funding Sponsor: Neuralstem, Inc.
Period: 02/01/12 – 07/31/12 (\$54,925 Annual Direct Costs)
Title: Establishment of Clinical Trial Infrastructure
Principal Investigator: Eva L. Feldman

Funding Sponsor: Omeros Corporation
Period: 07/01/12 – 06/30/13 (\$57,958 Annual Direct Costs)
Title: MASP-2 Antibodies for Diabetic Neuropathy
Principal Investigator: Eva L. Feldman

Funding Sponsor: American Diabetes Association
Period: 07/01/12 – 06/30/15 (\$100,000 Annual Direct Costs)
Title: Diabetic Dyslipidemia: A New Therapeutic Target for Diabetic Neuropathy
Principal Investigator: Eva L. Feldman

Funding Sponsor: NIH (Diabetic Complications Consortium)
Period: 07/16/12 – 07/15/13 (\$38,585 Annual Direct Costs)
Title: A Centralized Data Mining and Analysis Portal for Diabetic Neuropathy Research
Principal Investigator: Eva L. Feldman

Funding Sponsor: Prime: NIH Subcontracts 3-U24-DK-076169-07-S1
Direct: Georgia Health Sciences University
Period: 10/01/12 – 09/30/13 (\$26,533 Annual Direct Costs)
Title: A Centralized Data Mining and Analysis Portal for Diabetic Neuropathy Research
Site Principal Investigator: Eva L. Feldman

Funding Sponsor: ALS Association
Period: 11/16/12 – 11/15/14 (\$150,000 Annual Direct Costs)
Title: Cervical Intraspinial Human Stem Cell Transplantation for the Treatment of ALS
Principal Investigator: Eva L. Feldman

Funding Sponsor: Juvenile Diabetes Research Foundation
Period: 03/01/13 – 02/28/16 (\$55,384 Annual Direct Costs)
Title: Intersection of Bioenergetics with Oxidative Stress in Diabetic Neuropathy
Principal Investigator: Lucy Hinder
Sponsor: Eva L. Feldman

Funding Sponsor: NIH/NINDS K23 NS072279

Period: 04/01/13 – 08/31/15 (\$162,911 Annual Direct Costs)
Title: Validation of a Disease-Specific Instrument for Pediatric Inherited Neuropathy
Principal Investigator: Sindhu Ramchandren
Sponsor: Eva L. Feldman
Note: Transfer from Wayne State University
Funding Sponsor: Omeros Corporation
Period: 05/01/13 – 12/31/13 (\$75,346 Annual Direct Costs)
Title: MASP-2 Antibodies for Diabetic Neuropathy
Principal Investigator: Eva L. Feldman
Funding Sponsor: Muscular Dystrophy Association
Period: 09/01/13 – 01/31/14 (\$53,587 Annual Direct Costs)
Title: Neuromuscular Junction Transmission and Myotubular Myopathy
Principal Investigator: Eva L. Feldman

Funding Sponsor: NIH/NINDS K01 NS079461
Period: 09/28/13 – 07/31/16 (\$187,537 Annual Direct Costs)
Title: The Role of Diet-Induced Obesity in Cognitive Development
Principal Investigator: Catrina Robinson
Sponsor: Eva L. Feldman
Dr. Robinson Moved to Another Institution

Funding Sponsor: Prime: NIH R01 NS077982
Direct: Emory University
Period: 09/01/12 – 07/31/16 (\$37,206 Annual Direct Costs)
Title: Phase 1b Trial of Stem Cells in ALS
Principal Investigator: Eva L. Feldman

Funding Sponsor: Prime: NIH R01 DK113029
Direct: University of Colorado, Denver
Period: 06/01/13 – 05/31/17 (\$25,000 Annual Direct Costs)
Title: Complications and Comorbidities of Type 1 Diabetes
Principal Investigator: Eva L. Feldman

Funding Sponsor: NIH U24 DK076169
Direct: Medical College of Georgia
Period: 10/01/2016-07/31/2017 (\$64,516 Annual Direct Costs)
Title: Identifying Alterations in Mitochondrial Dynamics Associated with Diabetic Neuropathy
Principle Investigator: Eva L. Feldman

Funding Sponsor: Prime: NIH DP3DK104386
Direct: Mount Sinai Hospital
Period: 01/01/15 – 08/31/17 (\$32,428 Annual Direct Costs)

Title: Multinational Collaborative Evaluation of Corneal Confocal Microscopy as a Surrogate Endpoint for the Identification and Prediction of Diabetic Neuropathy in Type 1 Diabetes

Principal Investigator: Roni Shtein

Co-Investigator: Eva L. Feldman

Funding Sponsor: Centers for Disease Control/Agency for Toxic Substances and Disease Registry – CDC/ATSDR (Contract # 200-2013-56856)

Period: 09/01/13 – 08/31/17 (\$119,938 Annual Direct Costs)

Title: Identification and Validation of ALS Environmental Risk Factors

Principal Investigator: Eva L. Feldman

Funding Sponsor: NIH/NINDS R01 NS08230401A1

Period: 05/01/14 – 04/30/20 (\$399,488 Annual Direct Costs)

Title: Development of a Multi-Modal Neuroimaging Biomarker for Amyotrophic Lateral Sclerosis

Principal Investigators: Robert Welsh and Brad Foerster

Co-Investigator: Eva L. Feldman

Funding Sponsor: NIH/NIDDK F32 DK112642

Period: 04/01/2017 – 03/31/2018

Title: Identifying Alterations in Mitochondrial Dynamics Associated with Diabetic Neuropathy

Principle Investigator: Amy Rumora

Sponsor: Eva L. Feldman

Funding Sponsor: NIH/NINDS K23 NS079417

Period: 07/01/13 – 06/30/18 (\$185,669 Annual Direct Costs)

Title: The Impact of the Metabolic Syndrome on Neuropathy

Principal Investigator: Brian Callaghan

Sponsor: Eva L. Feldman

Period: 07/01/13 – 06/30/18 (\$154,904 Annual Direct Costs)

Title: Epigenetic Changes in Bone-Marrow Progenitor Cells Impair Diabetic Wound Healing

Principal Investigator: Katherine Gallagher

Sponsor: Eva L. Feldman

Funding Sponsor: NIH/NIA P01 AG051442

Period: 09/01/2016 – 08/31/18

Direct/Total Costs for Award: \$7,603,817/\$10,932,979

Title: Molecular Mechanisms of Neuromuscular Interactions Underlying Age-Related Atrophy

Principal Investigator: Susan Herzog

Co-Investigator: Eva L. Feldman

Clinical Trials

Funding Sponsor: Neuralstem, Inc.

Period: 01/01/10 – 10/1/2018

Title: A Phase I, Open-label, First-in-human Feasibility and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis – NS20008-1; followed by a Phase II.

Principal Investigator: Eva L. Feldman

Honors and Awards

1973	High Honors in the Sciences, Earlham College
1975-1977, 1979	NIH Research Service Award, The University of Michigan
1978	The University of Michigan Rackham Scholar
1979	Student Award, Michigan Society for Neuroscience
1987	The Johns Hopkins Hospital Annual Resident Award for Outstanding Medical Student Teaching
1990	Searle Scholar Semifinalist
1994	Member, American Neurological Association
1996	The Best Doctors in America, Midwest Region Who's Who in Science
1996	Jay Slotkin Visiting Professor of Neurology, The Johns Hopkins Hospital
1998	Fellow of the American Academy of Neurology
1999	The Best Doctors in America Who's Who in America Fellow, Hedwig van Ameringen Executive Leadership in Academic Medicine (ELAM) Benjamin Boshes Visiting Professor of Neurology, Northwestern University
2000	The Juvenile Diabetes Research Foundation Jane Cobb Promise Award for Medical Research
2001	University of Michigan Medical Center Alumni Society Early Career Distinguished Achievement Award
2002 to present (annual)	Castle Connolly Top Doctors in America The Best Doctors in America Who's Who in Medicine and Healthcare Who's Who of American Women
2003 and 2005	Juvenile Diabetes Research Foundation Mary Jane Kugel Award
2005	Jerome K. Merlis Neuroscience Lecturer, The University of Maryland American Association of Neuromuscular & Electrodiagnostic Medicine, Fellow
2006	American Diabetes Association Lifetime Achievement Award

2007 to present	America's Top Doctors
2010	Johns Hopkins Society of Scholars
2011	Bernard J. Alpers Lecturer, Thomas Jefferson University
2011	Chalmers J. Lyons Memorial Lecturer, AAOMS
2012	Gail Beach Memorial Lecturer, Miami Spinal Cord Project
2012	Michigan State Medical Society National President Award
2012	Health Honoree, The Braylon Edwards Foundation
2012	Distinguished Faculty Achievement Award, The University of Michigan
2014	National Academy of Medicine of the National Academies of Sciences, Engineering and Medicine, Member
2015	Michigan Israel Business Bridge (MIBB) Chuck Newman Impact Award
2016	Castle Connolly National Physician of the Year Award for Clinical Excellence
2016	Crain's Detroit Business 100 Most Influential Women in Michigan
2016	Society for Neuroscience Bernice Grafstein Award for Outstanding Accomplishments in Mentoring
2017	Gerald D. Aurbach Award for Outstanding Translational Research, Endocrine Society
2017	Esteemed Women of Michigan Recipient
2018	American Neurological Association Honorary Fellow
2018	Marquis Who's Who in the World Lifetime Award
2019	Michigan Medicine Alumni Society Distinguished Alumni Award

Memberships in Professional Societies

1987	American Academy of Neurology
1988	Michigan Neurological Association
1989	American Association of Electrodiagnostic Medicine
1989	Society for Neuroscience
1989	American Society for Neurological Investigation
1990	Michigan Society for Medical Research
1990	American Association Advancement of Science
1990	American Society for Neurochemistry
1990	International Society for Neurochemistry
1992	American Diabetes Association
1992	European Association for the Study of Diabetes
1992	Central Society for Neurologic Research
1993	Endocrine Society
1995	American Neurological Association
1996	Neurodiab, Diabetic Neuropathy Study Group of the EASD
1998	The American Society for Cell Biology

1998	European Federation of Neurological Societies Task Force
1998	The Peripheral Nerve Society
2001	American Association of University Professors
2002	American Society for Biochemistry and Molecular Biology
2003	American Society for Experimental NeuroTherapeutics (ASENT)
2013	La Societe Francaise De Neurologie (SFN)
2014	National Academy of Medicine
2017	American Academy of Physicians Member

Editorial Positions, Boards, and Peer-Review Service

Editorial Boards (Currently Serving as of 2012)

Current Opinion in Neurology
 Journal of the Peripheral Nervous System
 Lancet Neurology Network
 Experimental Neurology
 Nature Neurology
 Neurobiology of Disease
 NeuroRx (Journal of the American Society of Neurotherapeutics)
 Annals of Neurology

(Serving as of 2013)

Journal of Neurology, Neurosurgery and Psychiatry

(Serving as of 2014)

JAMA Neurology

(Serving as of 2016)

Oxford University Press, Contemporary Neurology Series (CNS), Editor-in-Chief

Committees, Offices and Board Memberships Outside the University of Michigan

Past:

1993-1995	Michigan Neurological Association, Program Chair
1996 - 1998	World Federation of Neurology ALS Committee, Board Member
1996 - 1999	American Neurological Association, Scientific Program Committee
1996 - 1999	International IGF Society, Scientific Program Committee
1996 - 1999	Michigan Amyotrophic Lateral Sclerosis Association

Board Member

1998 - 2001	The Amyotrophic Lateral Sclerosis Association Medical Advisory Committee, Member
1998 - 2005	Peripheral Nerve Society, Scientific Program Committee
2000 - 2002	American Diabetes Association, Council on Complications, Chair American Diabetes Association, Scientific Planning Committee
2000 - 2003	American Academy of Neurology, Young Investigator Award Subcommittee, Chair
2000 - 2004	Juvenile Diabetes Research Foundation, Executive Committee and Research Advisory Board
2001 - 2004	American Neurological Association, Councilor
2001 - 2008	American Neurological Association, Long Range Planning Committee
2002 - 2008	Research Group on Neuromuscular Diseases, World Federation of Neurology, Executive Committee Member AUPN Families in Neurology Task Force, Member
2003 - 2004	Peripheral Nerve Society, Scientific Program Committee, Chair
2005 - 2010	American Neurological Association, Junior Faculty Development Course, Chair
2006 - 2007	American Neurological Association, Second Vice President
2007 - 2009	Peripheral Nerve Society, President
2009 - 2011	American Neurological Association, President-Elect American Neurological Association, Audit Subcommittee, Member American Neurological Association, Finance and Investment Committee, Member

2010 - 2012 National Institutes of Health/National Cancer Institute
Clinical Community Oncology Program Planning
Committee, Member

2011 - 2013 American Neurological Association, President

2011 - 2016 American Academy of Neurology Foundation Board,
Member
American Academy of Neurology Clinician Research Task
Force, Member

Present:

1996 - Present Epidemiology of Diabetes Intervention and Complications
(EDIC) Neurology Consultant
Peripheral Neuropathy Association, Board Member

2003 - Present American Society for Experimental NeuroTherapeutics
(ASENT) Board of Directors, Member
The Dana Alliance for Brain Initiatives, Member

2008 - Present The Foundation for Peripheral Neuropathy, Scientific
Advisory Board, Member
Stem Cell Michigan, Board Member

2014 - Present World Federation of Neurology Nominating Committee,
Member

2015 - Present External Evaluation Committee (EEC) for the Diabetic
Complications Consortium

2016 – Present NAM Strategic Planning Committee

2017 – Present Chair of the Nominating Committee of the American
Neurological Association

2018 – Present Vice Chair of Section 07 National Academy of Medicine

2018-Present Peripheral Nerve Society Diabetes Neuropathy Consortium
Board of Directors Member

National Institutes of Health (NIH) Review Committees

1994 - Present National Institutes of Health, Ad Hoc Reviewer

1994 - Present Office of Orphan Products Development, Department of

	Health & Human Services, Ad Hoc Reviewer
2004 - 2006	National Institutes of Health, Tumor Microenvironment Study Section, Reviewer
2008 - 2012	Molecular and Cellular Endocrinology Study Section, Reviewer
2015 - Present	National Institute of Diabetes & Digestive & Kidney Diseases National Institutes of Health, DiaComp EEC, Reviewer

Private Foundation Review Committees

1992 - 1995	The Amyotrophic Lateral Sclerosis Association Scientific Review Committee, Member
2000 - 2005	Juvenile Diabetes Research Foundation Complications Study Section, Chair
2004 - 2008	American Diabetes Association Scientific Review Committee
2005 - present	Juvenile Diabetes Research Foundation Complications Study Section
2011 - present	Juvenile Diabetes Research Foundation Corneal Biomarkers Group

Teaching

Current Activities:	Neurology Grand Rounds and Basic Neuroscience Conferences, The University of Michigan, Ann Arbor, Michigan Neuromuscular Conferences, The University of Michigan, Ann Arbor, Michigan Endocrinology Conferences, The University of Michigan, Ann Arbor, Michigan
---------------------	---

Doctoral Students

Donna Martin - Neuroscience Program 1989-1992
Hsin-Lin Cheng - Neuroscience Program 1993-1996
Bhumsoo Kim - Neuroscience Program 1995-1998
Cynthia van Golen - Neuroscience Program 1995-1999
Gary Meyer - Neuroscience/MSTP Programs 1998-2003

Amy Meyer - Neuroscience Program 2000-2003
Gina Leininger - Neuroscience Program 2000-2005
Junguk Hur - Bioinformatics Program 2007-2010
Elizabeth Gibbs - Neuroscience Program 2007-2012
Rosemary Henn – Cellular and Molecular Biology/MSTP Program 2018-present

Past Postdoctoral Fellows

Caryn Vogel, M.D. 1990-1991
Venil Sumantran, Ph.D. 1991-1992
Kelli Sullivan, Ph.D. 1993-1995
Christopher Matthews, Ph.D. 1993-1995
J. Robinson Singleton, M.D. 1995-1996
Phillip Leventhal, Ph.D. 1994-1996
James Russell, M.D. 1995-1999
Hsin-Lin Cheng, M.D., Ph.D. 1996-2000
Daniel D. Mikol, M.D., Ph.D. 1996-2000
David Herrmann, M.D. 1997-1998
Catherine Delaney, Ph.D. 1998-2000
Nicholas Boulis, M.D. 1998-2000
Tracy Schwab, Ph.D. 1999-2001
Cynthia van Golen, Ph.D. 1999-2004
Adam Rubin, M.D. 2000-2002
Andrea Vincent, Ph.D. 2001-2003
Joseph Corey, M.D., Ph.D. 2002-2004
Amanda Peltier, M.D. 2002-2005
Kevin Fung, M.D. 2003-2004
Ming Hong, M.D. 2003-2004
Steven Heavner, M.D. 2004-2005
Dale Ekbom, M.D. 2005-2006
Lorena Perrone, Ph.D. 2005-2006
Sindhu Ramchandren, M.D. 2005-2007
Matthew Old, M.D. 2006-2007
Mahdieh Sadidi, Ph.D. 2005-2008
James Edwards, Ph.D. 2006-2008
Adam Schuyler, Ph.D. 2006-2009
Stacey Sakowski, Ph.D. 2006-2011
James Dowling, M.D., Ph.D. 2006-2013
John Simon Lunn, Ph.D. 2006-2013
Catrina Sims-Robinson, Ph.D. 2008-2011
Brad Bader, M.D. 2008-2009
Audrey Erman, M.D. 2008-2009
Hsin-Lin Cheng, M.D., Ph.D. 2008-2013
Brian Callaghan, M.D. 2009-2011
Garrett Griffin, M.D. 2009-2011

Robbie Kupfer, M.D. 2011-2013
Catherine Stables, Ph.D. 2011-2014
Diane Bender, Ph.D. 2011-2014
Junguk Hur, Ph.D. 2010-2014
Osama Kashlan, M.D., 2014-2015
Meeyoung Park, Ph.D., 2013-2017
Ximena Páez-Colasante, Ph.D., 2014-2017
Kevin Chen, M.D., 2014-2017
Lucy Hinder, Ph.D. 2009-2018

Present Postdoctoral Fellows and K09/K23 Mentees

Claudia Figueroa-Romero, Ph.D. 2007-Present
Phillipe O'Brien, Ph.D. 2011-Present
Lisa McGinley, Ph.D., 2013-Present
Benjamin Murdock, Ph.D., 2014-Present
Amy Rumora, Ph.D., 2014-Present
Sarah Elzinga, Ph.D., 2017-Present
Stephanie Eid, Ph.D., 2017-Present
Stephen Goutman, M.D., 2018-Present
Alina Monteagudo Caballero, Ph.D., 2018-Present
Osama Kashlan, M.D., 2019-Present

Research Scientists

Tracy Schwab, Ph.D. 1999-2007
Eric Schwab, Ph.D. 2000-2001
Cynthia van Golen, Ph.D. 2004-2006
Kelli Sullivan, Ph.D. 1995-2011
Andrea Vincent, Ph.D. 2003-2012
Bhumsoo Kim, Ph.D. 2000-Present
Catrina Sims-Robinson, Ph.D. 2011-2014

Sabbatical Investigators

Banu Anlar, M.D. 1998
George Werther, M.D. 1999
Denise Figlewicz, Ph.D. 2001

Ph.D. Thesis Committees

Jennifer Knight - Neuroscience Program 1992-1994
Kim McGinnis - Neuroscience Program 1997 - 1999
Michael Steketee - Neuroscience Program 1995 - 2000
Mary Benedict - Cell and Molecular Biology Program 1995 - 2001

Amy Leigh Miller - Neuroscience Program 1996 - 2000
 Eric Humke - Cell and Molecular Biology Program 1997 - 2002
 Bradley Layton - Bioengineering Program 2001 - 2003
 Kathryn Johnson - Immunology/MSTP Programs 2002 - 2005
 Peter Schlueter - Neuroscience Program 2005 - 2006
 Li Zhang - Pharmaceutical Science Program 2006 - 2008
 Hui Li – Molecular Cellular and Developmental Biology 2006 - 2009
 Aaron Reifler – Neuroscience Program 2011 - 2013
 Graham Atkin - Neuroscience Program 2011 – 2014
 Jessica Chen – Neuroscience Program 2015 - Present

Committee, Organizational, and Volunteer Service

University Committee and Administrative Services

Recent

1991-1998	Neurology Resident Selection Committee
1991-2000	Neurology Resident Education Committee, Chair
1995-1998	University of Michigan Faculty Senate Assembly President's Advisory Commission on Women's Issues
1995-2001	Student Biomedical Research Committee
1995-2001	Neurology Faculty Recruitment Committee, Chair
1997-1998	University of Michigan Rackham Faculty Grants & Fellowships, Divisional Board Member
1998-1999	University of Michigan Internal Medicine Chair Search Committee
1998-2000	Michigan Electrophysiological Reading Lab (MERL), Director
1998-2013	University of Michigan Conflict of Interest Committee
1999-2004	University of Michigan Strategic Planning Research Subcommittee Center for Gene Therapy Executive Committee
2000-2006	University of Michigan Space Master Planning Steering Committee

2000-2010	Michigan Diabetes Research and Training Center (MDRTC) Policy Committee University of Michigan Research Advisory Board for the Office of Research and Graduate Studies
2002-2003	University of Michigan Executive Vice President for Medical Affairs Search Advisory Committee
2003-2014	University of Michigan Robert Wood Johnson Foundation Institutional Advisory Committee, Member
2004-2005	University of Michigan Health Care Leadership Institute (HCLI) Leadership Development Program
2005-2010	Michigan Diabetes and Research Training Center (MDRTC) Morphology and Image Analysis Core (MIAC) Operating Committee, Member
2006-2009	University of Michigan Clinical and Translational Sciences Scientific Advisory Board, Member
<u>Present</u>	
1991-Present	Neurology Training Grant Executive Committee, Chair
1995-Present	Neurology Tenure and Promotions Committee
1996-Present	University of Michigan Medical Center Ombudsman
1997-Present	Faculty Affairs Advisory Committee
1998-Present	Pediatric Training Grant, "Cellular and Molecular Biology in Pediatrics," Advisory Committee
2001-Present	University of Michigan Bioinformatics Program, Faculty Affiliate
2002-Present	University of Michigan Medical Scientist Training Program Career Advisory Panel, Member Institutional Advisory Committee, Clinical Scholars Program Member
2005-Present	University of Michigan Training Program in Clinical Research Program Advisory Council, Member University of Michigan Comprehensive Diabetes Center

2006-Present	Operating Committee, Member University of Michigan Nathan Shock Center for Aging Research, Member University of Michigan Medical School Dean's Advisory Council, Member
2008-Present	University of Michigan Department of Neurology Executive Advisory Committee, Member
2009-Present	University of Michigan Clinical and Translational Sciences Education Core Admissions Committee, Member University of Michigan Consortium for Stem Cell Therapies Scientific Advisory Board, Member
2010-Present	University of Michigan Clinical and Translational Science Award (CTSA) and the Michigan Institute for Clinical and Health Research (MICHR) Internal Advisory Board, Member
2013-Present	University of Michigan Health System Development Leadership Advisory Group, Member
2014-Present	Michigan Alzheimer's Disease Research Center (ADRC) Internal Advisory Board, Member University of Michigan Division of Metabolism, Endocrinology, and Diabetes T32 Executive Committee, Member
2015-Present	University of Michigan Learning Health Systems for Diabetes (LHS4D) Advisory Board, Member University of Michigan K12 Career Development Program in Emergency Critical Care Research Steering Committee, Member
2016- Present	University of Michigan Medical School Major Awards Committee Member.
2017-Present	University of Michigan Frances and Kenneth Eisenberg Scholars Fund Review Committee Member.
2017-Present	University of Michigan Diabetes Research Center (MDRC) Internal Scientific Advisory Board Member.
2018-Present	University of Michigan Executive Committee on Clinical Affairs (ECCA) Committee Member

2019-Present	University of Michigan Distinguished Faculty Award Committee Member
2019-Present	University of Michigan M-Diabetes Clinical Research, Mentoring and Development Committee Member

Visiting Professorships, Seminars, Lectureships, and Extramural Invited Presentations

Syntex, Inc. Diabetic Polyneuropathy, Palo Alto, California, March 1991

American Academy of Neurology Annual Courses, Amyotrophic Lateral Sclerosis, Boston, Massachusetts, April 1991

Peripheral Nerve Study Group, Multifocal Motor Neuropathy, Arden House, New York, June 1991

International Symposium on Diabetic Neuropathy, sponsored by the World Health Organization, Diabetic Neuropathy: A Neurologist's Perspective, Melbourne, Australia, July 1991

European Association for the Study of Diabetes (EASD), The Neuropathy Rating Scale, Prague, Czechoslovakia, September 1992

Diabetic Neuropathy Study Group of the EASD, A New Screening Tool for Diabetic Neuropathy, Bratislava, Czechoslovakia, September 1992

Joslin Clinic Neuropathy Symposium, sponsored by the Joslin Clinic and the Juvenile Diabetes Association, Diabetic Neuropathy, Nice, France, November 1992

Endocrine Grand Rounds, University of Toronto Medical Center, Mount Sinai Hospital, Quantitative Assessment of Diabetic Neuropathy, Toronto, Ontario, March 1993

Medical Grand Rounds, University of Toronto Medical Center, The Toronto Hospital, Diabetic Neuropathy, Toronto, Ontario, March 1993

XXVIIIth Meeting of the Canadian Congress of Neurological Sciences, Clinical Testing in Diabetic Neuropathy, Toronto, Canada, June 1993

Greek Diabetes Association, Quantitative Assessment of Diabetic Neuropathy, Athens, Greece, June 1993

Northern Greek Diabetes Association, Quantitative Assessment of Diabetic Neuropathy, Thessaloniki, Greece, June 1993

European Association for the Study of Diabetes (EASD), Neurological Assessment in Neuropathy Diagnosis and Treatment, Istanbul, Turkey, September 1993

Diabetic Neuropathy Study Group of the EASD, IGF-II Mediates Autocrine Growth in Human Neuronal Cells, Istanbul, Turkey, September 1993

Joslin Clinic Neuropathy Symposium, sponsored by the Joslin Clinic and the Juvenile Diabetes Association, Quantitative Assessment of Diabetic Neuropathy, Buenos Aires, Argentina, October 1993

Joslin Clinic Neuropathy Symposium, sponsored by the Joslin Clinic and the Juvenile Diabetes Association, Quantitative Assessment of Diabetic Neuropathy, Puerto Vallarta, Mexico, November 1993

XIII Pan American Congress of Endocrinology, Diagnosis of Diabetic Neuropathy, Santiago, Chile, April 1994

Molecular Neuroscience Seminar Series, Insulin-like Growth Factors in the Peripheral Nervous System, Mayo Clinic, Rochester, Minnesota, April 1994

National Institute of Health Workshop, Neurotoxicology of Nerve Agents and Pesticides, Bethesda, Maryland, April 1994

Cephalon Corporation, The Pathogenesis of Diabetic Neuropathy: Role of IGF-I, West Chester, Pennsylvania, April 1994

American Academy of Neurology Dinner Seminar, Unusual Diagnostic and Management Problems in Neuromuscular Disease, Washington, D.C., May 1994

Steno Diabetes Center Course: Frontiers in Clinical and Experimental Diabetology, Screening and Monitoring of Diabetic Neuropathy, Copenhagen, Denmark, May 1994

Neurology Grand Rounds, University of California, San Diego, Medical Center, Diabetic Neuropathy: Experimental and Clinical Aspects, San Diego, California, June 1994

University of Michigan Endocrinology and Diabetes Update, Diagnosis of Atypical Neuropathies in Patients with Diabetes, Grand Traverse Village, Michigan, July 1994

European Association for the Study of Diabetes (EASD), Insulin-like Growth Factor I Regulates Schwann Cell Secreted Insulin-like Growth Factor Binding Proteins, Dusseldorf, Germany, September 1994

Diabetic Neuropathy Study Group of the EASD, Characterization of Insulin-like Growth Factor-I (IGF-I), IGF-I Receptor and Binding Proteins in Transected Nerves and Cultured Schwann Cells, Dusseldorf, Germany, September 1994

NEURO Critical Care Nursing Conference, Update on the Management of Guillian-Barre' Syndrome, Ann Arbor, Michigan, March 1995

Longwood Program/Joslin Clinic Research Conference, Insulin-like Growth Factors as Neural Osmoprotectants, Boston, Massachusetts, April 1995

American Diabetes Association Conference on the Diagnosis and Treatment of the Complications of Diabetes, Diagnosis and Classification of Neuropathy, Cambridge, Massachusetts, April 1995

Diabetic Neuropathy Study Group of the EASD, IGF-I and Programmed Cell Death, Stockholm, Sweden, September 1995

Diabetic Neuropathy Study Group of the EASD, IGF and IGF Binding Proteins, Stockholm, Sweden, September 1995

European Association for the Study of Diabetes (EASD), IGF-I Can Rescue Neurons From Hyperosmotic-Coupled Programmed Cell Death, Stockholm, Sweden, September 1995

European Association for the Study of Diabetes (EASD), IGF and IGF Binding Protein Expression in Sensory Neurons, Stockholm, Sweden, September 1995

Neurology Grand Rounds, The Johns Hopkins Hospital, Growth Factor Treatment in Neurological Disease, Baltimore, Maryland, March 1996

Axon, Schwann Cell, and Oligodendrocyte Conference, Focal Adhesion Kinase and Paxillin in Neurite Outgrowth, The Johns Hopkins Hospital, Baltimore, Maryland, March 1996

Therapy in Neurology II Course, Recent Advances in the Treatment of Motor Neuron Diseases, American Academy of Neurology 48th Annual Meeting, San Francisco, California, March 1996

Neurology Grand Rounds, The Franz Josef Hospital, Recent Advances in the Treatment of Motor Neuron Diseases, Vienna, Austria, September 1996

European Association for the Study of Diabetes (EASD), Insulin-like Growth Factor-I (IGF-I) Protects Neurons From Glucose-induced Cell Death, Vienna, Austria, September 1996

Michigan Neurological Association, Growth Factor Treatment in Neurological Disease, Troy, Michigan, October 1996

National Academy of Science, Institute of Medicine, The Diagnosis and Quantitative Assessment of Neuropathy, Georgetown, Maryland, December 1996

Neuroscience Conference, University of Kansas, Insulin-Like Growth Factors Regulate Neuronal Apoptosis, Kansas City, Missouri, January 1997

Anatomy and Cell Biology Seminar, University of Michigan, IGF-I in Neuronal Differentiation and Neuroprotection, Ann Arbor, Michigan, April 1997

Neurology Grand Rounds, Emory University, Insulin-Like Growth Factor-I in the Treatment of Neurologic Disease, Atlanta, Georgia, March 1997

Neurology Grand Rounds, Washington University, Insulin-Like Growth Factor-I is a Neuronal Survival Factor, St. Louis, Missouri, March 1997

Neurology Grand Rounds, Yale University, The Pleiotropic Effects of the Insulin-Like Growth Factors on the Nervous System, New Haven, Connecticut, April 1997

Symposium on IGFs in the Nervous System, IGF-I in Neuronal Differentiation and Neuroprotection, Milan, Italy, May 1997

International Diabetes Federation Congress, The Diagnosis and Staging of Diabetic Neuropathy, Helsinki, Finland, July 1997

International Symposium on Diabetic Neuropathy, Insulin-like Growth Factor-I (IGF-I) Promotes the Myelination of Sensory Neurons, The Netherlands, July 1997

American Neurological Association Presidential Public Policy Forum, Growth Factors in the Treatment of Neurologic Disease, San Diego, California, September 1997

American Society for Neurochemistry Symposium, New Directions in the Treatment of ALS: A Role for IGF?, Denver, Colorado, March 1998

University of Michigan Physiology Seminar, Insulin-like Growth Factor Signaling, Ann Arbor, Michigan, May 1998

The Endocrine Society Symposium, IGFs Regulate Apoptotic Proteins, New Orleans, Louisiana, June 1998

IX International Congress on Neuromuscular Diseases, The Role of IGF-I in Diabetic Neuropathy, Adelaide, Australia, August 1998

IX International Congress on Neuromuscular Diseases, Toxic Neuropathies, Adelaide, Australia, August 1998

IX International Congress on Neuromuscular Diseases, Insulin-like Growth Factor-I in Regeneration: From the Bench to the Bedside, Adelaide, Australia, August 1998

1st International Conference of the Neuropathy Association, Growth Factors as Therapy for Neuropathy, Sofiko Corinthias, Greece, August 1998

University of Michigan Neuroscience Conference, The Cell Biology of Neurons, Ann Arbor, Michigan, September 1998

Internal Medicine Grand Rounds, University of Texas, The Role of Insulin-like Growth Factors in Neuroblastoma Carcinogenesis, San Antonio, Texas, September 1998

Neurology Grand Rounds, University of Texas, Insulin-like Growth Factors: From Bench to Bedside, Houston, Texas, October 1998

Third International Conference on Charcot-Marie Tooth Disorders, Role of IGF-I in Peripheral Nervous System Regeneration, Montreal, Canada, October 1998

American Diabetes Association's Fall Leadership Forum, Diabetic Neuropathy is a Treatable Disease, Brighton, Michigan, October 1998

University of Michigan Cellular and Molecular Biology Seminar, The Role of Insulin-like Growth Factors in Neurologic Disorders, Ann Arbor, Michigan, November 1998

University of Michigan Organogenesis Seminar, Insulin-like Growth Factor-I in the Nervous System, Ann Arbor, Michigan, November 1998

The Neuropathy Association Neuropathy Centers Meeting, Growth Factors in the Treatment of Neuropathy: A Critical Review, Puerto Rico, January 1999

University of Michigan Pediatric Hematology/Oncology Seminar, The Role of Insulin-like Growth Factors in Neuroblastoma Carcinogenesis, Ann Arbor, Michigan, February 1999

Seminars in Molecular Medicine, Northwestern University, Insulin-like Growth Factors Prevent Glucose Mediated Injury, Chicago, Illinois, March 1999

Benjamin Boshes Annual Spring Lecture, Northwestern University, Insulin-like Growth Factor I: From Bench to Bedside, Chicago, Illinois, May 1999

University of Pennsylvania, Department of Neurology, Insulin-like Growth Factors: From Bench to Bedside, Philadelphia, Pennsylvania, June 1999

5th International Symposium on Insulin-Like Growth Factors, IGF-I and the Peripheral Nervous System, Brighton, United Kingdom, November 1999

Neurology Grand Rounds, Louisiana State University, Diabetic Neuropathy: Bench to Bedside, Baton Rouge, Louisiana, November 1999

University of Michigan Neuroscience Conference, Insulin-like Growth Factor-I: Not Just Any Growth Factor, Ann Arbor, Michigan, February 2000

Neurology Grand Rounds, Mayo Clinic, Insulin-like Growth Factor I: From Bench to Bedside, Rochester, Minnesota, March 2000

Neuromuscular Conference, Mayo Clinic, Gene Therapy in ALS, Rochester, Minnesota, March 2000

Neurology Grand Rounds, Vanderbilt University, The Therapeutic Potential of Growth Factors in Neurological Disease, Nashville, Tennessee, March 2000

Michigan Diabetes Research and Training Center Winter Symposium, Insights Into the Pathogenesis of Diabetic Neuropathy, Ann Arbor, Michigan, March 2000

American Diabetes Association Regional Meeting, Diabetic Neuropathy: Etiology and Treatment, Chicago, Illinois, April 2000

University of Minnesota Cancer Center Seminar Series, Insulin-like Growth Factors and Neuroblastoma, Minneapolis, Minnesota, May 2000

Juvenile Diabetes Foundation International Annual Conference Research Update, Oxidative Stress and Diabetic Complications, Washington, DC, May 2000

Juvenile Diabetes Foundation International, Michigan Chapter Research Update, Oxidative Stress and Diabetic Complications, Birmingham, Michigan, May 2000

Joslin Diabetes Center, Diabetic Neuropathies & Microvascular Complications: Clinical Strategies, Diabetic Neuropathies: Treatment Strategies, Columbus, Ohio, June 2000

The Neuropathy Association, Peripheral Neuropathy in the New Millennium, Management of Diabetic Neuropathies, Banff, Alberta, Canada, August 2000

Plenary Session of the American Association of Electrodiagnostic Medicine, Neuropathy: From Genes to Function, Growth Factors and Their Relevance to Neuropathies, Philadelphia, Pennsylvania, September 2000

Department of Neurology, Basic Neuroscience Conference, University of Michigan, Cell Health and Death in the Nervous System, Ann Arbor, Michigan, October 2000

Plenary Session of the American Neurological Association, Insulin-like Growth Factor I Regulates a Key Transcription Factor Involved in Neuronal Apoptosis, Boston, Massachusetts, October 2000

Neurology, Grand Rounds, University of Michigan, Stressed to Death or How Neurons Die, Ann Arbor, Michigan, November 2000

Plenary Session at the American Pain Society, Painful Diabetic Neuropathy, Phoenix, Arizona, April 2001

American Academy of Neurology, Diabetes and Impaired Glucose Tolerance Induce Neuropathy and Programmed Cell Death in the Obese Zucker Diabetic Rat, Philadelphia, Pennsylvania, May 2001

University of Michigan, Pediatric Hematology Conference, Neuroblastoma: An Update, Ann Arbor, Michigan, May 2001

Neurology Grand Rounds, University of California, The Therapeutic Potential of Growth Factors in Neurological Disease, Los Angeles, California, August 2001

The Neuropathy Association, Current Therapy of Peripheral Neuropathy, Diagnosis and Management of Diabetic Neuropathy, Rome, Italy, August 2001

Merck Pharmaceuticals, Apoptosis and Diseases of the Nervous System, Rahway, New Jersey, October 2001

Neurology Grand Rounds, Northwestern University, Diabetes in the Nervous System, Chicago, Illinois, February 2002

Neuroscience Seminar Series, Penn State College of Medicine, Stressed to Death: Diabetes and the Nervous System, Hershey, Pennsylvania, March 2002

University of Connecticut, Management of the Diabetic Patient 2002: Challenges and Opportunities for the Future, Glucose-Mediated Oxidative Stress Produces Diabetic Neuropathy & Retinopathy, Mashantucket, Connecticut, March 2002

U.S. Food and Drug Administration, Meeting of the Anesthetic and Life Support Drugs Advisory Committee, Scales Used in the Evaluation of Peripheral Neuropathy, Washington, DC, May 2002

Endocrinology Grand Rounds, University of Colorado, Is There a Therapeutic Future for IGF-I?, Denver, Colorado, May 2002

ALS Association's Leadership Development and Clinical Conference, Gene Therapy in Motor Neuron Disease, Washington, DC, May 2002

American Diabetes Association, Animal Models of Neuropathy, San Francisco, California, June 2002

Xth International Congress on Neuromuscular Diseases, Diabetic Neuropathies, Vancouver, Canada, July 2002

Neurology Grand Rounds, University of Michigan, Amyotrophic Lateral Sclerosis, Ann Arbor, Michigan, September 2002

University of Michigan, Continuing Medical Education, Recent Advances in Geriatric Neurology: Dementia, Stroke, Movement Disorders and Neuropathy, Diabetic Neuropathy, Ann Arbor, Michigan, September 2002

University of Michigan, Invited Grand Rounds Lecture, Diabetic Neuropathy: From Bench to Bedside, Ann Arbor, Michigan, November 2002

University of Michigan, Cell and Developmental Biology Seminar, Insulin-Like Growth Factors and Cancer, Ann Arbor, Michigan, December 2002

Physical Medicine and Rehabilitation Grand Rounds, University of Michigan Advances in the Treatment of Diabetic Neuropathy, Ann Arbor, Michigan, December 2002

Juvenile Diabetes Research Foundation, Lay Review Committee Retreat, Microvascular Complications in Type I Diabetes, Nashville, Tennessee, January 2003

University of Michigan, Bioinformatics Seminar Series, Diabetes and Bioinformatics: Perfect Partners, Ann Arbor, Michigan, February 2003

American Society for Experimental Neuro Therapeutics (ASENT), Update on Neuromuscular Clinical Trials, Washington, DC, March 2003

University of Michigan, The First Health Sciences Council Symposium, Diabetes Symposium, Diabetes and Its Complications, Ann Arbor, Michigan, March 2003

National Institutes of Health, 20th Anniversary Symposium of the DCCT/EDIC, Metabolic Imprinting and the Long-Term Complications of Diabetes Mellitus: Bench to Bedside and Back, New Investigative Tools in Neuropathy, Bethesda, Maryland, April 2003

The ALS Association, Greater New York Chapter, “A Time For a Cure” ALS Symposium, Gene Therapy and Drug Screening, New York, New York, June 2003

The Endocrine Society, IGF-I in the Treatment of Neurological Diseases, Philadelphia, Pennsylvania, June 2003

The Endocrine Society, Diabetic Neuropathy, Philadelphia, Pennsylvania, June 2003

Neurology Grand Rounds, University of Michigan, It Takes a Lot of Nerve: Metabolic Memory and Diabetes, Ann Arbor, Michigan, September 2003

DCCT/EDIC Planning Committee, Neuropathy, Bethesda, Maryland, September 2003

Myasthenia Gravis Association Annual Educational Symposium and Annual Meeting, Myasthenia Gravis: An Update, Troy, Michigan, September 2003

Diabetic Complications: Progress Through Animal Models, National Institutes of Health Symposium, Successes with Current Models – Neuropathy, Bethesda, Maryland, October 2003

Urologic Complications of Diabetes, National Institutes of Health Symposium, Neurologic Complications of Diabetes, Bethesda, Maryland, December 2003

Neurology Grand Rounds, The Johns Hopkins School of Medicine, Stressed to Death: Diabetes and the Nervous System, Baltimore, Maryland, February 2004

The American Academy of Neurology Education Program, Neurologic Complications of Medical Disease, Diabetes Mellitus, San Francisco, California, April 2004

The IGF-I and IGF Binding Protein Assessment and Therapeutic Benefit Workshop, Sero Symposia International, Pathophysiology of Neurological Disorders, New Orleans, Louisiana, June 2004

The Johns Hopkins University Advanced Studies in Medicine Symposium, Diabetic Microvascular Complications: New Concepts of Pathogenesis and New Strategies for Clinical Practice, Etiology of Diabetic Microvascular Disease and Scientific Rationale for New Therapeutic Targets, Munich, Germany, September 2004

Neurology Grand Rounds, Northwestern University, Stressed to Death: Diabetes and the Nervous System, Chicago, Illinois, November 2004

The European Neuro Muscular Centre (ENMC) 131st International Workshop on The Selection of Outcome Measures for Peripheral Neuropathy Clinical Trials, Diabetic Neuropathy: Clinician's Viewpoint, The Netherlands, December 2004

Neurology Grand Rounds, The University of Maryland, Jerome K. Merlis Neuroscience Lecture, Stressed to Death: Diabetes and the Nervous System, Baltimore, Maryland, April 2005

The University of Michigan, Neuroscience Graduate Program Annual Retreat, Magical Mystery Tour, Howell, Michigan, August 2005

The 9th Congress of the European Federation of Neurological Societies, Treatment of Diabetic Peripheral Neuropathic Pain, Athens, Greece, September 2005

Treatment Advances in Diabetic Peripheral Neuropathy, Pathophysiology and Assessment of Diabetic Neuropathic Pain, Monterey, California, September 2005

The American Neurological Association Annual Meeting Symposium, Neurodegenerative Diseases: Emerging Insights Into the Pathogenetic Mechanisms Suggest Novel Therapeutic Strategies, Mitochondria: New Therapeutic Targets in Neuropathy, San Diego, California, September 2005

The American Neurological Association, Junior Faculty Development Course, Staffing Your Laboratory, San Diego, California, September 2005

The Juvenile Diabetes Research Foundation and the American Diabetes Association Workshop, Similarities & Differences in the Complications of Type 1 and Type 2 Diabetes, Neuropathy in Patients with Type 1 Versus Type 2 Diabetes, Boston, Massachusetts, September 2005

Neurology Grand Rounds, Penn State University, Diabetic Neuropathy: From Bench to Bedside, Hershey, Pennsylvania, March 2006

Penn State University, Neuroscience Conference, IGF-I and Neurological Disease, Hershey, Pennsylvania, March 2006

MCDC Grand Rounds, The University of Michigan, Mitochondria: New Therapeutic Targets in Neuropathy, Ann Arbor, Michigan, March 2006

The American Neurological Association, Junior Faculty Development Course, Staffing Your Laboratory, Chicago, Illinois, October 2006

Endocrinology Grand Rounds, The John H. Stroger Hospital of Cook County, The Complications of Diabetes: An Update, Chicago, Illinois, October 2006

The University of Michigan, Dean's Lecture Series, It Takes a Lot of Nerve: Diabetes and its Complications, Ann Arbor, Michigan, October 2006

Vanderbilt University, 2nd Annual Irwin B. Eskin, M.D. Diabetes Research Symposium, Preventing Diabetic Complications in the 21st Century, Diabetic Neuropathy: Mechanisms and Management, Nashville, Tennessee, November 2006

Endocrine Grand Rounds Lecture Series, University of Utah School of Medicine, Diabetic Neuropathy Mechanisms to Treatment, Salt Lake City, Utah, January 2007

University of Utah School of Medicine, Clinical Endocrinology Conference, Diabetic Neuropathy Clinical Update, Salt Lake City, Utah, January 2007

University of California San Diego, California Stem Cell Initiative Rounds, Amyotrophic Lateral Sclerosis: A Disease in Medicine of Stem Cell Therapy, San Diego, California, March 2007

University of Siena, Italian Study Group on Peripheral Nervous System Scientific Committee Meeting, New Insights into Diabetic Neuropathies, Siena, Italy, April 2007

Neurology Grand Rounds, The John Hopkins Hospital, Oxidative Stress in Neurological Disease. Baltimore, Maryland, May 2007

Endocrine Society, Annual Meeting, Meet-The-Professor: Diabetic Neuropathy, Toronto, Canada, June 2007

AUPN/ANA/NINDS, Medical Students Mentoring Workshop, Physician-Scientist, Career and Family: Can you have it all? Washington, DC, June 2007

Peripheral Nerve Society, Biennial Meeting, Career options in the field of peripheral nerve, Snowbird, Utah, July 2007

Peripheral Nerve Society, Stem Cell Symposium, Stem Cell Therapy in Neuromuscular Disease, Snowbird, Utah, July, 2007

NeuroDiab 17th Annual Meeting of Diabetic Neuropathy Study Group of EASD, Overview of the 2007 NIH workshop: Experimental Surrogates for Clinical End Point of Diabetic Neuropathy, Utrecht, The Netherlands, September 2007

Neurology Grand Rounds, The University of Michigan, Oxidative Stress in Neurological Disease, Ann Arbor, Michigan, September 2007

American Neurological Association Meeting, Junior Faculty Development Course, Defining and Implementing Your Mission and Staffing Your Laboratory, Washington, DC, October 2007

AANEM 54th Annual Meeting, Stem Cell Therapy in Neuromuscular Disorders, Phoenix, Arizona, October 2007

Faculty Research Day and Poster Session, Keynote Symposium, KU Medical Center, Drug Discovery and Drug Targets in Diabetic Neuropathy, Kansas City, Kansas, November 2007

ASN Renal Week 2007, Non Renal Diabetic Complications Symposium, Moscone Center, Diabetic Neuropathy: Mechanisms and Management, San Francisco, California, November 2007

The University of Michigan, Department of Neurology, Clinical Research Conference, Drug Discovery and Drug Targets in Diabetic Neuropathy, Ann Arbor, Michigan, November 2007

The University of Michigan, Department of Neurology, Live Patient Conference. Dermatomyositis, Ann Arbor, Michigan, December 2007

- Neuroscience Grand Rounds, University of California San Diego, Oxidative Stress in Neurological Disease, San Diego, California, January 2008
- The University of Utah School of Medicine, Meeting of the Western Intermountain Neurological Organization, Eat, Drink and Be Numb and What Does the Future Hold for ALS Therapy?, Salt Lake City, Utah, March 2008
- 2008 Keystone Symposium on Metabolic Pathways of Longevity, Mitochondrial Fusion and Fission Mediate Senescence, Copper Mountain, Colorado, April 2008.
- University of Sydney, Brain & Mind Research Institute Symposium, Eat, Drink and Be Numb, Sydney, Australia, June 2008
- The Israel A.L.S Research Association, Symposium: A.L.S. Research: Today and Tomorrow, A.L.S. Therapy: Current and Future Directions, Tel Aviv, Israel, June 2008
- Neurology Grand Rounds, University of Rochester, Oxidative Stress in Neurological Disease, Rochester, New York, July 2008
- American Neurological Association, First Annual Summer Course for Clinical and Translational Investigators in Neurology and Neuroscience, Translational Research in ALS, Park City, Utah, August 2008
- 18th Annual Meeting of the Diabetic Neuropathy Study Group of the EASD, Neurodiab XVI, Neuropathy Among Patients with Type 1 Diabetes 14 Years After a Trial of Intensive Therapy, Orvieto, Italy, September 2008
- American Neurological Association Meeting, NINDS/ANA Career Development Symposium, Junior Faculty Development Course, Focus Panel: Unique Aspects of a Clinician Scientist's Career, Salt Lake City, Utah, September 2008
- American Neurological Association Meeting, NINDS/ANA Career Development Symposium, Junior Faculty Development Course, Staffing Your Laboratory, Salt Lake City, Utah, September 2008
- A. Alfred Taubman Medical Research Institute, University of Michigan, Symposium: New Frontiers in Stem Cell Therapies, Prospects for Stem Cell-Based Therapies in Neurology, Ann Arbor, Michigan, October 2008
- NINDS and Harvard University Workshop on Pain, Emerging Therapies in Painful Neuropathy, Boston, Massachusetts, October 2008

Neurology Grand Rounds, The Neurological Institute of New York, Columbia University Medical Center, Growth Factor and Stem Cell Therapies in ALS, New York, New York, October 2008

The Detroit Medical Center, Sinai-Grace Hospital Research Day, Stem Cells and the Future of Regenerative Medicine, Detroit, Michigan, April 2009

University of Pittsburgh, Diabetes Update 2009, Differential Diagnosis and Treatment of Painful Diabetic Neuropathy, Pittsburgh, Pennsylvania, May 2009

The Endocrine Society's Annual Meeting, Pathophysiology of Diabetic Complications Scientific Program, Hyperlipidemia: A New Therapeutic Target for Diabetic Neuropathy, Washington, DC, June 2009

University of New Mexico 33rd Annual Resident/Faculty Neurology Research Day and 4th Annual Neuroscience Research Day Grand Rounds, Diabetic Neuropathy: New Challenges and Opportunities, Albuquerque, New Mexico, June 2009

The Peripheral Nerve Society Presidential Lecture, Diabetic Neuropathy: Mechanisms to Management, Wurzburg, Germany, July 2009

The World Congress of Neurology, Dyslipidemia and Diabetic Neuropathy, Bangkok, Thailand, October 2009

The University of Michigan, Department of Neurology, Clinical Research Conference, Stem Cell Therapy in ALS, Ann Arbor, Michigan, November 2009

Neurology, Grand Rounds, University of Michigan, ALS: A Clinical and Research Update, Ann Arbor, Michigan, December 2009

The Detroit Economic Club Honored Guest Speaker, Stem Cells: The New Frontier of Medical Science, Detroit, Michigan, December 2009

ISF-Legacy Heritage Fund Inaugural Meeting on New Approaches to Neurodegenerative Diseases, Stem Cell Therapy in the Treatment of ALS, Dead Sea, Israel, January 2010

Michigan Seminars in California, On the Threshold of Discovery: Stem Cells and Lou Gehrig's Disease, San Francisco, California, April 2010

Juvenile Diabetes Research Foundation Prevention Trials for Complications of Type 1 Diabetes, Diabetic Neuropathy: What is the Risk?, Arlington, Virginia, April 2010

Juvenile Diabetes Research Foundation Prevention Trials for Complications of Type 1 Diabetes, Clinical Trial Design for Diabetic Neuropathy, Arlington, Virginia, April 2010

The Brookings Institution, Inaugural A. Alfred Taubman Forum, Improving Science and Technology Innovation in the United States, The Role of Higher Education, Washington, DC, June 2010

AUPN Leadership Course, American Neurological Association Annual Meeting, The Intersection of Science and Health Care, San Francisco, California, September 2010

A. Alfred Taubman Medical Research Institute, University of Michigan, Symposium: Translational Research: The Bridge from Discovery to Medical Practice, On the Threshold of Discovery: Stem Cells and Lou Gehrig's Disease, Ann Arbor, Michigan, October 2010

The Department of Clinical Neurological Sciences, The University of Western Ontario, 7th Neuromuscular Conference, Diabetic Neuropathy – From Mechanisms to Management, London, Ontario, Canada, November 2010

The Neuropathy Association's 2010 Physicians Conference, 2010 Neuropathy Summit, Review of Basic Science Advances for Diabetic Peripheral Neuropathy, Washington, DC, December 2010

JDRF Symposium Type 1 Diabetes Research Updates, Complications, New York, New York, March 2011

Endocrine Grand Rounds, Brown University, Understanding Diabetic Neuropathy: Sweet New Opportunities, Providence, Rhode Island, April 2011

The University of Michigan, Division of Metabolism, Endocrinology & Diabetes (MEND) Research Conference, Impaired Glucose Tolerance Neuropathy: A Sweet Revelation, Ann Arbor, Michigan, April 2011

The University of Michigan, Osher Lifelong Learning Institute, Stem Cell Therapy: The New Frontier of Medicine, Ann Arbor, Michigan, April 2011

American Society of Gene and Cell Therapy, Advancing Genes and Cells into the Clinic – Delivery on Target for CNS Disorders, Intraspinal Stem Cell Transplantation for Amyotrophic Lateral Sclerosis, Seattle, Washington, May 2011

Stem Cell Michigan, University of Michigan, Human Clinical Trial of a Stem Cell Treatment for ALS, Ann Arbor, Michigan, May 2011

The 2011 Bernard J. Alpers Lecture, Thomas Jefferson University, Department of Neurology, The Challenge of Stem Cell Therapy for the Treatment of ALS, Philadelphia, Pennsylvania, May 2011

Neurology Grand Rounds, Thomas Jefferson University, Diabetic Neuropathy: A Sweet Update, Philadelphia, Pennsylvania, May 2011

Neurology Grand Rounds, The Johns Hopkins University School of Medicine, Intraspinal Stem Cell Transplantation in ALS: Challenges and Opportunities, Baltimore, Maryland, May 2011

National Cancer Institute, National Institutes of Health, Chemotherapy-Induced Peripheral Neuropathy (CIPN) Workshop, The Biology of Diabetic Neuropathy: What Sweet Lessons Can We Learn?, Rockville, Maryland, June 2011

The Michigan Israel Business Bridge, The Israeli Stem Cell Connection, Ann Arbor, Michigan, June 2011

American Association of Oral and Maxillofacial Surgeons, Chalmers J. Lyons Memorial Lecture, Stem Cell Therapy: Opportunities and Challenges, Philadelphia, Pennsylvania, September 2011

Association of British Neurologists, 17th Gordon Holmes Lecture, Stem Cell Therapy: The New Frontier of Medicine, Edinburgh, Scotland, October 2011

Neurology Grand Rounds, The University of Michigan, Cellular and Gene Therapies in ALS, Ann Arbor, Michigan, November 2011

The Miami Project to Cure Paralysis, Gail F. Beach Memorial Visiting Lectureship Series, Intraspinal Stem Cell Therapy for ALS: Challenges and Opportunities, Miami, Florida, January 2012

The University of Colorado, Denver, 18th William L. Halseth ALS Visiting Professor, A Phase 1 Clinical Trial of Intraspinal Stem Cell Transplantation in ALS, Denver, Colorado, February 2012

The National Institutes of Health, Phoenix Branch, Diabetic Neuropathy: A Clinical Update with Opportunities for the Pima Indian Studies, Phoenix, Arizona, April 2012

American Academy of Neurology, 64th Annual Meeting, Training Opportunities in Neurology, New Orleans, Louisiana, April 2012

Food and Drug Administration, Center for Drug Evaluation and Research, Intraspinal Stem Cell Therapy in ALS: Results of a Phase 1 Trial, Silver Springs, Maryland, May 2012

International Society of Nephrology Symposium, Systems Biology and the Kidney, Cross-tissue Transcriptomics Provides Insight into Diabetic Complications, Ann Arbor, Michigan, June 2012

American Diabetes Association 72nd Scientific Session, Differentiation of Age-Related and Diabetic Neuropathy, Philadelphia, Pennsylvania, June 2012

Scientific Symposium Celebrating Guy McKhann, MD and the Induction of the Inaugural McKhann Scholar, Diabetic Neuropathy: One Disease or Two?, Baltimore, Maryland, June 2012

Longwood Area Neurology Grand Rounds, Beth Israel Deaconess Medical Center, Harvard Medical School, Intraspinal Stem Cell Therapy in ALS: Results of a Phase I Trial, Boston, Massachusetts, June 2012

Families of SMA 2012 Conference, Intraspinal Stem Cell Transplantation in ALS, Bloomington, Minnesota, June 2012

National Institutes of Health/Food and Drug Administration Workshop, Pluripotent Stem Cells in Translation: Preclinical Considerations, Intraspinal Stem Cell Therapy for ALS, Bethesda, Maryland, July 2012

AbbVie Laboratories Neuropathy Summit, Peripheral Neuropathy: Clinical Challenges and Opportunities, North Chicago, Illinois, August 2012

University of Michigan and Merck Research Laboratories Research Strengths in Diabetes, Diabetic Neuropathy: One Disease or Two? From Mice to Humans... and Back Again, Ann Arbor, Michigan, September 2012

The Mayo Clinic, Fifth Annual Marcia and Donald Pellar Distinguished Lectureship in Neurology, Stem Cell Therapy in ALS: A New Frontier, Scottsdale, Arizona, November 2012

Chinese Diabetes Oxidative Stress Forum, Oxidative Stress and Diabetic Neuropathy: A Mechanistic Update, Beijing, China, November 2012

Neurology Grand Rounds, Penn State University, Stem Cell Therapy in ALS: A New Frontier, Hershey, Pennsylvania, November 2012

Neurology Grand Rounds, Wake Forest University School of Medicine, Stem Cell Therapy in ALS: A New Frontier, Winston-Salem, North Carolina, January 2013

The 39th National Congress of the Romanian Society of Diabetes, Nutrition and Metabolic Diseases, Basic Mechanisms of Diabetic Neuropathy, Sibiu, Romania, May 2013

Romanian Neurodiab Society, Stem Cell Therapy: Where We Are Today, Bucharest, Romania, May 2013

Annual Congress of the Canadian Neurological Sciences Federation, Neuromuscular Course, Diabetic Neuropathy: One Disease or Two?, Montreal, Quebec, June 2013

Annual Congress of the Canadian Neurological Sciences Federation, Pierre Gloor Lecture, Intraspinal Stem Cell Transplantation in ALS, Montreal, Quebec, June 2013

The Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Intraspinal Stem Cell Transplantation in ALS, Queen Square, London, United Kingdom, September 2013

The University of Barcelona, Intraspinal Stem Cell Transplantation in ALS: Results of a Phase 1 FDA Trial, Barcelona, Spain, September 2013

23rd Annual Meeting of the Diabetic Neuropathy Study Group, Debate: Corneal Confocal Microscopy Versus Nerve Conduction Studies – Surrogate Measures? What is to be used in Diabetic Neuropathy?, Barcelona, Spain, September 2013

23rd Annual Meeting of the Diabetic Neuropathy Study Group, Identification of Factors Associated with Sural Nerve Regeneration and Degeneration in Diabetic Neuropathy, Barcelona, Spain, September 2013

XXI World Congress of Neurology, Diabetic Neuropathies, Vienna, Austria, September 2013

XXI World Congress of Neurology, Diagnosis and Treatment of Diabetic Peripheral Neuropathy, Vienna, Austria, September 2013

Stem Cell Michigan Annual Meeting, Clinical Trial Update: Intraspinal Stem Cell Transplantation in ALS, Ann Arbor, Michigan, October 2013

Neurology Grand Rounds, The University of Michigan, Intraspinal Stem Cell Transplantation in ALS, Ann Arbor, Michigan, November 2013

Jewish Working Women's Series, A Life in Science – One Woman's Perspective, Farmington Hills, Michigan, November 2013

INDO US Update on Diabetic Complications, Latest Insights in the Management of Diabetic Neuropathy, Chennai, India, March 2014

INDO US Update on Diabetic Complications, Diabetes and Cognitive Function: Is There a Relationship?, Chennai, India, March 2014

Keystone Symposia on Molecular and Cellular Biology, Clinical Progress for Stem Cell Therapies, Intraspinal Stem Cell Transplantation in ALS: Results of a Phase I Clinical Trial, Olympic Valley, California, April 2014

Pan Pacific Symposium on Stem Cells and Cancer Research, Keynote Address, Intraspinal Stem Cell Transplantation in ALS: A New Horizon, Taichung, Taiwan, April 2014

University of Iowa, Health Sciences Research Week, Metabolic Neuropathy and Cardiovascular Disease: The Chicken or the Egg?, Iowa City, Iowa, April 2014

University of Michigan, Radiology Research Conference, Functional Imaging in ALS, Ann Arbor, Michigan, April 2014

University of Michigan, Michigan Diabetes Research Center Annual Symposium, Diabetic Neuropathy: One Disease or Two?, Ann Arbor, Michigan, April 2014

Neurology Grand Rounds, Columbia University, Intraspinal Stem Cell Transplantation in ALS: Where We Are Now, New York, New York, May 2014

The 8th World Congress on Controversies in Neurology (CONy), Diabetic Neuropathy: One Disease or Two?, Berlin, Germany, May 2014

The 8th World Congress on Controversies in Neurology (CONy), Debate: Imaging is a Promising Biomarker of ALS, Berlin, Germany, May 2014

The 8th World Congress on Controversies in Neurology (CONy), Debate: Best Future Strategies for Neurorehabilitation: Stem Cell Therapy, Berlin, Germany, May 2014

University of Toronto, The 33rd J.L. Silversides Visiting Professor of Neurology, Diabetic Neuropathy: One Disease or Two?, Toronto, Canada, June 2014

13th International Congress on Neuromuscular Diseases (ICNMD), Intraspinal Stem Cell Transplantation in ALS: Results of a Phase 1/2 Clinical Trial, Nice, France, July 2014

University of Michigan, Epigenetics, Stem Cells, and Regenerative Medicine Symposium, Intraspinal Stem Cell Transplantation in Amyotrophic Lateral Sclerosis: A New Therapeutic Frontier, Ann Arbor, Michigan, September 2014

ALS Association TREAT ALS, Translational Research Advancing Therapy for ALS, Investigator Research Workshop, An Update on Stem Cell Therapy, Philadelphia, Pennsylvania, October 2014

American Neurological Association, 139th Annual Meeting, Advances in Peripheral Neuropathies, Baltimore, Maryland, October 2014

University of Rochester School of Medicine & Dentistry, Second Annual Goldberg Family Women in Neurology Lectureship, Intraspinal Stem Cell Transplantation in ALS: Where We Are Now, Rochester, New York, October 2014

AANEM 61st Annual Meeting, 9th Annual Richard K. Olney Lecture, Stem Cell Therapy in Motor Neuron Disease, Savannah, Georgia, October 2014

AANEM 61st Annual Meeting, Diabetic Neuropathy Symposium, Diabetic Neuropathy: One Disease or Two?, Savannah, Georgia, October 2014

AANEM 61st Annual Meeting, Ask the Expert Session, Diabetic Neuropathies, Savannah, Georgia, October 2014

The University of Texas Health Science Center at Houston, 26th Annual William S. Fields Lecture, Intraspinal Stem Cell Transplantation: Results of the Phase 1 Clinical Trial, Houston, Texas, November 2014

Reeve-Irvine Research Center, University of California, Irvine, 2015 Annual Symposium, Stem Cells for the Injured Spinal Cord, Intraspinal Stem Cell Transplantation in ALS: Clinical Trials Update, Irvine, California, February 2015

The 9th World Congress on Controversies in Neurology (CONy), Intraspinal Stem Cell Transplantation in ALS: Results of a Phase 1 Study, Budapest, Hungary, March 2015

The 9th World Congress on Controversies in Neurology (CONy), Debate Host: Will Stem Cell Therapy Become Important in Stroke Rehabilitation?, Budapest, Hungary, March 2015

Michigan-Toledo P30 Consortium 2015 Spring Meeting, Intraspinal Stem Cell Transplantation in ALS, Ann Arbor, Michigan, May 2015

Danish Diabetes Academy & Danish Endocrine Society (DES) Microvascular Complications in Diabetes, Metabolomics in Diabetic Neuropathy: From Bench to Bedside, Gentofte, Denmark, May 2015

American Diabetes Association 75th Scientific Session, Diabetic Neuropathy – The Treatable Neuropathy Symposium, Clinical Data on Prediabetes and Neuropathy, Boston, Massachusetts, June 2015

Fifth Annual Intensive Update in Neurology, Keynote Presentation, Swedish Education and Conference Center, Intraspinal Stem Cell Transplantation in ALS, Seattle, Washington, September 2015

University of Washington, Neurology Grand Rounds, Intraspinal Stem Cell Transplantation in ALS: Clinical Trials Update, Seattle, Washington, September 2015

American Neurological Association, 140th Annual Meeting, Current State of Stem Cell Therapies, Chicago, Illinois, September 2015

American Neurological Association, 140th Annual Meeting, Human Neural Stem Cells Expressing IGF-I: A Novel Cellular Therapy for Alzheimer's Disease, Chicago, Illinois, September 2015

ALS Association Greater Chicago Chapter, 5th Annual Educational and Scientific Symposium, Intraspinal Transplantation of Stem Cells: Clinical Trial Overview, Chicago, Illinois, October 2015

Workshop on Progress in Stem Cells Research for ALS/MND, Neural Transplantation in ALS: A Phase I/II Trial, Novara, Italy, October 2015

Neurology Grand Rounds, University of Michigan, Intraspinal Stem Cell Transplantation in ALS: Results of Completed Phase 1 and Phase 2 Trials, Ann Arbor, Michigan, December 2015

16th Annual Rachmiel Levine-Arthur Riggs Diabetes Research Symposium, Mechanisms of Nerve Injury in Diabetes, Long Beach, California, March 2016

Walker L. Cisler Memorial Science Lecture, Lawrence Technological University, Stem Cells in the Treatment of ALS: A New Way Forward, Southfield, Michigan, March 2016

68th Annual Meeting of the American Academy of Neurology, Hot Topics Plenary Session, Intraspinal Stem Cell Transplantation in ALS: Where We Are Today, Vancouver, British Columbia, Canada, April 2016

Neurology Grand Rounds, University of Pennsylvania, Stem Cell Therapy in ALS: A Clinical Trial Update, Philadelphia, Pennsylvania, April 2016

Case Western Research University, Department of Neurosciences Seminar Series, Diabetic Neuropathy: One Disease or Two?, Cleveland, Ohio, April 2016

Binational Science Foundation Panel Members Meeting in the Neurological & Sensory Systems, Intraspinal Stem Cell Transplantation in ALS: A Clinical Trial Update, Jerusalem, Israel, May 2016

16th Annual Podiatry Conference, University of Pittsburgh Medical Center, Pathogenesis of Peripheral Neuropathy, Cranberry Township, Pennsylvania, June 2016

International Diabetic Neuropathy Consortium, Animal Models, Aarhus, Denmark, June 2016

International Diabetic Neuropathy Consortium, Current Status of Metabolomics in T2D and T2DN, Aarhus, Denmark, June 2016

14th International Congress on Neuromuscular Diseases, Introduction to Autonomic Neuropathy, Toronto, Ontario, Canada, July 2016

14th International Congress on Neuromuscular Diseases, Stem Cell Therapy in ALS, Toronto, Ontario, Canada, July 2016

14th International Congress on Neuromuscular Diseases, Role of Skin Punch Biopsy in Clinical Practice, Toronto, Ontario, Canada, July 2016

14th International Congress on Neuromuscular Diseases, Role of Skin Punch Biopsy as a Research Outcome Measure, Toronto, Ontario, Canada, July 2016

Neurodiab EASD 2016, Chaired Keynote Session Urologic Complications and Autonomic Dysfunction in Diabetes – Aruna V Sarma, Bucharest, Romania, September 2016

Neurodiab EASD 2016, Chaired Oral Session Treatment, Bucharest, Romania, September 2016

UCSF Robert B Aird Visiting Professorship in Neurology, The Neurological Complications of Obesity: A Modern Epidemic, San Francisco, California, October 2016

San Francisco Neurological Society & UCSF, Annual Robert B Aird Lecture, Stem Cell Therapy in ALS: Where are We Today?, San Francisco, California, October 2016

Third Annual Protein Folding Diseases Initiative Symposium, Amyotrophic Lateral Sclerosis and Frontotemporal Dementia, Ann Arbor, Michigan, October 2016

Neurology Grand Rounds, University of Michigan, Neurological Complications of Obesity: A Modern Epidemic, Ann Arbor, Michigan, October, 2016

University of Alberta Dean's Lecture Series, The Alarming Diabetic Epidemic: What It Means To Neurologists, Alberta, Canada, October 2016

University of Alberta Dean's Lecture Series, Women In Medicine: Is There A Problem?, Alberta, Canada, October 2016

University of California Irvine Medical Scientist Training Program Distinguished Lecture Series, The Neurological Complications of Obesity: A Modern Epidemic, Irvine, California, December 2016

Satellite Symposium on Stem Cell Therapeis in ALS by World Federation of Neurology Research Group on ALS/MND, Feasibility of Turning a Medical Disease Like ALS into an Interventional One and Feasibility of Funding, Dublin, Ireland, December 2016

Georgia Regents University Department of Biotechnology & Genomic Medicine Seminar Guest, Big Data and Diabetic Complications, Augusta, Georgia, January 2017

Pediatric Endocrinology Grand Rounds Royal Melbourne Childrens Hospital, Diabetic Neuropathy in Youth: One Disease or Two?, Melbourne, Australia, March 2017

University of Melbourne Neural Engineering Lecture Series, Therapeutic Potential of Stem Cell Transplantation in Neurological Disorders, Melbourne, Australia, April 2017

David Danks “Leaders in Science” Seminar, Murdoch Childres Research Institute, The Neurological Complications of Obesity and Diabetes: A Modern Epidemic, Melbourne, Australia, April 2017

Neurology Grand Rounds University of Sydney, Australian Neurological Society, The Neurological Complications of Obesity and Diabetes: A Modern Epidemic, Sydney, Australia, May 2017

Pediatric Grand Rounds Royal Melbourne Childrens Hospital, The Promise and Reality of Stem Cell Therapy in Motor Neuron Disease, Melbourne, Australia May 2017

Royal Melbourne Childrens Hospital Diabetes Clinic, Neuropathy Clinical Outcomes, Melbourne, Australia May 2017

The Australian Society for Stem Cell Research and Australasian Gene and Cell Therapy Society Annual Meeting, A Comparison of Clinical Outcomes Between Two Open Label FDA Approved Trials of Intraspinal Stem Cell Transplantation of ALS Patients and Available Historical ALS Databases, Sydney, Australia, May 2017

The Australasian Society for Stem Cell Research and Australasian Gene and Cell Therapy Society Annual Meeting Ethics Session Panel Discussion: Road to Translation – What Are The Roadblocks For First In Man Trials?, Sydney, Australia, May 2017

Neurology Grand Rounds University of Melbourne, Stem Cell Transplantation in ALS: Where We Are Today, Melbourne, Australia May 2017

American Diabetes Association 77th Scientific Sessions, The New ADA Concensus Guidelines on Diabetic Peripheral Neuropathy – Will They Change your Practice?, San Diego, California, June 2017

American Diabetes Association 77th Scientific Sessions, Update on Neuropathy – The Forgotten Complication, San Diego, California, June 2017

International Society for Stem Cell Research Annual Meeting, Approaches to Treating ALS, Boston, Massachusetts, June 2017

Peripheral Nerve Society Annual Meeting, Diabetic Neuropathy: Branching Out, Stiges, Spain, July 2017

ALS Surveillance Meeting, Identification and Validation of ALS Environmental Risk Factors, Atlanta, Georgia, August 2017

ALS Surveillance Meeting, Environmental Risk Factors and Gene-Environment Interactions in ALS Risk and Progression, Atlanta, Georgia, August 2017

University of Michigan – Israel Partnership for Research and Education, Intraspinal Stem Cell Transplantation in ALS: Results of a Phase 1/2 Clinical Trial, Haifa, Israel, September 2017

University of Michigan Biointerfaces Institute and the A. Alfred Taubman Medical Research Institute, Diabetic Neuropathy and the Nerve, Ann Arbor, Michigan, September 2017

World Congress of Neurology, MS and Demyelinating Disease, Kyoto, Japan, September 2017

World Congress of Neurology, Peripheral Neuropathy, Kyoto, Japan, September 2017

5th Indo US Update on Diabetes and Diabetic Foot 2017, How do we diagnose and manage Diabetic Neuropathy in our Clinical Practice? Chennai, India, September 2017

Neurology Grand Rounds, University of Michigan, The Neurological Complications of Childhood Obesity: A Modern Epidemic, Ann Arbor, Michigan, November 2017

International Scientific Conference Stem Cells Translational Research, Stem Cell Therapy in ALS: Where We Are Today?, Warsaw, Poland, December 2017

CONCEPPT/IDNC Diabetic Peripheral Neuropathies, Evidence Based Taxonomy For Diabetic Peripheral Neuropathies, Discussion Moderator, Washington D.C., December 2017

Oregon Health & Science University Colloquium Neuromuscular Disorders, Stem Cell Treatment in ALS and Other Neuromuscular Disorders, Portland, Oregon, February 2018

CONCEPPT Small Fiber Neuropathy, Small Fiber Neuropathy Diagnostic Instruments, Discussion Moderator, Washington D.C., April 2018

Neurology Grand Rounds, Hartford Hospital, Stem Cell Therapy in Neurodegenerative Diseases: Where We Are Today, Hartford, Connecticut, May 2018

International Diabetic Neuropathy Consortium (IDNC) Annual Meeting, Lipid Changes In Diabetic Neuropathy, Aarhus, Denmark, June 2018

15th Annual Congress on Neuromuscular Diseases, Neuropathy - Plenary Session Chair, Vienna, Austria, July 2018

15th Annual Congress on Neuromuscular Diseases, Painful Diabetic Neuropathy: A Management Centered Approach, Vienna, Austria, July 2018

Romanian Neurodiab Summer School, Underlying Metabolic Mechanisms in the Pathogenesis of Diabetic Neuropathy, Sanaia, Romania, July 2018

Peripheral Nerve Society Annual Meeting, Neurophysiology Endpoint Talks, Discussion Moderator, Baltimore, Maryland, July 2018

Peripheral Nerve Society Annual Meeting, Perspective on Endpoints, Baltimore, Maryland, July 2018

Annual National ALS Registry Meeting, Identification and Validation of ALS Environmental Risk Factors, Atlanta, Georgia, August 2018

Australian Diabetes Congress, Paul Zimmet: A Celebration, Future Management of Diabetes – Session Chair, Adelaide, Australia, August 2018

Australian Diabetes Congress, Roads to Treatment in Diabetic Neuropathy, Adelaide, Australia, August 2018

Australian Diabetes Congress, Symposium Bench to Bedside-Diabetic Neurpathy, A Perspective on Clinical Management of Diabetic Neuropathy, Adelaide, Australia, August 2018

University Paris Descartes Faculty Seminar, New Horizons in Research and Treatment of Diabetic Neuropathy, Paris, France, September 2018

American University of Beirut, Stem Cell Therapy in Neurological Diseases: Where We Are in 2018, Beriut, Lebanon, September 2018

American University of Beirut, The Two Faces of Diabetic Neuropathy, Beriut, Lebanon, September 2018

University of Michigan – Israel Partnership for Research and Education Neuroscience Session Chair, Ann Arbor, Michigan October 2018

American Neurology Association Annual Meeting, Women Learning From Each Other, Atlanta, Georgia, October 2018

Alpha Epsilon Delta Pre-Medical Society at the University of Michigan, Navigating The Career Path of a Young Physician, Ann Arbor, Michigan, April 2019

Bibliography

Peer-Reviewed Journals and Publications (375 original articles)

1. Schwartz M, Axelrod D, **Feldman EL**, Agranoff BW. Histological localization of binding sites of alpha-bungarotoxin and of antibodies specific to acetylcholine receptors in goldfish optic nerve and tectum. *Brain Research*, 194, 171-180, 1980.

2. Agranoff BW, **Feldman EL**, Heacock AM, Schwartz M. The retina as a biochemical model of central nervous system regeneration. *Neurochemistry*, 1, 487-500, 1980.
3. **Feldman EL**, Axelrod D, Schwartz M, Heacock AM, Agranoff BW. Studies on the localization of newly added membrane in growing neurites. *Journal of Neurobiology*, 12, 591-598, 1981.
4. **Feldman EL**, Heacock, AM, Agranoff BW. Lectin binding to neurites of goldfish retinal explants. *Brain Research*, 248, 347-354, 1982.
5. Hanley DF, **Feldman EL**, Borel CO, Rosenbaum AE, Goldberg AL. Treatment of sagittal sinus thrombosis associated with cerebral hemorrhage and intracranial hypertension. *Stroke*, 19, 903-909, 1988.
6. Griffin JW, Cornblath DR, Alexander E, Campbell J, Low PA, Bird S, **Feldman EL**. Ataxic sensory neuropathy and dorsal root ganglionitis associated with Sjogren's syndrome. *Annals of Neurology*, 27, 304-315, 1990.
7. Pestronk A, Chaudhry V, **Feldman EL**, Griffin JW, Cornblath DR, Denys EH, Glasberg M, Kuncl RW, Olney RK, Yee WC. Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titers of antiglycolipid antibodies. *Annals of Neurology*, 27, 316-326, 1990.
8. Selwa JF, **Feldman EL**, Blaivas M. Mononeuropathy multiplex in tryptophan-associated eosinophilia-myalgia syndrome. *Neurology*, 40, 1632-1633, 1990.
9. **Feldman EL**, Bromberg MB, Albers JW, Pestronk A. Immunosuppressive treatment of multifocal motor neuropathy. *Annals of Neurology*, 30, 397-401, 1991.
10. **Feldman EL**, Randolph AE. Mannose 6-phosphate potentiates insulin-like growth factor-II effects in cultured human neuroblastoma cells. *Brain Research*, 562, 111-116, 1991.
11. **Feldman EL**, Randolph AE, Johnston GC, DelMonte MA, Greene DA. Receptor-coupled phosphoinositide hydrolysis in human retinal pigment epithelium. *Journal of Neurochemistry*, 56, 2094-2100, 1991.
12. **Feldman EL**, Bromberg MB, Blaivas M, Junck L. Acute pandysautonomic neuropathy. *Neurology*, 41, 746-748, 1991.
13. Pestronk A, Li F, Griffin J, **Feldman EL**, Cornblath D, Trotter J, Zhu S, Yee WC, Phillips D, Winslow B. Polyneuropathy syndromes associated with serum antibodies to sulfatide and myelin-associated glycoprotein. *Neurology*, 41, 357-362, 1991.

14. Martin DM, Yee D, **Feldman EL**. Gene expression of the insulin-like growth factors and their receptors in cultured human retinal pigment epithelial cells. *Molecular Brain Research*, 12, 181-186, 1992.
15. Bromberg MB, **Feldman EL**, Jaradeh S, Albers JW. Prognosis in long-term immunosuppressive treatment of refractory chronic inflammatory demyelinating polyradiculoneuropathy. *Journal of Clinical Epidemiology*, 45, 47-52, 1992.
16. Bromberg MB, **Feldman EL**, Albers JW. Chronic inflammatory demyelinating polyradiculoneuropathy: Comparison of patients with and without an associated monoclonal gammopathy. *Neurology*, 42, 1157-1163, 1992.
17. Martin DM, Yee D, Carlson RO, **Feldman EL**. Gene expression of the insulin-like growth factors and their receptors in human neuroblastoma cell lines. *Molecular Brain Research*, 15, 241-246, 1992.
18. Greene DA, Sima AAF, Stevens MJ, **Feldman EL**, Lattimer SA. Complications: neuropathy, pathogenetic considerations. *Diabetes Care*, 15, 1902-1925, 1992.
19. Simmons Z, Bromberg MB, **Feldman EL**, Blaivas M. Polyneuropathy associated with IgA monoclonal gammopathy of undetermined significance. *Muscle & Nerve*, 16, 77-83, 1993.
20. **Feldman EL**, Randolph A. Peptides stimulate phosphoinositide turnover in cultured human retinal pigment epithelium. *Investigative Ophthalmology & Visual Science*, 34(2), 431-437, 1993.
21. Martin DM, Carlson RO, **Feldman EL**. Interferon- γ inhibits DNA synthesis and insulin-like growth factor-II expression in human neuroblastoma cells. *Journal of Neuroscience Research*, 34, 489-501, 1993.
22. Connolly AM, Pestronk A, Trotter JL, **Feldman EL**, Cornblath DR, Olney RK. High-titer selective serum anti- β -tubulin antibodies in chronic inflammatory demyelinating polyneuropathy. *Neurology*, 43, 557-562, 1993.
23. Martin DM and **Feldman EL**. Regulation of insulin-like growth factor-II expression and its role in autocrine growth of human neuroblastoma cells. *Journal of Cellular Physiology*, 155, 290-300, 1993.
24. Sumantran VN and **Feldman EL**. Insulin-like growth factor-I regulates c-MYC and GAP-43 mRNA expression in SH-SY5Y human neuroblastoma cells. *Endocrinology*, 132, 2017-2023, 1993.
25. Jones JM, Albin RL, **Feldman EL**, Simin K, Schuster TG, Dunnick WA, Collins TJ, Chrisp CE, Taylor BA, Meisler MH. *mnd2*: A new mouse model of inherited motor neuron disease. *Genomics*, 16, 669-677, 1993.

26. Carlson RO, Martin DM, **Feldman EL**, Agranoff BW. PKC activity and PKC-a mRNA content are reduced in serum-deprived human neuroblastoma cells without concomitant induction of differentiation. *Experimental Cell Research*, 207, 340-347, 1993.
27. Meghani MA, Martin DM, Singleton JR, **Feldman, EL**. Effects of serum and insulin-like growth factors on human neuroblastoma cell growth. *Regulatory Peptides*, 48, 217-224, 1993.
28. Martin DM, Singleton JR, Meghani MA, **Feldman EL**. IGF receptor function and regulation in autocrine human neuroblastoma cell growth. *Regulatory Peptides*, 48, 225-232, 1993.
29. Simmons Z, Albers JW, Bromberg MB, **Feldman EL**. Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: Comparison of patients without and with monoclonal gammopathy. *Neurology*, 43, 2202-2209, 1993.
30. **Feldman EL**, Randolph A, Yee D. Insulin-like growth Factor Binding Protein Expression in SH-SY5Y Neuroblastoma Cells. *Annals of the New York Academ of Sciences* 692:262-264, 1993.
31. Martin DM, **Feldman EL**. Reversibility of Serum Removal Effects on IGF-II mRNA in Human Neuroblastoma Cells. *Annals of the New York Academy of Sciences* 692: 259-261, 1993.
32. Thomas TP, **Feldman EL**, Nakamura J, Kato K, Lien M, Stevens MJ, Greene DA. Ambient glucose and aldose reductase-induced *myo*-inositol depletion modulate basal and carbachol-stimulated inositol phospholipid metabolism and diacylglycerol accumulation in human retinal pigment epithelial cells in culture. *Proceedings of the National Academy of Sciences*, 90, 9712-9716, 1993.
33. Simmons Z, Blaivas M, Aguilera AJ, **Feldman EL**, Bromberg MM, Towfighi J. Low diagnostic yield of sural nerve biopsy in patients with peripheral neuropathy and primary amyloidosis. *Journal of Neurological Sciences*, 120, 60-63, 1993.
34. Greene DA, Sima AAF, Stevens MJ, **Feldman EL**, Killen PD, Henry DN, Thomas T, Dananberg J, Lattimer SA. Aldose reductase inhibitors: An approach to the treatment of diabetic nerve damage. *Diabetes/Metabolism Reviews*, 9, 189-217, 1993.
35. **Feldman EL**, Randolph AE. Regulation of insulin-like growth factor binding protein synthesis and secretion in human retinal pigment epithelial cells. *Journal of Cellular Physiology*, 158, 198-204, 1994.
36. Stevens MJ, Dananberg J, **Feldman EL**, Lattimer SA, Kamijo M, Thomas TP, Shindo H, Sima AAF, Greene DA. The linked roles of nitric oxide, aldose reductase and (Na⁺,K⁺)-

- ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. *Journal of Clinical Investigation*, 94, 853-859, 1994.
37. Sullivan KA, **Feldman EL**. Immunohistochemical localization of insulin-like growth factor II and insulin-like growth factor binding protein-2 during development in the rat brain. *Endocrinology*, 135, 540-547, 1994.
 38. Simmons Z, Wald J, Albers JW, **Feldman EL**. The natural history of a "benign" rib lesion in a patient with a demyelinating polyneuropathy and an unusual variant of POEMS syndrome. *Muscle and Nerve*, 17, 1055-1059, 1994.
 39. **Feldman EL**, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. *Diabetes Care*, 17, 1281-1289, 1994.
 40. **Feldman EL**, Stevens MJ. Clinical testing in diabetic peripheral neuropathy. *The Canadian Journal of Neurological Sciences*, 21:Suppl. 4-S3-S7, 1994.
 41. Felice KJ, Fratkin JD, **Feldman EL**, Sima AAF. Phrenic nerve involvement in Dejerine-Sottas Disease: A clinicopathological case study. *Pediatric Pathology*, 14, 905-911, 1994.
 42. Simmons Z, Albers JW, Bromberg MB, **Feldman EL**. Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. *Brain*, 118, 359-368, 1995.
 43. Stevens M, **Feldman EL**, Greene DA. The aetiology of diabetic neuropathy: The combined roles of metabolic and vascular defects. *Diabetic Medicine*, 12, 566-579, 1995.
 44. Leventhal PS, Randolph AE, Vesbit TE, Schenone A, Windebank AJ, **Feldman EL**. Insulin-like growth factor-II as a paracrine growth factor in human neuroblastoma cells. *Experimental Cell Research*, 221, 179-186, 1995.
 45. Sullivan KA, Castle VP, Hanash SM, **Feldman EL**. Insulin-like growth factor II (IGF-II) in the pathogenesis of human neuroblastoma. *American Journal of Pathology*, 147, 1790-1798, 1995.
 46. **Feldman EL**, Del Monte MA, Stevens MJ, Greene DA. Establishment and maintenance of in vitro cultures of human retinal pigment epithelium. *Methods in Molecular Medicine* 2: 517-524, 1996.
 47. Matthews CC, **Feldman EL**. IGF-I rescues SH-SY5Y human neuroblastoma cells from hyperosmotic induced programmed cell death. *Journal of Cellular Physiology*, 166, 323-331, 1996.
 48. Cheng H-L, Randolph A, Yee D, Delafontaine P, Tennekoon G, **Feldman EL**. Characterization of insulin-like growth factor-I (IGF-I), IGF-I receptor and binding

- proteins in transected nerves and cultured schwann cells. *Journal of Neurochemistry*, 66, 525-536, 1996.
49. Leventhal PS, **Feldman EL**. Tyrosine phosphorylation and enhanced expression of paxillin during neuronal differentiation *in vitro*. *Journal of Biological Chemistry*, 271, 5957-5960, 1996.
 50. Cheng H-L, Sullivan KA, **Feldman EL**. Immunohistochemical localization of insulin-like growth factor binding protein-5 in the developing rat nervous system. *Developmental Brain Research*, 92, 211-218, 1996.
 51. Kluin KJ, Bromberg MB, **Feldman EL**, Simmons Z. Dysphagia in elderly men with myasthenia gravis. *Journal of Neurological Sciences*, 138, 49-52, 1996.
 52. Stevens MJ, Lattimer SA, **Feldman EL**, Helton ED, Millington DS, Sima AAF, Greene DA. Acetyl-L-carnitine deficiency as a cause of altered nerve *myo*-Inositol content, Na, K-ATPase activity and motor conduction velocity in the streptozotocin-diabetic rat. *Metabolism*, 45, 865-872, 1996.
 53. Singleton JR, Randolph AE, **Feldman EL**. Insulin-like growth factor I receptor prevents apoptosis and enhances neuroblastoma tumorigenesis. *Cancer Research*, 56, 4522-4529, 1996.
 54. Singleton JR, Dixit VM, **Feldman EL**. Type I insulin-like growth factor receptor activation regulates apoptotic proteins. *Journal of Biological Chemistry*, 271, 31791-31794, 1996.
 55. Leventhal PS, **Feldman EL**. The tyrosine kinase inhibitor methyl 2,5-dihydroxycinnamate disrupts changes in the actin cytoskeleton required for neurite formation. *Molecular Brain Research*, 43, 338-340, 1996.
 56. Sullivan KA, Kim B, Buzdon M, **Feldman EL**. Suramin disrupts insulin-like growth factor-II (IGF-II) mediated autocrine growth in human SH-SY5Y neuroblastoma cells. *Brain Research*, 744, 199-206, 1997.
 57. Leventhal PS, Shelden EA, Kim B, **Feldman EL**. Tyrosine phosphorylation of paxillin and focal adhesion kinase during insulin-like growth factor-I stimulated lamellipodial advance. *Journal of Biological Chemistry*, 272, 5214-5218, 1997.
 58. Leventhal PS, **Feldman EL**. Insulin-like growth factors as regulators of cell motility: signaling mechanisms. *Trends in Endocrinology and Metabolism*, 8, 1-6, 1997.
 59. Cheng H-L, **Feldman EL**. Insulin-like growth factor-I (IGF-I) and IGF binding protein-5 in Schwann cell differentiation. *Journal of Cellular Physiology*, 171, 161-167, 1997.

60. Matthews C, Odeh H, **Feldman EL**. Insulin-like growth factor-I is an osmoprotectant in human neuroblastoma cells. *Neuroscience*, 79, 525-534, 1997.
61. Fedele D, Comi G, Coscelli C, Cucinotta D, **Feldman EL**, Ghirlanda G, Greene DA, Negrin P, Santeusanio F, Italian Diabetic Neuropathy Committee. A multicenter study on the prevalence of diabetic neuropathy in Italy. *Diabetes Care*, 20, 836-843, 1997.
62. Kim B, Leventhal PS, Saltiel AR, **Feldman EL**. Insulin-like growth factor (IGF)-I-mediated neurite outgrowth *in vitro* requires MAP kinase activation. *Journal of Biological Chemistry*, 272, 21268-21273, 1997.
63. Bromberg MB, Wald JJ, Forsheo DA, **Feldman EL**, Albers JW. Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis. *Journal of Neurological Sciences*, 150, 59-62, 1997.
64. **Feldman EL**, Stevens MJ, Greene DA. The pathogenesis of diabetic neuropathy. *Clinical Neuroscience*, 4, 365-370, 1997.
65. **Feldman EL**, Sullivan KA, Kim B, Russell JW. Insulin-like growth factors regulate neuronal differentiation and survival. *Neurobiology of Disease*, 4, 201-214, 1997.
66. Sawchuk KSLJ, Churchill S, **Feldman E**, Drury I. Status epilepticus amauroticus. *Neurology*, 49, 1467-1469, 1997.
67. Cheng H-L, **Feldman EL**. Bidirectional regulation of p38 kinase and c-Jun N-terminal protein kinase by insulin-like growth factor-I. *Journal of Biological Chemistry*, 273, 14560-14565, 1998.
68. Stevens MJ, Dayanikli F, Raffel DM, Allman KC, Sandford T, **Feldman EL**, Wieland DM, Corbett J, Schwaiger M. Scintigraphic assessment of regionalized defects in myocardial sympathetic innervation and blood flow regulation in diabetic patients with autonomic neuropathy. *Journal of the American College of Cardiology*, 31, 1575-1584, 1998.
69. Kim B, **Feldman EL**. Differential regulation of focal adhesion kinase and mitogen-activated protein kinase tyrosine phosphorylation during insulin-like growth factor-I-mediated cytoskeletal reorganization. *Journal of Neurochemistry*, 71, 1333-1336, 1998.
70. Russell JW, Windebank AJ, Schenone A, **Feldman EL**. Insulin-like growth factor-I prevents apoptosis in neurons after nerve growth factor withdrawal. *Journal of Neurobiology*, 36, 455-467, 1998.
71. Kim B, Leventhal PS, White MF, **Feldman EL**. Differential regulation of insulin receptor substrate-2 and mitogen-activated protein kinase tyrosine phosphorylation by phosphatidylinositol 3-kinase inhibitors in SH-SY5Y human neuroblastoma cells. *Endocrinology*, 139, 4881-4889, 1998.

72. Kim B, Cheng H-L, Margolis B, **Feldman EL**. Insulin receptor substrate-2 and Shc play different roles in insulin-like growth factor-I signaling. *Journal of Biological Chemistry*, 273, 34543-34550, 1998.
73. Hogikyan RV, Wald JJ, **Feldman EL**, Greene DA, Halter JB, Supiano MA. Acute effects of adrenergic-mediated ischemia on nerve conduction in subjects with type 2 diabetes. *Metabolism*, 48, 495-500, 1999.
74. Russell JW, **Feldman EL**. Insulin-like growth factor-I prevents apoptosis in sympathetic neurons exposed to high glucose. *Hormone and Metabolic Research*, 31, 90-96, 1999.
75. Anlar B, Sullivan KA, **Feldman EL**. Insulin-like growth factor-I and central nervous system development. *Hormone and Metabolic Research*, 31, 120-125, 1999.
76. Mikol DD, Hong H, Cheng H-L, **Feldman EL**. Caveolin-1 expression in Schwann cells. *Glia*, 27, 39-52, 1999.
77. Boulis NM, Turner DE, Dice JA, Bhatia V, **Feldman EL**. Characterization of adenoviral gene expression in spinal cord following remote vector delivery. *Neurosurgery*, 45, 131-138, 1999.
78. Greene DA, Stevens MJ, Obrosova I, **Feldman EL**. Glucose-induced oxidative stress and programmed cell death in diabetic neuropathy. *European Journal of Pharmacology*, 375, 217-223, 1999.
79. Cheng H-L, Russell JW, **Feldman EL**. IGF-I promotes peripheral nervous system myelination. *Annals of the New York Academy of Sciences*, 883, 124-130, 1999.
80. Cheng H-L, Shy M, **Feldman EL**. Regulation of insulin-like growth factor-binding protein-5 expression during Schwann cell differentiation. *Endocrinology*, 140, 4478-4485, 1999.
81. Mikol DD, **Feldman EL**. Neurophilins and the nervous system. *Muscle & Nerve*, 22, 1337-1340, 1999.
82. Greene DA, Stevens MJ, **Feldman EL**. Diabetic neuropathy: scope of the syndrome. *The American Journal of Medicine*, 107(2B), 2S-8S, 1999.
83. Russell JW, Sullivan KA, Windebank AJ, Herrmann DN, **Feldman EL**. Neurons undergo apoptosis in animal and cell culture models of diabetes. *Neurobiology of Disease*, 6, 347-363, 1999.
84. **Feldman EL**, Russell JW, Sullivan KA, Golovoy D. New insights into the pathogenesis of diabetic neuropathy. *Current Opinion in Neurology*, 12, 553-563, 1999.

85. Comi G, Fedele D, Coscelli C, Cucinotta D, **Feldman EL**, Ghirlanda G, Negrin P, Santeusano F, Maderna L. The Italian multicentre study on the prevalence of distal symmetric polyneuropathy: correlation between clinical variables and nerve conduction parameters. Italian Diabetic Neuropathy Committee. *Electroencephalography Clinical Neurophysiology Supplement* 50: 546-552, 1999.
86. Delaney CL, Cheng H-L, **Feldman EL**. Insulin-like growth factor-I prevents caspase mediated apoptosis in Schwann cells. *Journal of Neurobiology*, 41, 540-548, 1999.
87. van Golen CM, **Feldman EL**. Insulin-like growth factor I is the key factor in serum which protects neuroblastoma cells from hyperosmotic-induced apoptosis. *Journal of Cellular Physiology*, 182, 24-32, 2000.
88. Delaney CL, **Feldman EL**. The role of insulin-like growth factor-I and apoptosis in glial cell biology. *The Neuroscientist*, 6, 39-47, 2000.
89. van Golen CM, Castle VP, **Feldman EL**. IGF-I receptor activation and Bcl-2 overexpression prevent early apoptotic events in human neuroblastoma. *Cell Death and Differentiation*, 7, 654-665, 2000.
90. Herrmann DN, Blaivas M, Wald JJ, **Feldman EL**. Granulomatous myositis, primary biliary cirrhosis, pancytopenia, and thymoma. *Muscle & Nerve*, 23, 1133-1136, 2000.
91. Cheng H-L, Steinway M, Russell JW, **Feldman EL**. GTPases and phosphatidylinositol-3 kinase are critical for insulin-like growth factor-I mediated Schwann cell motility. *Journal of Biological Chemistry*, 275, 27197-27204, 2000.
92. Shelden EA, **Feldman EL**. Automated difference image analysis of lamellar ruffling: effect of temperature change on human SH-SY5Y neuroblastoma cells. *Journal of Neuroscience Methods*, 102, 143-154, 2000.
93. Cheng H-L, Steinway M, Delaney CL, Franke TF, **Feldman EL**. IGF-I promotes Schwann cell motility and survival via activation of Akt. *Molecular and Cellular Endocrinology*, 170, 211-215, 2000.
94. Simmons Z, **Feldman EL**. The pharmacological treatment of painful diabetic neuropathy. *Clinical Diabetes*, 18, 116-118, 2000.
95. Cheng H-L, Steinway M, Xin X, **Feldman EL**. Insulin-like growth factor-I and Bcl-X_L inhibit c-jun N-terminal kinase activation and rescue Schwann cells from apoptosis. *Journal of Neurochemistry*, 76, 935-943, 2001.

96. Delaney CL, Russell JW, Cheng H-L, **Feldman EL**. Insulin-like growth factor-I and over-expression of Bcl-xL prevent glucose-mediated apoptosis in Schwann cells. *Journal of Neuropathology and Experimental Neurology*, 60, 147-160, 2001.
97. Turner DE, Noordmans AJ, **Feldman EL**, Boulis NM. Remote adenoviral gene delivery to the spinal cord: Contralateral delivery and reinjection. *Neurosurgery*, 48, 1309-1317, 2001.
98. van Golen CM, Schwab TS, Woods Ignatoski KM, Ethier SP, **Feldman EL**. PTEN/MMAC1 overexpression decreases IGF-I mediated protection from apoptosis in neuroblastoma cells. *Cell Growth and Differentiation*, 12, 371-378, 2001.
99. Singleton JR, **Feldman EL**. Insulin-like growth factor-I in muscle metabolism and myotherapies. *Neurobiology of Disease*, 8, 541-554, 2001.
100. Russell JW, **Feldman EL**. Impaired glucose tolerance - does it cause neuropathy? *Muscle & Nerve*, 24, 1109-1112, 2001.
101. Jasty R, van Golen C, Lin H-J, Solomon G, Heidelberger K, Polverini P, Opiari A, **Feldman E**, Castle VP. Bcl-2 and N-Myc coexpression increases IGF-IR and features of malignant growth in neuroblastoma cell lines. *Neoplasia*, 3, 304-313, 2001.
102. Ad Hock Panel of Endpoints for Diabetic Neuropathy Trials. Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials. *Journal of the Neurological Sciences*, 189, 3-5, 2001.
103. Meyer GE, Shelden E, Kim B, **Feldman EL**. IGF-I promotes neuroblastoma cell motility. *Oncogene*, 20, 7542-7550, 2001.
104. Rubin AD, Hogikyan ND, Sullivan K, Boulis N, **Feldman EL**. Remote delivery of rAAV-GFP to the rat brainstem through the recurrent laryngeal nerve. *The Laryngoscope*, 111, 2041-2045, 2001.
105. Mikol DD, Scherer SS, Duckett SJ, Hong HL, **Feldman EL**. Schwann cell caveolin-1 expression increases during myelination and decreases following axotomy. *Glia*, 38, 191-199, 2002.
106. Noujaim D, van Golen C, van Golen K, **Feldman, EL**. N-Myc and Bcl-2 coexpression induces MMP-2 secretion and activation in human neuroblastoma cells. *Oncogene*, 21, 4549-4557, 2002.
107. Kim B, **Feldman EL**. Insulin-like growth factor I prevents mannitol-induced degradation of focal adhesion kinase and Akt. *Journal of Biological Chemistry*, 277, 27393-27400, 2002.

108. Vincent AM, **Feldman EL**. Control of cell survival by IGF signaling pathways. *Growth Hormone and IGF Research*, 12, 193-197, 2002.
109. Simmons Z, **Feldman EL**. Update on diabetic neuropathy. *Current Opinion in Neurology*, 15, 595-603, 2002.
110. Russell JW, Golovoy D, Vincent AM, Mahendru P, Olzmann JA, Mentzer A, **Feldman EL**. High glucose induced oxidative stress and mitochondrial dysfunction in neurons. *FASEB Journal*, 16, 1738-1748, 2002.
111. Meyer G, **Feldman EL**. Signaling mechanisms that regulate actin-based motility processes in the nervous system. *Journal of Neurochemistry*, 83, 490-503, 2002.
112. Boulis NM, Turner DE, Imperiale MJ, **Feldman EL**. Neuronal survival following remote adenovirus gene delivery. *Journal of Neurosurgery*, 96 (2 Suppl), 212-219, 2002.
113. Boulis NM, Willmarth N, Song DK, **Feldman EL**, Imperiale MJ. Intraneural colchicine inhibition of adenoviral and adeno-associated viral vector remote spinal cord gene delivery. *Neurosurgery*, 52, 381-387, 2003.
114. **Feldman EL**. Oxidative stress and diabetic neuropathy: a new understanding of an old problem. *Journal of Clinical Investigation*, 111, 431-433, 2003.
115. van Golen CM, Soules ME, Grauman AR, **Feldman EL**. N-Myc overexpression leads to decreased $\beta 1$ integrin expression and increased apoptosis in human neuroblastoma cells. *Oncogene*, 22, 2664-2673, 2003.
116. Rubin A, Mobley B, Hogikyan N, Bell K, Sullivan K, Boulis N, **Feldman EL**. Delivery of an adenoviral vector to the crushed recurrent laryngeal nerve. *The Laryngoscope*, 113, 985-989, 2003.
117. Kim B, van Golen CM, **Feldman EL**. Degradation and dephosphorylation of focal adhesion kinase during okadaic acid-induced apoptosis in human neuroblastoma cells. *Neoplasia*, 5, 405-416, 2003.
118. Singleton JR, Smith AG, Russell JW, **Feldman EL**. Microvascular complications of impaired glucose tolerance. *Diabetes*, 52, 2867-2873, 2003.
119. Boulis NM, Noordmans AJ, Song DK, Imperiale MJ, Rubin A, Leone P, During M, **Feldman EL**. Adeno-associated viral vector gene expression in the adult rat spinal cord following remote vector delivery. *Neurobiology of Disease*, 14, 535-541, 2003.
120. Corey JM, **Feldman EL**. Substrate patterning: An emerging technology for the study of neuronal behavior. *Experimental Neurology*, 184, S89-S96, 2003.

121. Nadeau TP, Sullivan KA, Teorey TJ, **Feldman EL**. Applying database technology to clinical and basic research bioinformatics projects. *Journal of Integrative Neuroscience*, 2, 210-217, 2003.
122. Berger AR, Bradley WG, Brannagan TH, Busis NA, Cros DP, Dalakas MC, Danon MJ, Donofrio P, Engel WK, England JD, **Feldman EL**, Freeman RL, Kinsella LJ, Lacomis D, Latov N, Menkes DL, Sander HW, Thomas FP, Triggs WJ, Windebank AJ, Wolfe GI. Guidelines for the diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy. *Journal of the Peripheral Nervous System*, 8, 282-284, 2003.
123. Kim B, van Golen C, **Feldman EL**. Insulin-like growth factor-I signaling in human neuroblastoma cells. *Oncogene*, 23, 130-141, 2004.
124. Leininger GM, Vincent AM, **Feldman EL**. The role of growth factors in diabetic peripheral neuropathy. *Journal of the Peripheral Nervous System*, 9, 26-53, 2004.
125. Consilvio C, Vincent AM, **Feldman EL**. Neuroinflammation, COX-2, and ALS – A dual role? *Experimental Neurology*, 187, 1-10, 2004.
126. Vincent AM, **Feldman EL**. New insights into the mechanisms of diabetic neuropathy. *Reviews in Endocrine & Metabolic Disorders*, 5, 227-236, 2004.
127. Leininger GM, Russell JW, van Golen CM, Berent A, **Feldman EL**. Insulin-like growth factor-I (IGF-I) regulates glucose-induced mitochondrial depolarization and apoptosis in human neuroblastoma. *Cell Death and Differentiation*, 11, 885-896, 2004.
128. Vincent AM, Mobley BC, Hiller A, **Feldman EL**. IGF-I prevents glutamate-induced motor neuron programmed cell death. *Neurobiology of Disease*, 16, 407-416, 2004.
129. Layton BE, Sastry AM, Wang H, Sullivan KA, **Feldman EL**, Komorowski TE, Philbert MA. Differences between collagen morphologies, properties and distribution in diabetic and normal BioBreeding and Sprague-Dawley rat sciatic nerves, *Journal of Biomechanics*, 37, 879-888, 2004.
130. Meyer A, van Golen CM, Kim B, van Golen KL, **Feldman EL**. Integrin expression regulates neuroblastoma attachment and migration. *Neoplasia*, 6, 332-342, 2004.
131. Vincent AM, Russell JW, Low P, **Feldman EL**. Oxidative stress in the pathogenesis of diabetic neuropathy. *Endocrine Reviews*, 25, 612-628, 2004.
132. Layton BE, Sastry AM, Lastoskie CM, Philbert MA, Miller TJ, Sullivan KA, **Feldman EL**, Wang C-W. In situ imaging of mitochondrial outer-membrane pores using atomic force microscopy. *BioTechniques*, 37, 564-573, 2004.

133. Leininger GM, Backus C, Uhler MD, Lentz SI, **Feldman EL**. Phosphatidylinositol 3-kinase and Akt effectors mediate insulin-like growth factor-I neuroprotection in dorsal root ganglia neurons. *FASEB Journal*, 18, 1544-1546, 2004.
134. Vincent AM, **Feldman EL**, Song DK, Jung V, Schild A, Zhang W, Imperiale MJ, Boulis NM. Adeno-associated viral-mediated insulin-like growth factor delivery protects motor neurons *in vitro*. *Neuromolecular Medicine*, 6, 79-85, 2004.
135. Leininger GM, **Feldman EL**. Insulin-like growth factors in the treatment of neurological disease. *Endocrine Development* 9: 135-159, 2005.
136. Vincent AM, McLean LL, Backus C, and **Feldman EL**. Short-term hyperglycemia produces oxidative damage and apoptosis in neurons. *FASEB Journal*, 19, 638-640, 2005.
137. Meyer G, Kim B, van Golen CM, **Feldman EL**. Cofilin activity during insulin-like growth factor I-stimulated neuroblastoma cell motility. *Cellular and Molecular Life Sciences*, 62, 461-470, 2005.
138. Meyer A, van Golen CM, Boyanapalli M, Kim B, Soules ME, **Feldman EL**. Integrin-linked kinase complexes with caveolin-1 in human neuroblastoma cells. *Biochemistry*, 44, 932-938, 2005.
139. Kim B, Oh SS, van Golen CM, **Feldman EL**. Differential regulation of insulin receptor substrate-1 degradation during mannitol and okadaic acid induced apoptosis in human neuroblastoma cells. *Cellular Signalling*, 17, 769-775, 2005.
140. Boulton AJM, Vinik AI, Arezzo JC, Bril V, **Feldman EL**, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D. Diabetic neuropathies: A statement by the American Diabetes Association. *Diabetes Care*, 28, 956-962, 2005.
141. Schwab TS, Madison BB, Grauman AR, **Feldman EL**. Insulin-like growth factor-I induces the phosphorylation and nuclear exclusion of forkhead transcription factors in human neuroblastoma cells. *Apoptosis*, 10, 831-840, 2005.
142. Vincent AM, Backus C, Taubman AA, **Feldman EL**. Identification of candidate drugs for the treatment of ALS. *Amyotrophic Lateral Sclerosis*, 6, 29-36, 2005.
143. Stevens MJ, Larkin DD, **Feldman EL**, Del Monte MA, Greene DA. Establishment, maintenance, and transfection of *in vitro* cultures of human retinal pigment epithelium. *Methods in Molecular Medicine*, 107, 343-351, 2005.
144. Russo VC, Gluckman P, **Feldman EL**, Werther GA. The insulin-like growth factor system and its pleiotropic functions in brain. *Endocrine Reviews*, 26, 916-943, 2005.

145. Sullivan KA, **Feldman EL**. New developments in diabetic neuropathy. *Current Opinion in Neurology*, 18, 586-590, 2005.
146. Kim B, **Feldman EL**. Insulin-like growth factor I induces preferential degradation of insulin receptor substrate-2 through the phosphatidylinositol 3-kinase pathway in human neuroblastoma cells. *Endocrinology*, 146, 5350-5357, 2005.
147. Gruis KL, Brown DL, Schoennemann A, Zebarah VA, **Feldman EL**. Predictors of noninvasive ventilation tolerance in patients with amyotrophic lateral sclerosis. *Muscle Nerve*, 32, 808-811, 2005.
148. **Feldman EL**. Biomedical research: a culture in crisis? *Nature Clinical Practice Neurology*, 1, 61, 2005.
149. Vincent AM, Stevens MJ, Backus C, McLean LL, **Feldman EL**. Cell culture modeling to test therapies against hyperglycemia-mediated oxidative stress and injury. *Antioxidant and Redox Signaling*, 7, 1494-1506, 2005.
150. van Golen CM, Schwab TS, Kim B, Soules ME, Su OH S, Fung K, van Golen KL, **Feldman EL**. Insulin-like growth factor-I receptor expression regulates neuroblastoma metastasis to bone. *Cancer Research*, 66, 6570-6578, 2006.
151. Martin CL, Albers J, Herman WH, Cleary P, Waberski B, Greene DA, Stevens MJ, **Feldman EL**. Neuropathy among the Diabetes Control and Complications Trial Cohort 8 years after trial completion. *Diabetes Care*, 29, 340-344, 2006.
152. Gruis KL, Brown DL, Weatherwax KJ, **Feldman EL**, Chervin RD. Evaluation of sham noninvasive ventilation for randomized, controlled trials in ALS. *Amyotrophic Lateral Sclerosis*, 7, 96-99, 2006.
153. Smith AG, Russell J, **Feldman EL**, Goldstein J, Peltier A, Smith S, Hamwi J, Pollari D, Bixby B, Howard J, Singleton JR. Lifestyle intervention for prediabetic neuropathy. *Diabetes Care*, 29, 1294-1299, 2006.
154. Leininger GM, Backus C, Sastry AM, Yi Y-B, Wang C-W, **Feldman EL**. Mitochondria in DRG neurons undergo hyperglycemic mediated injury through Bim, Bax and the fission protein Drp1. *Neurobiology of Disease*, 23, 11-22, 2006.
155. Leininger GM, Edwards JL, Lipshaw MJ, **Feldman EL**. Mechanisms of disease: Mitochondria as new therapeutic targets in diabetic neuropathy. *Nature Clinical Practice Neurology*, 2, 620-628, 2006.
156. Gruis KL, Brown DL, Lisabeth LD, Zebarah VA, Chervin RD, **Feldman EL**. Longitudinal assessment of noninvasive positive pressure ventilation adjustments in ALS patients. *Journal of the Neurological Sciences*, 247, 59-63, 2006.

157. Little AA, Edwards JL, **Feldman, EL**. Diabetic neuropathies. *Practical Neurology*, 7, 82-92, 2007.
158. Vincent AM, Perrone L, Sullivan KA, Backus C, Sastry AM, Lastoskie C, **Feldman EL**. Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. *Endocrinology*, 148, 548-558, 2007.
159. Cornblath DR, Vinik A, **Feldman E**, Freeman R, Boulton AJ. Surgical decompression for diabetic sensorimotor polyneuropathy. *Diabetes Care*, 30, 421-422, 2007.
160. Heavner SB, Rubin AD, Fung K, Old M, Hogikyan ND, **Feldman EL**. Dysfunction recurrent laryngeal nerve and the potential of gene therapy. *Annals of Otolaryngology Rhinology and Laryngology*, 116, 441-448, 2007.
161. Corey JM, Lin DY, Mycek KB, Chen Q, Samuel S, **Feldman EL**, Martin DC. Aligned electrospun nanofibers specify the direction of dorsal root ganglia neurite growth. *Journal of Biomedical Materials Research A*, 1;83, 636-645, 2007.
162. Sullivan KA, Hayes JM, Wiggin TD, Backus C, Oh S, Lentz SI, Brosius F, **Feldman EL**. Mouse models of diabetic neuropathy. *Neurobiology of Disease*, 28, 276-285, 2007.
163. Vincent AM, Russell JW, Sullivan KA, Backus C, Hayes JM, McLean LL, **Feldman EL**. SOD2 protects neurons from injury in cell culture and animal models of diabetic neuropathy. *Experimental Neurology*, 208, 216-227, 2007.
164. Vincent AM and **Feldman, EL**. Can drug screening lead to candidate therapies for testing in diabetic neuropathy? *Antioxidants & Redox Signaling*, 10, 387-393, 2008.
165. **Feldman EL**. Diabetic neuropathy. *Current Drug Targets*, 9, 1-2, 2008. Not funded by NIH.
166. Sullivan KA, Lentz SI, Roberts JL Jr, **Feldman EL**. Criteria for creating and assessing mouse models of diabetic neuropathy. *Current Drug Targets*, 9, 3-13, 2008. PMCID: PMC4026946
167. Vincent AM, Edwards JL, Sadidi M, **Feldman EL**. The antioxidant response as a drug target in diabetic neuropathy. *Current Drug Targets*, 9, 94-100, 2008. Not funded by NIH.
168. Vincent AM, Sakowski SA, Schuyler A, **Feldman EL**. Strategic approaches to developing drug treatments for ALS. *Drug Discovery Today*, 13, 67-72, 2008. PMCID: PMC2259461

169. **Feldman EL**, Cornblath DR, Porter J, Dworkin R, Scherer S. National Institute of Neurological Disorders and Stroke (NINDS) Meeting Summary: Advances in understanding and treating neuropathy, October 24-25, 2006, Bethesda, Maryland. *Journal of the Peripheral Nervous System*, 13, 1-6, 2008. PMID: PMC2680078
170. Dowling JJ, Gibbs E, Russell M, Goldman D, Minarcik J, Golden JA, **Feldman EL**. Kindlin-2 is an essential component of intercalated discs and is required for vertebrate cardiac structure and function. *Circulation Research*, 102, 423-431, 2008.
171. Fung K, Hogikyan ND, Heavner SB, Ekbohm D, **Feldman EL**. Development and characterisation of an experimental recurrent laryngeal nerve injury model for the study of viral gene therapy. *The Journal of Laryngology and Otology*, 122, 500-505, 2008.
172. Russell JW, Berent-Spillson A, Vincent AM, Freiman CL, Sullivan KA, **Feldman EL**. Oxidative injury and neuropathy in diabetes and impaired glucose tolerance. *Neurobiology of Disease*, 30, 420-429, 2008. PMID: PMC2453225
173. Corey JM, Gertz CC, Wang BS, Birrell LK, Johnson SL, Martin DC, **Feldman EL**. The design of electrospun PLLA nanofiber scaffolds compatible with serum-free growth of primary motor and sensory neurons. *Acta Biomaterials*, 4, 863-875, 2008. PMID: PMC2922842
174. Dowling JJ, Vreede AP, Kim S, Golden J, **Feldman EL**. Kindlin-2 is required for myocyte elongation and is essential for myogenesis. *BMC Cell Biology*, 9, 36, 2008. PMID: PMC2478659
175. Muller KA, Ryals JM, **Feldman EL**, Wright DE. Abnormal muscle spindle innervation and large-fiber neuropathy in diabetic mice. *Diabetes*, 57, 1693-1701, 2008. PMID: PMC2156563
176. Dowling JJ, Gibbs EM, **Feldman EL**. Membrane traffic and muscle: Lessons from human disease. *Traffic*, 9, 1035-1043, 2008. PMID: PMC2935664
177. Singleton JR, Bixby B, Russell J, **Feldman E**, Peltier A, Goldstein J, James H, Smith AG. The Utah Early Neuropathy Scale: A sensitive scale for early sensory predominant neuropathy. *Journal of the Peripheral Nervous System*, 13, 218-227, 2008.
178. Figueroa-Romero C, Sadidi M, **Feldman EL**. Mechanisms of disease: The oxidative stress theory of diabetic neuropathy. *Reviews in Endocrine and Metabolic Disorders*, 9, 301-314, 2008. PMID: PMC4239697
179. Zhang H, Saha J, Byun J, Schin ML, Lorenz M, Kennedy RT, Kretzler M, **Feldman EL**, Pennathur S, Brosius III FC. Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic

- nephropathy. *American Journal of Physiology – Renal Physiology*, 295, F1071-1081, 2008. PMID: PMC2576144
180. Edwards JL, Vincent AM, Cheng HL, **Feldman EL**. Diabetic neuropathy: Mechanisms to management. *Pharmacology and Therapeutics*, 120, 1-34, 2008.
181. Wiggin TD, Kretzler M, Pennathur S, Sullivan KA, Brosius FC, **Feldman EL**. Rosiglitazone treatment reduces diabetic neuropathy in STZ treated DBA/2J mice. *Endocrinology*, 149, 4928-4937, 2008. PMID: PMC2582925
182. Qian Y, **Feldman E**, Pennathur S, Kretzler M, Brosius III FC. From fibrosis to sclerosis. Mechanisms of glomerulosclerosis in diabetic nephropathy. *Diabetes*, 57, 1439-1445, 2008. PMID: PMC4239998
183. Sullivan KA, Kim B, **Feldman EL**. Insulin-like growth factors in the peripheral nervous system. *Endocrinology*, 149, 5963-5971, 2008. PMID: PMC2613061
184. Sorenson EJ, Windebank AJ, Mandrekar JN, Bamlet WR, Appel SH, Armon C, Barkhaus PE, Bosch P, Boylan K, David WS, **Feldman E**, Glass J, Gutmann L, Katz J, King W, Luciano CA, McCluskey LF, Nash S, Newman DS, Pascuzzi RM, Pioro E, Sams LJ, Scelsa S, Simpson EP, Subramony SH, Tiriyaki E, Thornton CA. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. *Neurology*, 71, 1770-1775, 2008. PMID: PMC2617770
185. Kern TS, Berkowitz BA, **Feldman EL**. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) meeting summary. Advances toward measuring diabetic retinopathy and neuropathy: From the bench to the clinic and back again (April 4-5, 2007, Baltimore, Maryland). *Journal of Diabetes and its Complications*, 23, 219-223, 2009. Not funded by NIH.
186. Dowling JJ, Vreede AP, Low SE, Gibbs EM, Kuwada JY, Bonnemann CG, **Feldman EL**. Loss of myotubularin function results in t-tubule disorganization in Zebrafish and human myotubular myopathy. *PloS Genetics*, 5(2):e1000372, 2009. PMID: PMC2631153
187. Hur J, Schuyler AD, States DJ, **Feldman EL**. SciMiner: Web-based literature mining tool for target identification and functional enrichment analysis. *Bioinformatics*, 25, 838-840, 2009. PMID: PMC2654801
188. Franz CK, Federici T, Yang J, Backus C, Oh SS, Teng Q, Carlton E, Bishop KM, Gasmi M, Bartus RT, **Feldman EL**, Boulis NM. Intraspinal cord delivery of IGF-I mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS. *Neurobiology of Disease*, 33, 473-481, 2009. Not funded by NIH.

189. Vincent AM, Kato K, McLean LL, Soules ME, **Feldman EL**. Sensory neurons and Schwann cell respond to oxidative stress by increasing antioxidant defense mechanisms. *Antioxidants and Redox Signaling*, 3, 425-438, 2009. PMID: PMC2933574
190. Lunn JS, Hefferan MP, Marsala M, **Feldman EL**. Stem cells: comprehensive treatments for amyotrophic lateral sclerosis in conjunction with growth factor delivery. *Growth Factors*, 27, 133-140, 2009.
191. Sadidi M, Lentz SI, **Feldman EL**. Hydrogen peroxide-induced Akt phosphorylation regulates Bax activation. *Biochimie*, 91, 577-585, 2009. PMID: PMC2697849
192. Peltier A, Smith AG, Russell JW, Sheikh K, Bixby B, Howard J, Goldstein J, Song Y, Wang L, **Feldman EL**, Singleton JR. Reliability of quantitative sudomotor axon reflex testing and quantitative sensory testing in neuropathy of impaired glucose regulation. *Muscle Nerve*, 39, 529-535, 2009.
193. Erman AB, Kejner AE, Hogikyan ND, **Feldman EL**. Disorders of cranial nerves IX and X. *Seminars in Neurology*, 29, 85-92, 2009. PMID: PMC4239699
194. Kim B, **Feldman EL**. Insulin receptor substrate (IRS)-2, not IRS-1, protects human neuroblastoma cells against apoptosis. *Apoptosis*, 14, 665-673, 2009. Not funded by NIH.
195. Sakowski SA, Schuyler AD, **Feldman EL**. Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis*, 10, 63-73, 2009. PMID: PMC3211070
196. Pop-Busui R, Low PA, Waberski BH, Martin CL, Albers JW, **Feldman EL**, Sommer C, Cleary PA, Lachin JM, Herman WH; for the DCCT/EDIC Research Group. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in Type 1 diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC). *Circulation*, 119, 2886-2893, 2009. PMID: PMC2757005
197. Schuyler AD, Carlson HA and **Feldman EL**. Computational methods for predicting sites of functionally important dynamics. *Journal of Physical Chemistry*, 113, 6613-6622, 2009. PMID: PMC2761153
198. Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AA, **Feldman EL**. Elevated triglycerides correlate with progression of diabetic neuropathy. *Diabetes*, 58, 1634-1640, 2009. PMID: PMC2699859
199. Lunn JS, Sakowski SA, Kim B, Rosenberg AA, **Feldman EL**. Vascular endothelial growth factor prevents G93A-SOD1-induced motor neuron degeneration. *Developmental Neurobiology*, 69, 871-874, 2009. PMID: PMC2853013

200. Figueroa-Romero C, Iniguez-Lluh JA, Stadler J, Change CR, Arnoult D, Keller PJ, Hong Y, Blackstone C, **Feldman EL**. SUMOylation of the mitochondrial fission protein Drp1 occurs at multiple nonconsensus sites within the B domain and is linked to its activity cycle. *FASEB Journal*, 23, 3917-3927, 2009. PMID: PMC2775011
201. Vincent AM, Hayes JM, McLean LL, Vivekanandan-Giri A, Pennathur S, **Feldman EL**. Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. *Diabetes*, 58, 2376-2385, 2009. PMID: PMC2750230
202. Cheng HT, Dauch JR, Hayes JM, Hong Y, **Feldman EL**. Nerve growth factor mediates mechanical allodynia in a mouse model of type 2 diabetes. *Journal of Neuropathology and Experimental Neurology*, 68, 1229-1243, 2009. PMID: PMC3163104
203. Sakowski SA, Heavener SB, Lunn JS, Fung K, Oh SS, Spratt SK, Hogikyan ND, **Feldman EL**. Neuroprotection using gene therapy to induce vascular endothelial growth factor-A expression. *Gene Therapy*, 16, 1292-1299, 2009. PMID: PMC4215171
204. Vincent AM, Hinder LM, Pop-Busui R, **Feldman EL**. Hyperlipidemia: a new therapeutic target for diabetic neuropathy. *Journal of the Peripheral Nervous System*, 14, 257-267, 2009. PMID: PMC4239691
205. Kim B, Backus C, Oh SS, Hayes JM, **Feldman EL**. Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. *Endocrinology*, 150, 5294-5301, 2009. PMID: PMC2795717
206. Edwards JL, Quattrini A, Lentz SI, Figueroa-Romero C, Cerri F, Backus C, Hong Y, **Feldman EL**. Diabetes regulates mitochondrial biogenesis and fission in neurons. *Diabetologia*, 53, 160-169, 2010. PMID: PMC4011390
207. Lentz SI, Edwards JL, Backus C, McLean LL, Haines KM, **Feldman EL**. Mitochondrial DNA (mtDNA) biogenesis: Visualization and dual incorporation of BrdU and EdU into newly synthesized mtDNA in vitro. *Journal of Histochemistry and Cytochemistry*, 58, 207-218, 2010. PMID: PMC2803709
208. Pop-Busui R, Roberts L, Pennathur S, Kretzler M, Brosius FC, **Feldman EL**. The management of diabetic neuropathy in CKD and dialysis patients. *American Journal of Kidney Diseases*, 55, 365-385, 2010. PMID: PMC4007054
209. Corey JM, Gertz CC, Sutton TJ, Chen Q, Mycek KB, Wang BS, Martin AA, Johnson SL, **Feldman EL**. Patterning N-type and S-type neuroblastoma cells with Pluronic F108 and ECM proteins. *Journal of Biomedical Materials and Research*, 93, 673-686, 2010. PMID: PMC2845720

210. Vincent AM, Edwards JL, McLean LL, Hong Y, Cerri F, Lopez I, Quattrini A, **Feldman EL**. Mitochondrial biogenesis and fission in axons in cell culture and animal models of diabetic neuropathy. *Acta Neuropathologica*, 120, 477-489, 2010. PMID: PMC4254759
211. Oh SS, Hayes JM, Sims-Robinson C, Sullivan KA, **Feldman EL**. The effects of anesthesia on measures of nerve conduction velocity in male C57B16/J mice. *Neuroscience Letters*, 483, 127–131, 2010. PMID: PMC2941214
212. Sims-Robinson C, Kim B, Rosko A, **Feldman EL**. How does diabetes accelerate Alzheimer disease pathology? *Nature Reviews Neurology*, 6, 551-559, 2010. PMID: PMC3199576
213. Gibbs EM, **Feldman EL**, Dowling JJ. The role of MTMR14 in autophagy and in muscle disease. *Autophagy*, 6, 819-820, 2010.
214. Kakoki M, Sullivan KA, Backus C, Hayes JM, Oh SS, Hua K, Gasim AM, Tomita H, Grant R, Nossov SB, Kim HS, Jennette JC, **Feldman EL**, Smithies O. Lack of both bradykinin B1 and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita diabetic mice. *Proceedings of the National Academy of Sciences USA*, 107, 10190-10195, 2010. PMID: PMC2890475
215. Gertz CC, Leach MK, Birrell LK, Martin DC, **Feldman EL**, Corey JM. Accelerated neuritogenesis and maturation of primary spinal motor neurons in response to nanofibers. *Developmental Neurobiology*, 70, 589-603, 2010. PMID: PMC2914271
216. Albers JW, Herman WH, Pop-Busui R, **Feldman EL**, Martin CL, Cleary PA, Waberski BH, Lachin JM; for the DCCT/EDIC Research Group. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions, and Complications (EDIC) Study. *Diabetes Care*, 33, 1090-1096, 2010. PMID: PMC2858182
217. Telfer WR, Busta AS, Bonnemann CG, **Feldman EL**, Dowling JJ. Zebrafish models of collagen VI related myopathies. *Human Molecular Genetics*, 19, 2433-2444, 2010. PMID: PMC2876888
218. Cheng HT, Dauch JR, Oh SS, Hayes JM, Yu H, **Feldman EL**. P38 mediates mechanical allodynia in a mouse model of type 2 diabetes. *Molecular Pain*, 6, 28, 2010. PMID: PMC2881061
219. Dowling JJ, Low SE, Busta AS, **Feldman EL**. Zebrafish MTMR14 is required for excitation-contraction coupling, developmental motor function and the regulation of autophagy. *Human Molecular Genetics*, 19, 2668-2681, 2010. PMID: PMC2883342

220. Pop-Busui R, Herman WH, **Feldman EL**, Low PA, Martin CL, Cleary PA, Waberski BH, Lachin JM, Albers JW for the DCCT/EDIC Research Group. DCCT and EDIC studies in type 1 diabetes: Lessons for diabetic neuropathy regarding metabolic memory and natural history. *Current Diabetes Reports*, 10, 276-282, 2010. PMID: PMC3608672
221. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P, **Toronto Diabetic Neuropathy Expert Group**. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. *Diabetes Care*, 33, 2285-2293, 2010. PMID: PMC2945176
222. Hur J, Sullivan K, Schuyler A, Hong Y, Pande M, States D, Jagadish H, **Feldman E**. Literature-based discovery of diabetes- and ROS-related targets. *BMC Medical Genomics*, 3, 49, 2010. PMID: PMC2988702
223. Haines KM, **Feldman EL**, Lentz SI. Visualization of mitochondrial DNA replication in individual cells by EdU signal amplification. *Journal of Visualized Experiments*, 45, 2147, 2010. PMID: PMC 3159597
224. Lunn JS, Pacut C, Backus C, Hong Y, Johe K, Hefferan M, Marsala M, **Feldman EL**. The pleiotrophic effects of IGF-I on human spinal cord neural progenitor cells. *Stem Cells and Development*, 12, 1983-1993, 2010. Not funded by NIH.
225. Martin C, Waberski B, Pop-Busui R, Cleary P, Catton S, Albers J, **Feldman E**, Herman W, DCCT/EDIC Research Group. Vibration perception threshold as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: results from the DCCT/EDIC study. *Diabetes Care*, 33, 2635-2641, 2010. PMID: PMC2992204
226. Schuyler AD, Carlson HA, **Feldman EL**. Computational methods for identifying a layered allosteric regulatory mechanism for ALS-causing mutations of Cu-Zn superoxide dismutase 1. *Proteins*, 79, 417-427, 2011. PMID: PMC3058251
227. Callaghan B, Feldman D, Gruis K, **Feldman E**. The association of exposure to lead, mercury, and selenium and the development of amyotrophic lateral sclerosis (ALS) and the epigenetic implications. *Neurodegenerative Diseases*, 8, 1-8, 2011. Not funded by NIH.
228. Callaghan BC, **Feldman E**, Liu J, Kerber K, Pop-Busui R, Moffet H, Karter AJ. Triglycerides and amputation risk in patients with diabetes: 10 year follow-up in the DISTANCE study. *Diabetes Care*, 34, 635-640, 2011. PMID: PMC3041196
229. Raore B, Federici T, Taub J, Wu MC, Riley J, Franz CK, Kliem MA, Snyder B, **Feldman EL**, Johe K, Boulis NM. Cervical multilevel intraspinal stem cell therapy: assessment of surgical risks in Gottingen minipigs. *Spine*, 36, E164-171, 2011. Not funded by NIH.

230. Lunn JS, Sakowski SA, Federici T, Glass JD, Boulis NM, **Feldman EL**. Stem cell technology for the study and treatment of motor neuron diseases. *Regenerative Medicine*, 6, 201-213, 2011. PMID: PMC3154698
231. Hur J, Xiang Z, **Feldman EL**, He Y. Ontology-based Brucella vaccine literature indexing and systematic analysis of gene-vaccine association network. *BMC Immunology*, 12, 49, 2011. PMID: PMC3180695
232. **Feldman EL**. Comment: career guidelines promote neurologist satisfaction. *Neurology*, 77, 689, 2011. Not funded by NIH.
233. Pande M, Hur J, Hong Y, Backus C, Hayes JM, Oh SS, Kretzler M, **Feldman EL**. Transcriptional profiling of diabetic neuropathy in the BKS db/db mouse; a model of type 2 diabetes. *Diabetes*, 60, 1981-1989, 2011. PMID: PMC3121428
234. Bril V, England JD, Franklin GM, Backonja M, Cohen JA, Del Toro DR, **Feldman E**, Iverson DJ, Perkins B, Russell JW, Zochodne DW. Evidence-based guideline: treatment of painful diabetic neuropathy - report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine and Rehabilitation. *Physical Medicine and Rehabilitation*, 3, 345-352, 2011. Not funded by NIH.
235. Bril V, England JD, Franklin GM, Backonja M, Cohen JA, Del Toro DR, **Feldman EL**, Iverson DJ, Perkins B, Russell JW, Zochodne DW. Evidence-based guideline: treatment of painful diabetic neuropathy - report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine and Rehabilitation. *Muscle & Nerve*, 43, 910-917, 2011. Not funded by NIH.
236. Bril V, England JD, Franklin GM, Backonja M, Cohen JA, Del Toro DR, **Feldman E**, Iverson DJ, Perkins B, Russell JW, Zochodne DW. Evidence-based guideline: treatment of painful diabetic neuropathy - report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. *Neurology*, 76, 1758-1765, 2011. PMID: PMC3100130
237. Zilliox L, Peltier AC, Wren PA, Anderson A, Smith AG, Singleton JR, **Feldman EL**, Alexander NB, Russell JW. Assessing autonomic dysfunction in diabetic neuropathy: the survey of autonomic symptoms. *Neurology*, 76, 1099-1105, 2011. PMID: PMC3068012
238. Kim B, Sullivan KA, Backus C, **Feldman EL**. Cortical neurons develop insulin resistance and blunted Akt signaling: a potential mechanism contributing to enhanced ischemic injury in diabetes. *Antioxidants and Redox Signaling*, 14, 1829-1839, 2011. PMID: PMC3078499

239. Old MO, Oh SS, **Feldman E**, Hogikyan ND. Novel model to assess laryngeal function, innervation, and reinnervation. *The Annals of Otolaryngology, Rhinology & Laryngology*, 120, 331-338, 2011. Not funded by NIH.
240. de Boer IH, Rue TC, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Sun W, Zinman B, Brunzell JD, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group, White NH, Danis RP, Davis MD, Hainsworth D, Hubbard LD, Nathan DM. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. *Archives of Internal Medicine*, 171, 412-420, 2011. PMID: PMC3085024
241. Vincent A, Callaghan B, Smith A, **Feldman E**. Diabetic neuropathy: cellular mechanisms as therapeutic targets. *Nature Reviews Neurology*, 7, 573-583, 2011. Not funded by NIH.
242. Kim B, McLean LL, Philip SS, **Feldman EL**. Hyperinsulinemia induces insulin resistance in dorsal root ganglion neurons. *Endocrinology*, 152, 3638-3647, 2011. PMID: PMC3176655
243. Hur J, Sullivan KA, Pande M, Hong Y, Sima AA, Jagadish HV, Kretzler M, **Feldman EL**. The identification of gene expression profiles associated with progression of human diabetic neuropathy. *Brain*, 134 (Pt 11), 3222-3235, 2011. PMID: PMC3212712
244. Lunn JS, Sakowski SA, Hur J, **Feldman EL**. Stem cell technology for neurodegenerative diseases. *Annals of Neurology*, 70, 353-361, 2011. PMID: PMC3177143
245. Hefferan MP, Johe K, **Feldman EL**, Lunn JS, Marsala M. Optimization of immunosuppressive therapy for spinal grafting of human spinal stem cells in a rat model of ALS. *Cell Transplantation*, 20, 1153-1161, 2011. Not funded by NIH.
246. Larkin LM, Davis CS, Sims-Robinson C, Kostrominova TY, Van Remmen H, Richardson A, **Feldman EL**, Brooks SV. Skeletal muscle weakness due to deficiency of Cu,Zn superoxide dismutase is associated with loss of functional innervation. *American Journal of Physiology, Regulatory, Integrative and Comparative Physiology*, 301, R1400-R1407, 2011. PMID: PMC3213934
247. Dyck PJ, Albers JW, Andersen H, Arezzo JC, Biessels GJ, Bril V, **Feldman EL**, Litchy WJ, O'Brien PC, Russell JW; on behalf of the Toronto Expert Panel on Diabetic Neuropathy*. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. *Diabetes/Metabolism Research and Reviews*, 27, 620-628, 2011. Not funded by NIH.

248. Boulis N, Federici T, Glass J, Lunn JS, Sakowski S, **Feldman E**. Translational stem cell therapy for amyotrophic lateral sclerosis. *Nature Reviews Neurology*, 8, 172-176, 2011. Not funded by NIH.
249. Cheng HT, Dauch JR, Hayes JM, Yanik BM, **Feldman EL**. Nerve growth factor/p38 signaling increases intraepidermal nerve fiber densities in painful neuropathy of type 2 diabetes. *Neurobiology of Disease*, 45, 280-287, 2012. PMID: PMC3225563
250. Peltier AC, Bagai K, Artibee K, Diedrich A, Garland E, Elasy T, Shi Y, Wang L, **Feldman EL**, Robertson D, Malow BA. Effect of mild hyperglycemia on autonomic function in obstructive sleep apnea. *Clinical Autonomic Research*, 22, 1-8, 2012. PMID: PMC3925507
251. Callaghan B, McCammon R, Kerber K, Xu X, Langa KM, **Feldman E**. Tests and expenditures in the initial evaluation of peripheral neuropathy. *Archives of Internal Medicine*, 172, 127-132, 2012. PMID: PMC3694340
252. Roberts SF, Fischhoff MA, Sakowski SA, **Feldman EL**. Perspective: Transforming science into medicine: how clinician-scientists can bridge research's "valley of death." *Academic Medicine*, 87, 266-270, 2012. Not funded by NIH.
253. Rubin AD, Griffin GR, Hogikyan ND, **Feldman EL**. A new member of the multidisciplinary team: the otolaryngologist. *Amyotrophic Lateral Sclerosis*, 13, 229-232, 2012. Not funded by NIH.
254. Sakowski SA, Lunn JS, Busta AS, Palmer M, Dowling JJ, **Feldman EL**. A novel approach to study motor neurons from zebrafish embryos and larvae in culture. *Journal of Neuroscience Methods*, 205, 277-282, 2012. PMID: PMC3433854
255. Kim B, **Feldman EL**. Insulin resistance in the nervous system. *Trends in Endocrinology and Metabolism*, 23, 133-141, 2012. PMID: PMC3392648
256. Rubin AD, Hogikyan ND, Oh A, **Feldman EL**. Potential for promoting recurrent laryngeal nerve regeneration by remote delivery of viral gene therapy. *The Laryngoscope*, 122, 349-355, 2012. Not funded by NIH.
257. Lunn JS, Pacut C, Stern E, Sakowski SA, Velkey JM, O'Shea S, **Feldman EL**. Intraspinal transplantation of neurogenin-expressing stem cells generates spinal cord neural progenitors. *Neurobiology of Disease*, 46, 59-68, 2012. PMID: PMC3299886
258. Callaghan B, Kerber K, Smith AL, Fendrick AM, **Feldman EL**. The evaluation of distal symmetric polyneuropathy: a physician survey of clinical practice. *Archives of Neurology*, 69, 339-345, 2012. PMID: PMC4254745

259. Petrou M, Pop-Busui R, Foerster BR, Edden RA, Callaghan BC, Harte SE, Harris RE, Clauw DJ, **Feldman EL**. Altered excitation-inhibition balance in the brain of patients with diabetic neuropathy. *Academic Radiology*, 19, 607-612, 2012. PMID: PMC3374728
260. Herman WH, Pop-Busui R, Braffett BH, Martin CL, Cleary PA, Albers JW, **Feldman EL**, The DCCT/EDIC Research Group. Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. *Diabetic Medicine*, 29(7), 937-944, 2012. PMID: PMC3641573
261. Hinder LM, Vincent AM, Burant CF, Pennathur S, **Feldman EL**. Bioenergetics in diabetic neuropathy: what we need to know. *Journal of the Peripheral Nervous System*, 17(Suppl. 2), 10-14, 2012. PMID: PMC3589977
262. Glass J, Boulis N, Johe K, Rutkove S, Federici T, Polak M, Kelly C, **Feldman E**. Lumbar intraspinal injection of neural stem cells in patients with ALS: Results of a Phase I trial in 12 patients. *Stem Cells*, 30(6), 1144-1151, 2012. Not funded by NIH.
263. Foerster BR, Callaghan BC, Petrou M, Edden RAE, Chenevert TL, **Feldman EL**. Decreased motor cortex γ -aminobutyric acid in amyotrophic lateral sclerosis. *Neurology*, 78, 1596-1600, 2012. PMID: PMC3348851
264. Oh SS, Sullivan KA, Wilkinson JE, Backus C, Hayes JM, Sakowski SA, **Feldman EL**. Neurodegeneration and early lethality in superoxide dismutase 2-deficient mice: a comprehensive analysis of the central and peripheral nervous systems. *Neuroscience*, 212, 201-213, 2012. PMID: PMC3367053
265. Callaghan BC, Cheng HT, Stables CL, Smith AL, **Feldman EL**. Diabetic neuropathy: Clinical manifestations and current treatments. *Lancet Neurology*, 11, 521-534, 2012. PMID: PMC4254767
266. Sakowski SA, **Feldman EL**. IGFs in the peripheral nervous system. *Endocrinology and Metabolism Clinics of North America*, 41, 375-393, 2012. Not funded by NIH.
267. Callaghan BC, Kerber K, Longoria R, **Feldman EL**, Lisabeth L. Capturing cases of distal symmetric polyneuropathy (DSP) in a community. *Muscle & Nerve*, 46, 943-947, 2012.
268. Sims-Robinson C, Zhao S, Hur J, **Feldman EL**. Central nervous system endoplasmic reticulum stress in a murine model of type 2 diabetes. *Diabetologia*, 55(8), 2276-2284, 2012. PMID: PMC3391332
269. Riley J, Federici T, Polak M, Kelly C, Glass J, Raore B, Taub J, Kessner V, **Feldman E**, Boulis N. Intraspinal stem cell transplantation in ALS: A phase I safety trial, technical

- note & lumbar safety outcomes. *Neurosurgery*, 71(2), 405-416, 2012. Not funded by NIH.
270. Callaghan BC, Hur J, **Feldman EL**. Diabetic neuropathy: one disease or two? *Current Opinion in Neurology*, 25, 536-541, 2012. PMID: PMC4239661
271. Sakowski SA, Lunn JS, Busta AS, Oh SS, Zamora-Berridi G, Palmer M, Rosenberg AA, Philip SG, Dowling JJ, **Feldman EL**. Neuromuscular effects of G93A-SOD1 expression in zebrafish. *Molecular Neurodegeneration*, 7(1), 44, 2012. PMID: PMC3506515
272. Callaghan BC, Little AA, **Feldman EL**, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. *Cochrane Database System Review*, 13(6), CD007543, 2012. PMID: PMC4048127
273. Hefferan MP, Galik J, Kakinohana O, Sekerkova G, Santucci C, Marsala S, Navarro R, Hruska-Plochan M, Johe K, **Feldman E**, Cleveland DW, Marsala M. Human neural stem cell replacement therapy for amyotrophic lateral sclerosis by spinal transplantation. *PLoS ONE*, 7(8): e42614, 2012. PMID: PMC3423406
274. Figueroa-Romero C, Hur J, Bender DE, Delaney CE, Cataldo MD, Smith AL, Yung R, Ruden DM, Callaghan BC, **Feldman EL**. Identification of epigenetically altered genes in sporadic amyotrophic lateral sclerosis. *PLoS ONE*, 7(12), e52672, 2012. PMID: PMC3530456
275. Vincent AM, McLean LL, Pande M, Oh SS, **Feldman EL**. LOX-1-mediated injury in sensory neurons in type 2 diabetes. *International Journal of Diabetes and Metabolism*, 20, 59-63, 2012. Not funded by NIH.
276. Sakowski SA, **Feldman EL**. Additional perspectives on transforming science into medicine. *Academic Medicine*, 87, 1311-1312, 2012. Not funded by NIH.
277. Hinder LM, Vincent AM, Hayes JM, McLean LL, **Feldman EL**. Apolipoprotein E knockout as the basis for mouse models of dyslipidemia-induced neuropathy. *Experimental Neurology*, 239, 102-110, 2013. PMID: PMC3534788
278. Hinder LM, Vivekanandan-Giri A, McLean LL, Pennathur S, **Feldman EL**. Decreased glycolytic and tricarboxylic acid cycle intermediates coincide with peripheral nervous system oxidative stress in a murine model of type 2 diabetes. *The Journal of Endocrinology*, 216, 1-11, 2013. PMID: PMC3665007
279. Nathan DM, Bayless M, Cleary P, Genuth S, Gubitosi-Klug R, Lachin JM, Lorenzi G, Zinman B, DCCT/EDIC Research Group. Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. *Diabetes*, 62, 3976-3986, 2013. PMID: PMC3837056

280. Gibbs EM, Clarke NF, Rose KJ, Oates EC, Webster R, **Feldman EL**, Dowling JJ. Neuromuscular junction abnormalities in DNMT2-related centronuclear myopathy. *Journal of Molecular Medicine*, 91, 727-737, 2013.
281. Kim B, Backus C, Oh S, **Feldman EL**. Hyperglycemia-induced tau cleavage in vitro and in vivo: a possible link between diabetes and Alzheimer's disease. *Journal of Alzheimers Disease*, 34, 727-739, 2013. PMID: PMC5545747
282. Gibbs EM, Davidson AE, Trickey-Glassman A, Backus C, Hong Y, Sakowski SA, Dowling JJ, **Feldman EL**. Two dynamin-2 genes are required for normal zebrafish development. *PLoS One*, 8(2), e55888. PMID: PMC3572173
283. Sims-Robinson C, Hur J, Hayes JM, Dauch JR, Keller PJ, Brooks SV, **Feldman EL**. The role of oxidative stress in nervous system aging. *PLoS One*, 8(7), e68011, 2013. PMID: PMC3699525
284. Pop-Busui R, Stevens MJ, Raffel DM, White EA, Mehta M, Plunkett CD, Brown MB, **Feldman EL**. Effects of triple antioxidant therapy on measures of cardiovascular autonomic neuropathy and on myocardial blood flow in type 1 diabetes. *Diabetologia*, 56, 1835-1844, 2013. PMID: PMC3730828
285. Grote C, Groover AL, Ryals JM, Geiger PC, **Feldman EL**, Wright DE. Peripheral nervous system insulin resistance in ob/ob mice. *Acta Neuropathologica Communications*, 1, 15, 2013. PMID: PMC3893412
286. Stables CL, Glasser RL, **Feldman EL**. Diabetic cardiac autonomic neuropathy: insights from animal models. *Autonomic Neuroscience*, 177, 74-80, 2013. Not funded by NIH.
287. Kupfer R, Oh SS, Old M, **Feldman E**, Hogikyan N. Spontaneous laryngeal reinnervation following chronic recurrent laryngeal nerve injury. *The Laryngoscope*, 123, 2216-2227, 2013. Not funded by NIH.
288. Cheng HT, Dauch JR, Porzio MT, Yanik BM, Hsieh W, Smith AG, Singleton JR, **Feldman EL**. Increased axonal regeneration and swellings in intraepidermal nerve fibers characterize painful phenotypes of diabetic neuropathy. *Journal of Pain*, 14, 941-947, 2013. PMID: PMC3994562.
289. Foerster BR, Pomper MG, Callaghan BC, Petrou M, Edden RA, Mohamed MA, Welsh RC, Carlos RC, Barker PB, **Feldman EL**. An imbalance between excitatory and inhibitory neurotransmitters in amyotrophic lateral sclerosis revealed by use of 3-T proton magnetic resonance spectroscopy. *JAMA Neurology*, 70, 1009-1016, 2013. Not funded by NIH.
290. Foerster BR, Welsh RC, **Feldman EL**. 25 years of neuroimaging in amyotrophic lateral sclerosis. *Nature Reviews Neurology*, 9, 513-524, 2013. PMID: PMC4182931

291. Foerster BR, Dwamena BA, Petrou M, Carlos RC, Callaghan BC, Churchill CL, Mohamed MA, Bartels C, Benatar M, Bonzano L, Ciccarelli O, Cosottini M, Ellis CM, Ehrenreich H, Filippini N, Ito M, Kalra S, Melhem ER, Pyra T, Roccatagliata L, Senda J, Sobue G, Turner MR, **Feldman EL**, Pomper MG. Diagnostic accuracy of diffusion tensor imaging in amyotrophic lateral sclerosis: a systematic review and individual patient data meta-analysis. *Academic Radiology*, 20, 1099-1106, 2013. Not funded by NIH.
292. Callaghan B, **Feldman E**. The metabolic syndrome and neuropathy: therapeutic challenges and opportunities. *Annals of Neurology*, 74, 397-403, 2013. PMID: PMC3881591
293. Vincent AM, Calabek B, Roberts L, **Feldman EL**. Biology of diabetic neuropathy. *Handbook of Clinical Neurology*, 115, 591-606, 2013. Not funded by NIH.
294. Hur J, Sullivan KA, Callaghan BC, Pop-Busui R, **Feldman EL**. Identification of factors associated with sural nerve regeneration and degeneration in diabetic neuropathy. *Diabetes Care*, 36, 4043-4049, 2013. PMID: PMC3836098
295. Callaghan BC, Burke JF, Rodgers A, McCammon R, Langa KM, **Feldman EL**, Kerber KA. Expenditures in the elderly with peripheral neuropathy: where should we focus cost-control efforts? *Neurology Clinical Practice*, 3, 421-430, 2013. PMID: PMC3806930
296. Jaiswal M, Lauer A, Martin CL, Bell RA, Divers J, Dabelea D, Pettitt DJ, Saydah S, Pihoker C, Standiford DA, Rodriguez BL, Pop-Busui R, **Feldman EL**, SEARCH for Diabetes in Youth Study Group. Peripheral neuropathy in adolescents and young adults with type 1 and type 2 diabetes from the SEARCH for Diabetes in Youth follow-up cohort: a pilot study. *Diabetes Care*, 36, 3903-3908, 2013. PMID: PMC3836139
297. Berger JR, Choi D, Kaminski HJ, Gordon MF, Hurko O, D'Cruz O, Pleasure SJ, **Feldman EL**. Importance and hurdles to drug discovery for neurological disease. *Annals of Neurology*, 74, 441-446, 2013. Not funded by NIH.
298. Riley J, Glass J, **Feldman EL**, Polak M, Bordeau J, Federici T, Johe K, Boulis NM. Intraspinal stem cell transplantation in ALS: a phase 1 trial, cervical microinjection and final surgical safety outcomes. *Neurosurgery*, 74, 77-87, 2014. Not funded by NIH.
299. Gibbs EM, Davidson AE, Telfer WR, **Feldman EL**, Dowling JJ. The myopathy-causing mutation DNM2-S619L leads to defective tabulation in vitro and in developing zebrafish. *Disease Models & Mechanisms*, 7, 157-161, 2014. PMID: PMC3882057
300. Foerster BR, Carlos RC, Dwamena BA, Callaghan BC, Petrou M, Edden RAE, Mohamed MA, Welsh RC, Barker PB, **Feldman EL**, Pomper MG. Multimodal MRI as a diagnostic

- biomarker for amyotrophic lateral sclerosis. *Annals of Clinical and Translational Neurology*, 1(2), 107-114, 2014. PMID: PMC4212480
301. O'Brien PD, Sakowski SA, **Feldman EL**. Mouse models of diabetic neuropathy. *Institute for Laboratory Animal Research*, 54, 259-272, 2014. PMID: PMC3962259
 302. **Feldman EL**, Boulis NM, Hur J, Johe K, Rutkove SB, Federici T, Polak M, Bordeau J, Sakowski SA, Glass JD. Intraspinal neural stem cell injections in ALS subjects: phase I trial outcomes. *Annals of Neurology*, 75, 363-373, 2014. PMID: PMC4005820.
 303. Little N, **Feldman EL**. Therapeutic hypothermia after cardiac arrest without return of consciousness – skating on thin ice. *JAMA Neurology*, 71, 823-824, 2014. Not funded by NIH.
 304. Hur J, Guo AY, Loh WY, **Feldman EL**, Bai JP. Integrated systems pharmacology analysis of clinical drug-induced peripheral neuropathy. *CPT: Pharmacometrics & Systems Pharmacology*, May 14;3:e114. doi: 10.1038/psp.2014.11, 2014. PMID: PMC4051377
 305. Nguyen TT, Oh SS, Weaver D, Lewandowska A, Maxfield D, Schuler MH, Smith NK, Macfarlane J, Saunders G, Palmer CA, Debattisti V, Koshiba T, Pulst S, **Feldman EL**, Hajnoczky G, Shaw JM. Loss of Miro 1-directed mitochondrial movement results in a novel murine model for neuron disease. *Proceedings of the National Academy of Science, USA*, 111(35), E3631-3640, 2014. PMID: PMC4156725
 306. Callaghan BC, Kerber KA, Lisabeth LL, Morgenstern LB, Longoria R, Rodgers A, Longwell P, **Feldman EL**. Role of neurologists and diagnostic tests on the management of distal symmetric polyneuropathy. *JAMA Neurology*, 71(9), 1143-1149, 2014. PMID: PMC4266395
 307. Yu Y, Su F-C, Callaghan BC, Goutman SA, Batterman SA, **Feldman EL**. Environmental risk factors and amyotrophic lateral sclerosis (ALS): a case-control study of ALS in Michigan. *PLOS ONE*, Jun. 30;9(6):e101186. Doi: 10.1371/journal.pone.0101186. eCollection 2014. PMID: PMC4076303
 308. Biessels GJ, Bril V, Calcutt NA, Cameron NE, Cotter MA, Dobrowsky R, **Feldman EL**, Fernyhough P, Jakobsen J, Malik RA, Mizisin AP, Oates PJ, Obrosova IG, Pop-Busui R, Russell JW, Sima AA, Stevens MJ, Schmidt RE, Tesfaye S, Veves A, Vinik AI, Wright DE, Yagihashi S, Yorek MA, Ziegler D, Zochodne DW. Phenotyping animal models of diabetic neuropathy: a consensus statement of the diabetic neuropathy study group of the EASD (Neurodiab). *Journal of the Peripheral Nervous System*, 19(2), 77-87, 2014. PMID: PMC4303044

309. Kim B, Srinivasan A, Sabb B, **Feldman EL**, Pop-Busui R. Diffusion tensor imaging of the sural nerve in normal controls. *Clinical Imaging*, 38, 648-654, 2014. Not funded by NIH.
310. Callaghan BC, Burke JF, **Feldman EL**. How neurologists can choose (even more) wisely: prioritizing waste reduction targets and identifying gaps in knowledge. *JAMA*, 311, 1607-1608, 2014. PMID: PMC4159669
311. Foerster BR, **Feldman EL**. A brighter future for ALS through imaging? *JAMA Neurology*, 71, 539-540, 2014. Not funded by NIH.
312. Lunn JS, Sakowski SA, **Feldman EL**. Concise review: Stem cell therapies for amyotrophic lateral sclerosis: recent advances and prospects for the future. *Stem Cells*, 32, 1099-1109, 2014. PMID: PMC4225704
313. O'Brien PD, Hinder LM, Sakowski SA, **Feldman EL**. ER stress in diabetic peripheral neuropathy: a new therapeutic target. *Antioxidant and Redox Signaling*, 21, 621-633, 2014. Not funded by NIH.
314. Hinder LM, Figueroa-Romero C, Pacut C, Hong Y, Vivekanandan-Giri A, Pennathur S, **Feldman EL**. Long-chain acyl coenzyme A synthetase 1 overexpression in primary cultured Schwann cells prevents long chain fatty acid-induced oxidative stress and mitochondrial dysfunction. *Antioxidants and Redox Signaling*, 21, 588-600, 2014. PMID: PMC4086511
315. Ramchandren S, Jaiswal M, **Feldman E**, Shy M. Effect of pain in pediatric inherited neuropathies. *Neurology*, 82, 793-797, 2014. PMID: PMC3945655
316. Hamid HS, Mervak CM, Munch AE, Robell NJ, Hayes JM, Porzio MT, Singleton JR, Smith AG, **Feldman EL**, Lentz SI. Hyperglycemia- and neuropathy-induced changes in mitochondria within sensory nerves. *Annals of Clinical and Translational Neurology*, 1(10), 799-812, 2014. PMID: PMC4241807
317. Calabek B, Callaghan B, **Feldman E**. Therapy for diabetic neuropathy. *Handbook of Clinical Neurology*, 126, 317-333, 2014. Not funded by NIH.
318. Callaghan BC, **Feldman EL**. Painful diabetic neuropathy: many similarly effective therapies with widely dissimilar costs. *Annals of Internal Medicine*, 161(9), 674-675, 2014.
319. Little NE, **Feldman EL**. Therapeutic hypothermia and targeted temperature management after cardiac arrest-reply. *JAMA Neurology*, 71(12), 1578, 2014. Not NIH funded.
320. Filla LA, Yuan W, **Feldman EL**, Li S, Edwards JL. Global metabolomic and isobaric tagging capillary liquid chromatography-tandem mass spectrometry approaches for

- uncovering pathway dysfunction in diabetic mouse aorta. *Journal of Proteome Research*, 13(12), 6121-6134, 2014. PMID: PMC4261973
321. Tadesse AT, Gearing M, Saxe DF, Bray RA, Gebel H, Hill CE, Boulis N, Riley J, **Feldman E**, Johe K, Hazel T, Polak M, Bordeau J, Buchman T, Glass JD. Analysis of graft survival in a trial of stem cell transplant in ALS. *Annals of Clinical and Translational Neurology*, 1(11), 900-908, 2014. PMID: PMC4265061
322. O'Brien PD, Hur JH, Hayes JM, Backus C, Sakowski SA, **Feldman EL**. BTBR ob/ob mice as a novel diabetic neuropathy model: neurological characterization and gene expression analyses. *Neurobiology of Disease*, 73, 348-355, 2014. PMID: PMC4416075
323. Kim B, **Feldman EL**. Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome. *Experimental and Molecular Medicine*, 47, e149, 2015. PMID: PMC4351418
324. Murdock BJ, Bender DE, Segal BM, **Feldman EL**. The dual roles of immunity in ALS: Injury overrides protection. *Neurobiology of Disease*, 77:1-12, 2015. Not funded by NIH.
325. Gallagher K, Joshi A, Carson W, Schaller M, Allen R, Mukergee S, Kittan N, **Feldman E**, Henke P, Cory H, Burant C, Kunkel S. Epigenetic changes in bone marrow progenitor cells influence the inflammatory phenotype and alter wound healing in type 2 diabetes. *Diabetes*, 64, 1420-1430, 2015. PMID: PMC4375075
326. Kashlan ON, Kashlan BN, Oh SS, McGinley LM, Chen KS, Kupfer R, Erman A, Sakowski SA, **Feldman EL**. Histologic bulbar manifestations in the ALS rat. *Neurodegenerative Diseases*, 15, 121-126, 2015. Not funded by NIH.
327. Lunn JS, Sakowski SA, McGinley LM, Pacut C, Hazel TG, Johe K, **Feldman EL**. Autocrine production of IGF-I increases stem cell-mediated neuroprotection. *Stem Cells*, 33, 1480-1489, 2015. Not funded by NIH.
328. Sarma AV, Hotaling J, Dunn RL, Cleary PA, Braffett BH, Kim C, Martin C, Herman W, Gatcomb P, Jacobson AM, Holt SK, Wessells H, DCCT/EDIC Research Group. Poor glycemic control is associated with reduced prostate specific antigen concentrations in men with type 1 diabetes. *Journal of Urology*, 193, 786-793, 2015. PMID: PMC4363040
329. Ben-Shushan E, **Feldman E**, Reubinoff BE. Notch signaling regulates motor neuron differentiation of human embryonic stem cells. *Stem Cells*, 33, 403-415, 2015. Not funded by NIH.
330. Ramchandren S, Shy M, **Feldman E**, Hillery M. Defining disability: development and validation of a mobility-Disability Severity Index (mDSI) in Charcot-Marie-tooth

- disease. *Journal of Neurology, Neurosurgery and Psychiatry*, 86, 635-639, 2015. PMID: PMC4920058
331. Goutman SA, Chen KS, **Feldman EL**. Recent advances and the future of stem cell therapies in amyotrophic lateral sclerosis. *Neurotherapeutics*, 12, 428-448, 2015. PMID: PMC4404436
 332. Sakowski SA, **Feldman EL**. The spectrum of motor neuron diseases: from childhood spinal muscular atrophy to adult amyotrophic lateral sclerosis. *Neurotherapeutics*, 12, 287-289, 2015. PMID: PMC4404463
 333. Callaghan B, Kerber K, Langa KM, Banerjee M, Rodgers A, McCammon R, Burke J, **Feldman E**. Longitudinal patient-oriented outcomes in neuropathy: importance of early detection and falls. *Neurology*, 85, 71-79, 2015. PMID: PMC4501944
 334. Kim B, Figueroa-Romero C, Pacut C, Backus C, **Feldman EL**. Insulin resistance prevents AMPK-induced tau dephosphorylation through Akt-mediated increase in AMPKSer-485 phosphorylation. *Journal of Biological Chemistry*, 290, 19146-19157, 2015. PMID: PMC4521037
 335. Paez-Colasante X, Figueroa-Romero C, Sakowski SA, Goutman SA, **Feldman EL**. Amyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era. *Nature Reviews Neurology*, 11, 266-279, 2015.
 336. DCCT/EDIC Research Group, Aiello LP, Sun W, Das A, Gangaputra S, Kiss S, Klein R, Cleary PA, Lachin JM, Nathan DM. Intensive diabetes therapy and ocular surgery in type 1 diabetes. *New England Journal of Medicine*, 372, 1722-1733, 2015. PMID: PMC4465212
 337. Hur J, Dauch JR, Hinder LM, Hayes JM, Backus C, Pennathur S, Kretzler M, Brosius FC 3rd, **Feldman EL**. The metabolic syndrome and microvascular complications in a murine model of type 2 diabetes. *Diabetes*, 64, 3294-3304, 2015. PMID: PMC4542440
 338. Callaghan BC, Price RS, **Feldman EL**. Distal symmetric polyneuropathy: a review. *JAMA*, 314, 2172-2181, 2015. PMID: PMC5125083.
 339. Goutman SA, **Feldman EL**. Clinical trials of therapies for amyotrophic lateral sclerosis: one size does not fit all. *JAMA Neurology*, 72, 743-744, 2015. PMID: PMC4681497.
 340. Callaghan BC, Price RS, Chen KS, **Feldman EL**. The importance of rare subtypes in diagnosis and treatment of peripheral neuropathy: a review. *JAMA Neurology*, 72, 1510-1518, 2015. PMID: PMC5087804.
 341. Jaiswal M, Martin CL, Brown MB, Callaghan B, Albers JW, **Feldman EL**, Pop-Busui R. Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes:

- results from an 18-month proof-of-concept open label randomized study. *Diabetes and Its Complications*, 29, 1287-1294, 2015. PMID: PMC4656068
342. Eny KM, Orchard TJ, Miller RG, Maynard J, Grant DM, Costacou T, Cleary PA, Braffett BH, Paterson AD, DCCT/EDIC Research Group. Caffeine consumption contributes to skin intrinsic fluorescence in type 1 diabetes. *Diabetes Technology and Therapeutics*, 17, 726-734, 2015. PMID: PMC5475521
343. Sims-Robinson C, Bakeman A, Rosko A, Glasser R, **Feldman EL**. The role of oxidized cholesterol in diabetes-induced lysosomal dysfunction in the brain. *Molecular Neurobiology*, DOI 10.1007/s12035-015-9207-1, 2015. PMID: PMC4644712.
344. **Feldman E**, Hughes R, Willison H. Progress in inflammatory neuropathy-the legacy of Dr. Jack Griffin. *Nature Reviews Neurology*, 11, 646-650, 2015. Not funded by NIH.
345. Wheelock KM, Jaiswal M, Martin CL, Weil EJ, Lemley KV, Yee B, **Feldman EL**, Brosius FC, Knowler WC, Nelson RG, Pop-Busui R. Cardiovascular autonomic neuropathy associates with neuropathy lesions in American Indians with type 2 diabetes. *Journal of Diabetes and Its Complications*, 30(5):873-9, 2016. PMID: PMC4912901
346. Callaghan BC, Kerber KA, Banerjee M, **Feldman EL**, Morgenstern LB, Longoria R, Rodgers A, Longwell P, Lisabeth LD. The evaluation of distal symmetric polyneuropathy: utilisation and expenditures by community neurologists. *Journal of Neurology, Neurosurgery and Psychiatry*, 87(1), 113-114, 2016
347. O'Brien PD, Hur J, Robell NJ, Hayes JM, Sakowski SA, **Feldman EL**. Gender-specific differences in diabetic neuropathy in BTBR ob/ob mice. *Journal of Diabetes and Its Complications*, 30, 30-37, 2016. PMID: PMC4698064
348. Pop-Busui R, Ang L, Holmes C, Gallagher K, **Feldman EL**. Inflammation as a therapeutic target for diabetic neuropathies. *Current Diabetes Reports*, 16(3), 1-10, 2016. PMID: PMC5127166.
349. Figueroa-Romero C, Hur J, Lunn JS, Paez-Colasante X, Bender DE, Yung R, Sakowski SA, **Feldman EL**. Expression of microRNAs in amyotrophic lateral sclerosis provides insight into disease mechanisms. *Molecular and Cellular Neuroscience*, 71, 34-45, 2016. PMID: PMC4761498
350. Callaghan BC, Burke JF, **Feldman EL**. Electrodiagnostic tests in polyneuropathy and radiculopathy. *JAMA*, 315(3), 297-298, 2016. PMID: PMC5087909.
351. Sims-Robinson C, Bakeman A, Glasser R, Boggs J, Pacut C, **Feldman EL**. The role of endoplasmic reticulum stress in hippocampal insulin resistance. *Experimental Neurology*, 277, 261-267, 2016. PMID: PMC4802497

352. Jacobson RD, **Feldman EL**. Antisense oligonucleotides for Duchenne Muscular Dystrophy: why no neurologist should skip this. *JAMA Neurology*, 73(3), 259-260, 2016. Not funded by NIH.
353. McGinley LM, Sims E, Lunn JS, Kashlan ON, Chen KS, Bruno ES, Pacut CM, Hazel T, Johe K, Sakowski SA, **Feldman EL**. Human cortical neural stem cells expressing insulin-like growth factor-I: a novel cellular therapy for Alzheimer's disease. *Stem Cells Translational Medicine*, 5(3), 379-391, 2016. PMID: PMC4807660.
354. Stables CL, Auerbach DS, Whitesall SE, D'Alecy LG, **Feldman EL**. Differential impact of type-1 and type-2 diabetes on control of heart rate in mice. *Autonomic Neuroscience*, 194, 17-25, 2016. PMID: PMC4724221
355. Chen KS, Sakowski SA, **Feldman EL**. Intraspinal stem cell transplantation for amyotrophic lateral sclerosis. *Annals of Neurology*, 79(3), 342-353, 2016. PMID: PMC4789073
356. Callaghan BC, Xia R, Banerjee M, de Rekeneire N, Harris TB, Newman AB, Satterfield S, Schwartz AV, Vinik AI, **Feldman EL**, Strotmeyer ES, Health ABC Study. Metabolic syndrome components are associated with symptomatic polyneuropathy independent of glycemic status. *Diabetes Care*, 39, 801-807, 2016. PMID: PMC4839175
357. Jaiswal M, Fufaa GD, Martin CL, Pop-Busui R, Nelson RG, **Feldman E**. Burden of diabetic peripheral neuropathy in Pima Indians with type 2 diabetes. *Diabetologia*, 39, e63-e64, 2016. PMID: PMC4806773
358. Hur J, O'Brien PD, Nair V, Hinder LM, McGregor BA, Jagadish HV, Kretzler M, Brosius III FC, **Feldman EL**. Transcriptional networks of murine diabetic peripheral neuropathy and nephropathy: common and distinct gene expression patterns. *Diabetologia*, 59, 1297-1306, 2016. PMID: PMC4862920
359. Lenherr SM, Clemens JQ, Braffett BH, Cleary PA, Dunn RL, Hotaling JM, Jacobson AM, Kim C, Herman W, Brown JS, Wessells H, Sarma AV; DCCT/EDIC Research Group. Glycemic control and urinary tract infections in women with type 1 diabetes: Results from the DCCT/EDIC. *J. Urol.*, 196(4), 1129-35, 2016. PMID: PMC5025347
360. Su F-C, Goutman SA, Chernyak S, Mukherjee B, Callaghan BC, Batterman S, **Feldman EL**. Association of environmental toxins with Amyotrophic Lateral Sclerosis. *JAMA Neurology*, 73(7), 803-11, 2016. PMID: PMC5032145
361. Chen Z, Miao F, Paterson AD, Lachin JM, Zhang L, Schones DE, Wu X, Wang J, Tompkins JD, Genuth S, Braffett BH, Riggs AD; DCCT/EDIC Research Group, Natarajan R. Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort. *Proc. Natl. Acad. Sci. USA*, 113(21), E3002-11, 2016. PMID: PMC4890596

362. Callaghan BC, Price RS, **Feldman EL**. Leprosy as a cause of distal symmetric polyneuropathy. *JAMA*, 315(19), 2123-4, 2016.
363. He F, Jones JM, Figueroa-Romero C, Zhang D, **Feldman EL**, Goutman SA, Meisler MH, Callaghan BC, Todd PK. Screening for novel hexanucleotide repeat expansions at ALS- and FTD-associated loci. *Neurol Genet.*, 2(3), e71, 2016. PMID: PMC4865132
364. Murdock BJ, Bender DE, Kashlan SR, Figueroa-Romero C, Backus C, Callaghan BC, Goutman SA, **Feldman EL**. Increased ratio of circulating neutrophils to monocytes in amyotrophic lateral sclerosis. *Neurology: Neuroimmunology & Neuroinflammation*, 3(4), e242, 2016. PMID: PMC4897983
365. Glass JD, Hertzberg VS, Boulis NM, Riley JP, Polak M, Bordeau J, Fournier CN, Johe K, Hazel T, Cudkowicz M, Atassi N, Borges LF, Rutkove S, Duell J, Patil PG, Goutman SA, **Feldman EL**. Transplantation of spinal cord-derived neural stem cells for ALS: analysis of phase 1 and phase 2 trials. *Neurology*, 87(4), 392-400, 2016. PMID: PMC4977116
366. Sabha N, Volpatti JR, Gonorazky H, Reifler A, Davidson AE, Li X, Eltayeb NM, Dall'Armi C, Di Paolo G, Brooks SV, Buj-Bello A, **Feldman EL**, Dowling JJ. PIK3C2B inhibition improves function and prolongs survival in myotubular myopathy animal models. *J Clin Invest.*, 126(9), 3613-25, 2016. PMID: PMC5004942
367. Sims-Robinson C, Bakeman A, Bruno E, Jackson S, Glasser R, Murphy GG, **Feldman EL**. Dietary reversal ameliorates short- and long-term memory deficits induced by high-fat diet early in life. *PLoS One*, 11(9), e0163883, 2016. PMID: PMC5038939.
368. Sas KM, Kayampilly P, Byun J, Nair V, Hinder LM, Hur J, Zhang H, Lin C, Qi NR, Michailidis G, Groop PH, Nelson RG, Darshi M, Sharma K, Schelling JR, Sedor JR, Pop-Busui R, Weinberg JM, Soleimanpour SA, Abcouwer SF, Gardner TW, Burant CF, **Feldman EL**, Kretzler M, Brosius FC, Pennathur A. Tissue-specific metabolic reprogramming drives nutrient flux in diabetic complications. *JCI Insight*, 1(15), e86976, 2016. PMID: PMC5033761
369. Goutman SA, Hamilton JD, Swihart B, Foerster B, **Feldman EL**, Rubin JM. Speckle tracking as a method to measure hemidiaphragm excursion. *Muscle Nerve*, 55(1), 125-127, 2016.[Epub ahead of print]
370. Atassi N, Beghi E, Blanquer M, Boulis NM, Cantello R, Caponnetto C, Chio A, Dunnett SB, **Feldman EL**, Vescovi A, Mazzini L; attendees of the International Workshop on Progress in Stem Cells Research for ALS/MND. Intraspinal stem cell transplantation for amyotrophic lateral sclerosis: Ready for efficacy clinical trials? *Cytherapy*, 18(12), 1471-1475, 2016. [Epub ahead of print]

371. Callaghan BC, Xia R, Reynolds E, Banerjee M, Rothberg AE, Burant CF, Villegas-Umana E, Pop-Busui R, **Feldman EL**. Association Between Metabolic Syndrome Components and Polyneuropathy in an Obese Population. *JAMA Neurology* 73(12), 1468-1476, 2016. PMID: PMC5217829
372. Sims-Robinson C, Bakerman A, Rosko A, Glasser R, **Feldman EL**. The Role of Oxidized Cholesterol in Diabetes-Induced Lysosomal Dysfunction in the Brain. *Molecular Neurobiology* 53(4):2287-96, 2016. PMID: PMC4644712.
373. Grisold A, Callaghan BC, **Feldman EL**. Mediators of diabetic neuropathy: is hyperglycemia the only culprit? *Curr Opin Endocrinol Diabetes Obes* 10.1097, 2017. PMID: PMC5831542
374. Pop-Busui R, Boulton AJ, **Feldman EL**, Bril V, Freeman R, Malik RA, Sosenko JM, Ziegler D. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. *Diabetes Care*, 40(1), 136-154, 2017.
375. Hinder LM, Park M, Rumora AE, Hur J, Eichinger F, Pennathur S, Kretzler M, Brosius FC 3rd, **Feldman EL**. Comparative RNA-Seq transcriptome analyses reveal distinct metabolic pathways in diabetic nerve and kidney disease. *JCell Mol Med*, 20; 1-13, 2017. PMID: PMC5571536.
376. **Feldman EL**, Nave KA, Jensen TS, Bennett DL. New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain. *Neuron*, 93(6); 1296-1313, 2017, PMID: PMC5400015.
377. O'Brien PD, Hinder LM, Parlee SD, Hayes JM, Backus C, Zhang H, Ma L, Sakowski SA, Brosius FC 3rd, **Feldman EL**. Dual CCR2/CCR5 antagonist treatment attenuates adipose inflammation, but not microvascular complications in ob/ob mice. *Diabetes, Obesity and Metabolism*. 10.1111/dom. 12950, 2017. PMID: PMC5610585.
378. Harte SE, Clauw DJ, Hayes JM, **Feldman EL**, St Charles IC, Watson CJ. Reduced intradermal nerve fiber density following a sustained increase in insular glutamate: a proof of concept study examining the pathogenesis of small fiber pathology in fibromyalgia. *Pain Reports*, D-16-0044R1, 2017. PMID: PMC5741296
379. Hinder LM, O'Brien PD, Hayes JM, Backus C, Solway AP, Sims-Robinson C, **Feldman EL**. Dietary reversal of neuropathy in a murine model of prediabetes and the metabolic syndrome. *Disease Models & Mechanisms*, 10(6):717-725, 2017. PMID: PMC5483005.
380. Callaghan BC, Burke JF, Kerber KA, Albers JW, **Feldman EL**, Electrodiagnostic tests are unlikely to change management in those with a known cause of typical distal symmetric polyneuropathy. *Muscle Nerve*, doi: 10.1002, 2017. PMID: PMC5561003.

381. O'Brien PD, Hinder LM, Callaghan BC, **Feldman EL**, Neurological consequences of obesity. *Lancet Neurol*, 16(6):465-577. 2017. PMID: PMC5647398.
382. Flak JN, Arble D, Pan W, Patterson C, Lanigan T, Goforth PB, Sacksner J, Joosten M, Morgan DA, Allison MB, Hayes J, **Feldman EL**, Seeley RJ, Olson DP, Rahmouni K, Myers Jr MG. A Leptin-regulated Circuit Controls Glucose Mobilization During Noxious Stimuli. *Journal of Clinical Investigation*, 127(8): 3103-3113, 2017. PMID: PMC5531403.
383. Jaiswal M, Divers J, Davelea D, Isom S, Bell RA, Martin CL, Pettitt DJ, Saydah S, Pihoker C, Standiford DA, Doan LM, Marcovina S, Linder B, Liese AD, Pop-Busui R, **Feldman EL**. Prevalence of and Risk Factors for Diabetic Peripheral Neuropathy in Youth With Type 1 and Type 2 Diabetes: SEARCH for Diabetes in Youth Study. *Diabetes Care*, 40(9): 1226-1232, 2017. PMID: PMC5566278.
384. DCCT/EDIC Research Group, Nathan DM, Bebu I, Hainsworth D, Klein R, Tamborlane W, Lorenzi G, Gubitosi-Klug R, Lachin JM. Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes. *The New England Journal of Medicine*, 376(16): 1507-1516, 2017. PMID: PMC5557280.
385. Hamid HS, Hayes JM, **Feldman EL**, Lentz SI. Three-dimensional Imaging and Analysis of Mitochondria within Human Intraepidermal Nerve Fibers. *JoVE*, doi: 10.3791-53369, 2017. PMID: PMC5752341
386. Murdock BJ, Zhou T, Kashlan SR, Little RJ, Goutman SA, **Feldman EL**. Correlation of Peripheral Immunity With Rapid Amyotrophic Lateral Sclerosis Progression. *JAMA Neurology*, 1;74(12):1446-1454, 2017, PMID: PMC5822195
387. Callaghan BC, O'Brien PD, Hinder LM, **Feldman EL**. Obesity and the Nervous System: More Questions – Authors' reply. *The Lancet Neurology*, 16(10):774, 2017.
388. Rumora AE, Lentz SI, Hinder LM, Jackson SW, Valesano A, Levinson GE, **Feldman EL**. Dyslipidemia impairs mitochondrial trafficking and function in sensory neurons. *FASEB Journal*, 32(1):195-207, 2018, PMID: PMC6191072
389. McGinley LM, Kashlan ON, Chen KS, Bruno ES, Hayes JM, Backus C, Feldman S, Kashlan BN, Johe K, **Feldman EL**. Human neural stem cell transplantation into the corpus callosum of Alzheimer's mice. *Annals of Clinical and Translational Neurology*, 4(10), 749-755, 2017. PMID: PMC5634341
390. Meurer WJ, Ward K, **Feldman EL**, Emergency Department Stroke Care, *JAMA Neurology*, 1;75(2): 257-258, 2017, [Epub ahead of print]

391. Rosko AJ, Kupfer RA, Oh SS, Haring CT, **Feldman EL**, Hogikyan ND. Immunohistologic analysis of spontaneous recurrent laryngeal nerve reinnervation in a rat model, *Laryngoscope*, 128(3):E117-E122, 2017, [Epub ahead of print]
392. Jaiswal M, Divers J, Urbina EM, Dabelea D, Bell RA, Pettitt DJ, Imperatore G, Pihoker C, Dolan LM, Liese AD, Marcovina S, Linder B, **Feldman EL**, Pop-Busui R; SEARCH for Diabetes in Youth Study Group. Cardiovascular autonomic neuropathy in adolescents and young adults with type 1 and type 2 diabetes: The SEARCH for Diabetes in Youth Cohort Study. *Pediatric Diabetes*, doi. 10.1111/pedi.12633, 2018. PMID: PMC5938122
393. Callaghan BC, Xia R, Reynolds E, Banerjee M, Burant C, Rothberg A, Pop-Busui R, Villegas-Umana E, **Feldman EL**. Better diagnostic accuracy of neuropathy in obesity: A new challenge for neurologists. *Clinical Neurophysiology*, 129(3):654-662, 2018, PMID: PMC5808853
394. Hinder LM, Murdock BJ, Park M, Bender DE, O'Brien PD, Rumora AE, Hur J, **Feldman EL**. Transcriptional Networks of Progressive diabetic peripheral neuropathy in the db/db mouse model of type 2 diabetes: An inflammatory story. *Experimental Neurology*, doi: 10.1016. PMID: PMC5955815
395. Andersen ST, Witte DR, Dalsgaard EM, Andersen H, Nawroth P, Fleming T, Jensen TM, Finnerup NB, Jensen TS, Lauritzen T, **Feldman EL**, Callaghan BC, Charles M, Risk Factors for Incident Diabetic Polyneuropathy in a Cohort With Screen-Detected Type 2 Diabetes Followed for 13 Years: Addition-Denmark, *Diabetes Care*, dc 172062, doi: 10.2337/dc17-2062, PMID: PMC5955815
396. Goutman SA, Chen KS, Paez-Colasante X, **Feldman EL**, Emerging understanding of the genotype-phenotype relationship in atrophic lateral sclerosis, *Handbook of Clinical Neurology*, 148:603-623, [Epub ahead of print]
397. Jaiswal M, Divers J, Pop-Busui R, **Feldman EL**. Response to Comment on Jaiswal et al. Prevalence of and Risk Factors for Diabetic Peripheral Neuropathy in Youth With Type 1 and Type 2 Diabetes: SEARCH for Diabetes in Youth Study, 41(3):e37, 2018, PMID: PMC5829960
398. Callaghan BC, **Feldman EL**. Measuring neuropathy in obese populations: Challenge accepted. Reply to “Diagnostic accuracy of neuropathy tests in obese population remains elusive”. *Clin Neurophysiology*, 1388-2457(18)30655-2, 2018. [Epub ahead of print].
399. Callaghan BC, Gao L, Li Y, Zhou X, Reynolds E, Banerjee M, Pop-Busui R, **Feldman EL**, Ji L. Diabetes and obesity are the main metabolic drivers of peripheral neuropathy. *Ann Clin Transl Neurol*, 14;5(4):397-405. PMID: PMC5899909
400. Nicholas A, Kenna KP, Renton AE... **Feldman EL**, Genome-wide Analyses Identify KIF5A as a Novel ALS Gene, *Neuron*, 97(6):1268-1283, 2018. PMID: PMC5867896

401. Tank EM, Figueroa-Romero C, Hinder LM, Bedi K, Archbold HC, Li X, Weskamp K, Safren N, Paez-Colasante X, Pacut C, Thumma S, Paulsen MT, Guo K, Hur J, Ljungman M, **Feldman EL**, Barmada SJ. Abnormal RNA Stability in Amyotrophic Lateral Sclerosis, *Nat Commun*, 9(1):2845, 2018. PMID: PMC6054632
402. Malik AM, Miguez RA, Li X, Ho YS, **Feldman EL**, Barmada SJ. Matrin 3-dependent Neurotoxicity is Modified by Nucleic Acid Binding and Nucleocytoplasmic Localization, *Elife*, doi: 10.7554/eLife.35977, 2018. PMID: PMC6050042
403. Goutman SA, Brown MB, Glass JD, Boulis NM, Johe K, Hazel T, Cudkowicz M, Atassi N, Borges L, Patil PG, Sakowski SA, **Feldman EL**. Long-term Phase ½ intraspinal Stem Cell Transplantation Outcomes in ALS, *Ann Clin Transl Neurol*, 2;5(6):730-740, 2018. PMID: PMC5989736
404. McGinley LM, Kashlan ON, Burno ES, Chen KS, Hayes JM, Kashlan SR, Raykin J, Johe K, Murphy GG, **Feldman EL**. Human Neural Stem Cell transplantation Improves Cognition in a Murine Model of Alzheimer’s Disease. *Sci Rep*,8(1);14776, 2018; PMID: PMC6170460
405. Callaghan BC, **Feldman EL**. Reply to Diagnosing Neuropathy in an Obese Patient: Measuring neuropathy in obese populations: Nerve conduction studies, *Clin Neurophysiol*, 129(9);2050, 2018 [Epub ahead of print].
406. Rumora AE, LoGrasso G, Haidar JA, Dolkowski JJ, Lentz SI, **Feldman EL**. Chain Length of Saturated Fatty Acids Regulates Mitochondrial Trafficking and Function in Sensory Neurons, *J Lipid Res*, 60(1):58-70, 2018. PMID: PMC6314260
407. O’Brien PD, Hinder LM, Rumora AE, Hayes JM, Dauch JR, Backus C, Mendelson FE, **Feldman EL**. Juvenile Murine Models of Prediabetes and Type 2 Diabetes Develop Neuropathy, *Dis Model Mech*, doi: 10.1242/dmm.037374, 2018, PMID: PMC6307897
408. McGregor BA, Eid S, Rumora AE, Murdock B, Guo K, deAnda-Jauregui G, Porter JE, **Feldman EL**, Hur J. Conserved Transcriptional Signatures in Human and Murine Diabetic Peripheral Neuropathy, *Sci Rep*, Doi: 10.1038/s41598-018-36098-5, 2018. PMID: PMC6281650
409. Hinder LM, Sas KM, O’Brien PD, Backus C, Kayampilly P, Hayes KM, Lin C, Zhang H, Shanmugam S, Abcouwer SF, Brosius FC III, Pennathur S, **Feldman EL**. Mitochondrial uncoupling is ineffective in preventing microvascular complications in type 2 diabetes. *Scientific Reports*. 29;9(1):881, 2019. PMID: PMC6351661
410. de Anda-Jauregui G, Guo K, McGregor B, **Feldman EL**, Hur J. Pathway crosstalk perturbation network modeling for identification of connectivity changes induced by

diabetic neuropathy and pioglitazone. *BMC Systems Biology*, 13(1):1, 2019, PMID: PMC6322225

411. Goutman SA, Boss J, Patterson A, Mukherjee B, Batterman S, **Feldman EL**. High plasma concentrations of organic pollutants negatively impact survival in amyotrophic lateral sclerosis. *J Neurol neurosurg Psychiatry*. Koi: 10.1136/jnnp-2018-319785, 2019. [Epub ahead of print]
412. Chen KS, McGinley LM, Kashlan ON, Bruno ES, Chang JS, Mendelson FE, Tabbey MA, Johe K, Sakowski SA, **Feldman EL**. Targeted intraspinal injections to assess therapies in rodent models of neurological disorders. *Nat Protoc*, 14(2):331-349, 2019. [Epub ahead of print]
413. Van den Berg LH, Sorenson E, Gronseth G, Macklin EA, Andrews J, Baloh RH, Benatar M, Berry JD, Chio A, Corcia P, Genge A, Gubituz, AK, Lomen-Hoerth C, McDermott CJ, Piro EP, Rosenfeld J, Silani V, Turner MR, Weber M, Brooks BR, Miller RG, Mitsumoto H, Airlie House ALS Clinical Trials Guidelines Group. Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials, *Neurology*, 10.1212/WNL, 2019. [Epub ahead of print]
414. Rumora AE, LoGrasso G, Hayes JM, Mendelson FE, Tabbey MA, Haidar JA, Lentz SI, **Feldman EL**. The divergent roles of dietary saturated and monounsaturated fatty acids on nerve function in murine models of obesity. *J Neurosci*, pii: 3173-18, doi:10.1523, 2019, [Epub ahead of print].
415. De Anda-Jauregui G, Guo K, McGregor BA, **Feldman EL**, Hur J. Correction to: Pathway crosstalk perturbation network modeling for identification of connectivity changes induced by diabetic neuropathy and pioglitazone. *BMC Syst Biol*, 13;13(1):31, 2019. PMID: PMC6416955.

Book Chapters

1. Agranoff BW, Axelrod D, **Feldman EL**, Heacock AM, Schwartz M: Biochemical properties and concomitants of neurite outgrowth in regeneration. 7th Meeting of the International Society for Neurochemistry, 1979.
2. Stevens MJ, **Feldman EL**, Funnell MM, Sima AAF, Greene DA. Optimal methods for detecting early neuropathy and its progression. In: *Diabetes Forum IV. Concepts for the Ideal Diabetes Clinic*, Walter de Gruyter, NY, CE Mogensen and E Standl, eds., pp. 315-332, 1993.
3. Greene DA, **Feldman EL**, Stevens MJ. Neuropathy in the diabetic foot: New concepts in etiology and treatment. In: *The Diabetic Foot*, Fifth Edition, C.V. Mosby Co., M. Levin and L. O'Neal, eds., pp. 135-148, 1993.

4. Sima AAF, Stevens MJ, **Feldman EL**, Cherian PV, Greene DA: Animal models as tools for the testing of preventive and therapeutic measures in diabetic neuropathy. In: *Lessons from Animal Diabetes*, IV, Smith Gordon, publisher, E. Shafrir, ed., pp. 177-191, 1993.
5. **Feldman EL**, Simmons Z. Chronic inflammatory demyelinating polyradiculoneuropathy. In: *Current Therapy in Neurologic Disease*, Fourth Edition, C.V. Mosby, Philadelphia, PA, Richard Johnson, ed., pp. 349-353, 1993.
6. Martin DM and **Feldman EL**. Reversibility of serum removal effects on IGF-II mRNA in human neuroblastoma cells. In: *The Role of Insulin-Like Growth Factors in the Nervous System*, Annals of the New York Academy of Sciences, The New York Academy of Sciences, New York, NY, M.K. Raizada and D. LeRoith, eds., pp. 259-261, 1993.
7. **Feldman EL**, Randolph A, Yee D. Insulin-like growth factor binding protein expression in SH-SY5Y neuroblastoma cells. In: *The Role of Insulin-Like Growth Factors in the Nervous System*, Annals of the New York Academy of Sciences, The New York Academy of Sciences, New York, NY, M.K. Raizada and D. LeRoith, eds., pp. 262-264, 1993.
8. Randolph A, Yee D and **Feldman EL**. Insulin-like growth factor binding protein expression in human retinal pigment epithelial cells. In: *The Role of Insulin-Like Growth Factors in the Nervous System*, Annals of the New York Academy of Sciences, The New York Academy of Sciences, New York, NY, M.K. Raizada and D. LeRoith, eds., pp. 265-267, 1993.
9. **Feldman EL**, Stevens MJ, Greene DA. Treatment of diabetic neuropathy. In: *Advances in Endocrinology and Metabolism*, Mazzaferri EL, Bar RS and Kreisberg RA, eds., 5:393-428, 1994.
10. Gandhi D, Matthews CC, **Feldman EL**. IGF-I rescues neurons from hyperglycemic, hyperosmotic injury. In: *Excerpta Medica International Congress Series 1084*, Diabetic Neuropathy: New Concepts and Insights, Elsevier Science B.V., pp. 183-189, 1995.
11. Stevens MJ, Lattimer SA, **Feldman EL**, Sima AAF, Greene DA. Potential effects of acetyl-L-carnitine on sciatic nerve function in the streptozotocin diabetic rat. In: *Diabetic Neuropathy: New Concepts and Insights*, Hotta N, Greene DA, Ward JD, Sima AAF and Boulton AJM, eds., pp. 243-248, 1995.
12. **Feldman EL**, Del Monte MA, Stevens MJ, Greene DA. Establishment and maintenance of *in vitro* cultures of human retinal pigment epithelium. In: *Methods in Molecular Medicine, Human Cell Culture Protocols*, Jones GE, ed., pp. 517-524, 1996.
13. Wald JJ, **Feldman EL**. Diabetic neuropathy. In: *Neurobase*, Gilman S, Goldstein G, Waxman S, eds., Arbor Publishing, La Jolla, CA, 1996.

14. **Feldman EL**, Greene DA, Stevens MJ. Diabetic neuropathy. In: *UpToDate*TM (CD-ROM), Rose BD, ed., vol. 4(3), 1996.
15. Greene DA, Stevens MJ, **Feldman EL**. The sorbitol-osmotic and sorbitol-redox hypothesis. In: *Diabetes Mellitus: A Fundamental and Clinical Text*, LeRoith D, Taylor SI, Olefsky JM, eds., Lippincott-Raven, 1996.
16. Greene DA, **Feldman EL**, Stevens MJ, Sima AAF, Albers JW, Pfeifer MA. Diabetic neuropathy. In: *Ellenberg and Rifkin's Diabetes Mellitus, 5th Edition*, Porte Jr D, Sherwin RS, Rifkin H editors, pp. 1009-1076, 1997.
17. Singleton JR, Russell JW, **Feldman EL**. Electrodiagnosis of neuromuscular disease. In: *Adult Neurology*, Corey-Bloom J, ed., pp. 37-53, 1997.
18. Stevens MJ, **Feldman EL**, Greene DA. Diabetic Peripheral Neuropathy. In: *Current Therapy of Diabetes Mellitus*, DeFronzo RA, ed., pp. 160-165, 1997.
19. Sullivan KA, Kim B, Russell JW, **Feldman EL**. IGF-I in neuronal differentiation and neuroprotection. In: *IGFs in the Nervous System*, Muller E, ed., Springer-Verlag Italia Srl, Milan, Italy, pp. 28-46, 1998.
20. Stevens MJ, **Feldman EL**, Thomas T, Greene DA. Pathogenesis of diabetic neuropathy. In: *Clinical Management of Diabetic Neuropathy*, Veves A, ed., Humana Press, pp. 13-48, 1998.
21. **Feldman EL**, Stevens MJ, Greene DA. Clinical management of diabetic neuropathy. In: *Clinical Management of Diabetic Neuropathy*, Veves A, ed., Humana Press, pp. 89-105, 1998.
22. Greene DA, Stevens MJ, **Feldman EL**. Glycemic control. In: *Diabetic Neuropathy*, 2nd edition, Dyck PJ and Thomas PK, eds., W.B. Saunders, pp. 297-315, 1998.
23. **Feldman EL**, Windebank AJ. Growth factors and peripheral neuropathy. In: *Diabetic Neuropathy*, 2nd edition, Dyck PJ and Thomas PK, eds., W.B. Saunders, pp. 377-386, 1998.
24. Leventhal PS, Russell JW, **Feldman EL**. IGFs and the nervous system. In: *Contemporary Endocrinology: The IGF System*, Rosenfeld R and Roberts Jr C, eds., Humana Press, pp. 425-455, 1999.
25. **Feldman EL**, Stevens MJ, Russell JW, Greene DA. Diabetic neuropathy. In: *Current Review of Diabetes*, Taylor S, ed., Current Medicine, Inc., pp. 71-83, 1999.

26. **Feldman EL**, Stevens MJ, Greene DA. Diabetic neuropathy. In: *Diabetes in the New Millennium*, Turtle JR, Kaneko T and Osato S, eds., The Endocrinology and Diabetes Research Foundation of the University of Sydney, pp. 387-402, 1999.
27. **Feldman EL**. Degenerative diseases of the nervous system. In: *Cecil Textbook of Medicine*, Goldman L and Bennett JC, eds., 21st ed., W.B. Saunders, pp. 2087, 1999.
28. **Feldman EL**. Hereditary cerebellar ataxias and related disorders. In: *Cecil Textbook of Medicine*, Goldman L and Bennett JC, eds., 21st ed., W.B. Saunders, pp. 2088-2089, 1999.
29. **Feldman EL**. Hereditary spastic paraplegias. In: *Cecil Textbook of Medicine*, Goldman L and Bennett JC, eds., 21st ed., W.B. Saunders, p. 2089, 1999.
30. **Feldman EL**. Motor neuron diseases. In: *Cecil Textbook of Medicine*, Goldman L and Bennett JC, eds., 21st ed., W.B. Saunders, pp. 2089-2092, 1999.
31. Comi G, Fedele D, Coscelli C, Cucinotta D, **Feldman EL**, Ghirlanda G, Negrin P, Santeusanio F, Maderna L, Italian Diabetic Neuropathy Committee. The Italian multicenter study on the prevalence of distal symmetric polyneuropathy: correlation between clinical variables and nerve conduction parameters. In: *Clinical Neurophysiology: From Receptors to Perception (EEG Suppl. 50)*, Comi G, Lucking CH, Kimura J, Rossini PM, eds., Elsevier Science, pp. 546-552, 1999.
32. Greene DA, Obrosova IG, Stevens MJ, **Feldman EL**. Pathways of glucose-mediated oxidative stress in diabetic neuropathy. In: *Antioxidants in Diabetes Management*, Packer L, Rosen P, Tritschler HJ, King GL, Azzi, A, eds., Marcel Dekker, Inc., pp. 111-119, 2000.
33. Windebank AJ, **Feldman EL**. Diabetes and the nervous system. In: *Neurology and General Medicine*, 3rd edition, Aminoff MJ, ed., Churchill Livingstone, pp. 341-364, 2001.
34. **Feldman EL**, Stevens MJ, Russell JW, Greene DA. Diabetic neuropathy. In: *Principles and Practice of Endocrinology and Metabolism*, 3rd edition, Becker KL, ed., Lippincott Williams & Wilkins, pp. 1391-1399, 2001.
35. Stevens MJ, Obrosova I, Pop-Busui R, Greene DA, **Feldman EL**. Pathogenesis of diabetic neuropathy. In: *Ellenberg and Rifkin's Diabetes Mellitus, 6th Edition*, Porte Jr D, Sherwin RS, Baron A, eds., McGraw Hill, pp. 747-770, 2002.
36. **Feldman EL**, Stevens MJ, Russell JW, Greene DA. Somatosensory neuropathy. In: *Ellenberg and Rifkin's Diabetes Mellitus, 6th Edition*, Porte Jr D, Sherwin RS, Baron A, eds., McGraw Hill, pp. 771-788, 2002.

37. Vinik AI, Erbas T, Pfeifer MA, **Feldman EL**, Stevens MJ, Russell JW. Diabetic autonomic neuropathy. In: *Ellenberg and Rifkin's Diabetes Mellitus, 6th Edition*, Porte Jr D, Sherwin RS, Baron A, eds., McGraw Hill, pp. 789-804, 2002.
38. **Feldman EL**, Stevens MJ, Russell JW. Diabetic peripheral and autonomic neuropathy. In: *Contemporary Endocrinology: Type 1 Diabetes: Etiology and Treatment*, Sperling MA, ed., Humana Press, pp. 437-461, 2002.
39. Simmons Z, **Feldman EL**. Treatment of diabetic neuropathy. In: *The Evidence Base for Diabetes Care*, Williams R, Herman W, Kinmonth A-L, Wareham NJ, eds., John Wiley & Sons, pp. 555-576, 2002.
40. **Feldman EL**, Sullivan KA, Stevens MJ. Polyol pathway: Aldose reductase inhibitors - - Hope for the future? In: *Textbook of Diabetic Neuropathy*, Gries FA, Cameron NE, Low PA, Ziegler D, eds., Georg Thieme Verlag, pp. 112-115, 2003.
41. Song DK, **Feldman EL**. Diabetes Insipidus. In: *The NORD Guide to Rare Disorders*, Lippincott, Williams & Wilkins, Philadelphia, pp. 313-314, 2003.
42. Leininger GM, Meyer GE, **Feldman EL**. IGFs and the Nervous System. In: *Insulin-Like Growth Factors*, LeRoith D, Zumkeller W, Baxter R, eds., Eurekah.com/Landes Bioscience and Kluwer Academic/Plenum Publishers, pp. 158-187, 2003.
43. **Feldman EL**. Hereditary cerebellar ataxias and spastic paraplegias. In: *Cecil Textbook of Medicine*, Goldman L and Ausiello D, eds., 22nd ed., W.B. Saunders, pp. 2314-2316, 2004.
44. **Feldman EL**. Amyotrophic lateral sclerosis and other motor neuron diseases. In: *Cecil Textbook of Medicine*, Goldman L and Ausiello D, eds., 22nd ed., W.B. Saunders, pp. 2316-2319, 2004.
45. Sullivan KA, **Feldman EL**. Diabetic nerve disease, neuropathy. In: *Encyclopedia of Endocrine Diseases*, Martini L, ed., Elsevier, Inc., pp. 677-679, 2004.
46. Meyer G, Bole A, **Feldman EL**. Insulin-like growth factors and nervous system disorders. In: *IGF and Nutrition in Health and Disease*, Houston MS, Holly JMP, Feldman EL, eds., Humana Press, pp. 211-225, 2004.
47. Vinik AI, Erbas T, Pfeifer MA, **Feldman EL**, Stevens MJ, Russell JW. Diabetic autonomic neuropathy. In: *The Diabetes Mellitus Manual*, Inzucchi S, Porte Jr D, Sherwin RS, Baron A, eds., 6th ed., McGraw-Hill, pp. 347-365, 2005.
48. **Feldman EL**, Stevens MJ, Russell JW, Peltier A. Somatosensory neuropathy. In: *The Diabetes Mellitus Manual*, Inzucchi S, Porte Jr D, Sherwin RS, Baron A, eds., 6th ed., McGraw-Hill, pp. 366-384, 2005.

49. Leininger GM, **Feldman EL**. Insulin-like growth factors in the treatment of neurological disease. In: *Endocrine Development*, Cianfarani S, Clemmons DR, Savage MO, eds., vol. 9, S. Karger AG, pp. 135-159, 2005.
50. Singleton JR, Russell JW, **Feldman EL**. Electrodiagnosis of neuromuscular disease. In: *Adult Neurology*, Corey-Bloom J, ed., 2nd ed., Blackwell Publishing, pp. 34-49, 2005.
51. Russell JW, Cowell RM, **Feldman EL**. Neuronal and Schwann cell death in diabetic neuropathy. In: *Clinical Management of Diabetic Neuropathy*, 2nd ed., Veves A, Malik R, eds., Humana Press, pp 113-132, 2007.
52. Hughes RAC, **Feldman E**, Bland J. Peripheral nerve disorders. In: *Evidence-based Neurology and Neurosurgery*, Candelise L, Hughes R, Liberati A, Uitdehaag B, Warlow C, eds., Blackwell Publishing, pp. 244-257, 2007.
53. Sadidi M, Sastry AM, Lastoskie CM, Vincent AM, Sullivan KA, **Feldman EL**. Oxidative stress in the pathogenesis of diabetic neuropathy. In: *Apoptosis and Human Diseases: Molecular Mechanisms*, Srivastava R, Humana Press, pp 365-394, 2007.
54. Pop-Busui R, Sullivan KA, **Feldman EL**. Diabetes and the nervous system. In: *Neurology and the General Medicine*, 4th ed, Aminoff MJ, Churchill Livingstone Elsevier, pp. 383-407, 2008.
55. Edwards JL, Little AA, **Feldman EL**. Neuropathy. In: *Type I Diabetes in Adults: Principles and Practice*, Jabbour S, Stephens EA, Informa Healthcare USA, Inc., pp. 173-193, 2008.
56. Vincent AM, **Feldman EL**. Primary sensory and motor neuron cultures. In: *Protocols for Neural Cell Culture*, 4th ed, Doering LC, Humana Press, pp 161-174, 2010.
57. Cheng HT, Callaghan B, Dauch JR, **Feldman EL**. Cytoskeleton, axonal transport, and the mechanisms of axonal neuropathy. In: *Cytoskeleton of the Nervous System Series: Advances in Neurobiology*, 1st ed, Vol. 3, Chapter 27, Nixon RA, Yuan A, eds, Springer Publishers, pp 657-678, 2010.
58. Pop-Busui R, Simmons Z, **Feldman EL**. Treatment of diabetic neuropathy. In: *Evidence Base for Diabetes Care*, 2nd ed, Chapter 19, Herman WH, Kinmonth A-L, Wareham NJ, Williams R, eds, BMJ Publishing Group Ltd, pp 317-340, 2010.
59. Cheng HT, Callaghan B, Dauch JR, **Feldman EL**. Painful diabetic neuropathy. In: *Neuropathic Pain: Mechanisms, Diagnosis and Treatment*. Chapter 11, Simpson DM, McArthur JC, Dworkin RH, eds, Oxford University Press, pp 165-189, 2012.
60. Kato K, **Feldman EL**, Nakamura, J. Pathogenesis of diabetic neuropathy from the point of view of schwann cell abnormalities. In: *Schwann Cell Development and Pathology*. Chapter 9, Sango K, Yamauchi J, eds, Springer Japan, pp 135-146, 2014.

61. Goutman SA, Smith AL, Sakowski SA, **Feldman EL**. Diabetic neuropathy. In: *Oxford Textbook of Neuromuscular Disorders*. Chapter 17, Hilton-Jones D, Turner MR, eds, Oxford University Press, pp 158-166, 2014.
62. Sakowski SA, Lunn JS, **Feldman EL**. Stem cell therapy for motor neuron disease. In: *Motor Neuron Disease in Adults, Contemporary Neurology Series*. Volume 88, Bruijn L, Bromberg MB, eds, Oxford University Press, pp 312-317, 2015.
63. Sims-Robinson C, Kim B, **Feldman EL**. Diabetes and cognitive dysfunction. In: *Neurobiology of Brain Disorders: Biological Basis of Neurological and Psychiatric Disorders*. Zigmond MJ, Rowland LP, Coyle JT, eds, Elsevier Inc, pp 189-201, 2015.
64. Hinder LM, Sullivan KA, Sakowski SA, **Feldman EL**. Mechanisms contributing to the development and progression of diabetic polyneuropathy. In: *Neurobiology of Disease*. 2E, Chapter 114, 831-837, Gilman S, Markovac J, eds, Oxford University Press.
65. Chen KS, **Feldman EL**. Peripheral neuropathies. In: *Youmans & Winn Neurological Surgery*. 7th ed, Ch 246, Elsevier, Inc, in press.
66. Sabha N, Volpatti JR, Gonorazky H, Reifler A, Davidson AE, Li X, Eltayeb NM, Dall'Armi C, Di Paolo G, Brooks SV, Buj-Bello A, **Feldman EL**, Dowling JJ. PIK3C2B inhibition improves function and prolongs survival in myotubular myopathy animal models. *J Clin Invest*. 2016 Sep 1;126 (9):3613-25. Epub 2016 Aug 22.
67. Sas KM, Kayampilly P, Byun J, Nair V, Hinder LM, Hur J, Zhang H, Lin C, Qi NR, Michailidis G, Groop PH, Nelson RG, Darshi M, Sharma K, Schelling JR, Sedor JR, Pop-Busui R, Weinberg JM, Soleimanpour SA, Abcouwer SF, Gardner TW, Burant CF, **Feldman EL**, Kretzler M, Brosius FC 3rd, Pennathur S. Tissue-specific metabolic reprogramming drives nutrient flux in diabetic complications. *JCI Insight*. 2016 Sep 22;1(15).
68. Atassi N, Beghi E, Blanquer M, Boulis NM, Cantello R, Caponnetto C, Chiò A, Dunnett SB, **Feldman EL**, Vescovi A, Mazzini L; attendees of the International Workshop on Progress in Stem Cells Research for ALS/MND. Intraspinial stem cell transplantation for amyotrophic lateral sclerosis: Ready for efficacy clinical trials? *Cytotherapy*. 2016 Oct 6. [Epub ahead of print]
69. Chen KS, **Feldman EL**. Stem Cell Therapy for Amyotrophic Lateral Sclerosis. In: *Molecular and Cellular Therapies for Motor Neuron Diseases*. Elsevier Inc, Chap 9; pp 207-232, 2017.
70. Goutman SA, Chen KS, Paez-Colasante X, **Feldman EL**. Emerging understanding of the genotype-phenotype relationship in amyotrophic lateral sclerosis. In: *Handbook of Clinical Neurology*. Elsevier Inc, Part II, Section VII, Chapter 39; pp 603-623, 2018.

Books

1. **Feldman EL.** Glycoconjugates in the regenerating goldfish visual system. Thesis, The University of Michigan, Ann Arbor, Michigan, 1979.
2. Houston MS, Holly JMP, **Feldman EL.** *IGF and Nutrition in Health and Disease*, Humana Press, Totowa, New Jersey, 2004.
3. **Feldman EL,** Grisold W, Russell JW, Zifko UA. *Atlas of Neuromuscular Diseases*, Springer-Verlag/Wien, Austria, 2005.
4. **Feldman EL,** Grisold W, Russell JW, Löscher WN. *Atlas of Neuromuscular Diseases*, 2nd ed., Springer-Verlag/Wien, Austria, 2014.